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ABSTRACT 
Statistical models of DNA sequence evolution for analysing protein-coding 
genes can be used to estimate rates of molecular evolution and to detect signals 
of natural selection. Genes that have undergone positive selection during 
evolution are indicative of functional adaptations that drive species differences.  
 
Genes that underwent positive selection during the evolution of humans and four 
mammals used to model human diseases (mouse, rat, chimpanzee and dog) were 
identified, using maximum likelihood methods. I show that genes under positive 
selection during human evolution are implicated in diseases such as epithelial 
cancers, schizophrenia, autoimmune diseases and Alzheimer’s disease. 
Comparisons of humans with great apes have shown such diseases to display 
biomedical disease differences, such as varying degrees of pathology, differing 
symptomatology or rates of incidence.  
 
The chimpanzee lineage was found to have more adaptive genes than any of the 
other lineages. In addition, evidence was found to support the hypothesis that 
positively selected genes tend to interact with each other. This is the first such 
evidence to be detected among mammalian genes and may be important in 
identifying molecular pathways causative of species differences. 
 
The genome scan analysis spurred an in-depth evolutionary analysis of the 
nuclear receptors, a family of transcription factors. 12 of the 48 nuclear receptors 
were found to be under positive selection in mammalia. The androgen receptor 
was found to have undergone positive selection along the human lineage. 
Positively selected sites were found to be present in the major activation domain, 
which has implications for ligand recognition and binding. 
 
Studying the evolution of genes which are associated with biomedical disease 
differences between species is an important way to gain insight into the 
molecular causes of diseases and may provide a method to predict when animal 
models do not mirror human biology.  
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1.1 NATURAL SELECTION 
 
“Natural selection is daily, hourly, scrutinising the slightest variations, 
rejecting those that are bad, preserving and adding up all those that are 
good.”  
– Charles Darwin, The Origin of Species (1859)  
 
The nineteenth-century attempt by Darwin to explain the mechanistic action by 
which evolutionary processes bring about variation between species was, in 
hindsight, only partially correct. The 1920s and 1930s brought forth the theory of 
neo-Darwinism from pioneers such as R.A. Fisher, J.B.S. Haldane and S. Wright, 
where mutation was recognised as the major source of genetic variation and 
natural selection was the dominant factor in shaping genetic makeup. The 
discovery of DNA in 1953 and the advancement of molecular techniques enabled 
the search for evidence of adaptation at the molecular level and challenged the 
Darwinian concept of natural selection.  
 The generally accepted present day viewpoint is that the great majority of 
evolutionary changes at the molecular level are caused by random drift of 
selectively neutral or nearly neutral mutations. These neutral mutations have a 
fitness coefficient which is equal to that of the common allele in the population. 
The relevant consequence of such a mechanism is that mutations become fixed at 
a constant rate within the population. This is known as the neutral theory of 
evolution (Kimura, 1968; King and Jukes, 1969). However, a large proportion of 
mutations that occur confer a selective disadvantage to the individual. Lethal 
mutations and mutations that reduce the fitness level of the carrier within a 
population are removed over time, due to the decreased reproductive success of 
their carriers. This process is known as negative or purifying selection. In 
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general, genes that are crucial for the basic functions needed for the sustenance 
of the cell are under purifying selection. A very small proportion of mutations 
confer a selective advantage to the individual. These mutations, said to be under 
positive selection, are driven to fixation within the population at rates higher than 
for neutral mutations. The majority of variation that we see today between 
species is a result of the interaction of these complex processes, as well as the 
effects of recombination.  
 Positive selection, the fixation of advantageous mutations, is an exciting 
topic as it is ultimately responsible for differences in protein function between 
species and hence genes involved in adaptation. Positive selection leading to 
functional divergence in homologous genes may help explain at the molecular 
level the divergence in the anatomy, biology and cognitive abilities of mammals.  
 
1.2 HOMOLOGOUS GENES 
Homology is defined as similarity between a pair of genes that is the result of 
inheritance from a common ancestor. The accurate identification and analysis of 
homologies is key to the study of phylogenetic systematics. Homologous genes 
are subdivided into orthologues and paralogues (Figure 1.1). Orthologous genes 
are homologous genes in two or more organisms that are the result of speciation 
and not gene duplication (Fitch, 2000). Paralogous genes are homologous genes 
that are the result of gene duplication. These are further classified as 
inparalogues and outparalogues: the term inparalogues indicates paralogues in a 
given lineage that all evolved by gene duplications that happened after the 
speciation event that separated the given lineage from the other lineage under 
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consideration, whereas outparalogues are paralogs in the given lineage that 
evolved by gene duplications that happened before the speciation event. 
  
Figure 1.1   Relationships between orthologous and paralogous genes 
Genes A1 and A2 are inparalogues, arising from a duplication of Gene A. Genes M1 and 
H1 are orthologues since they arose from the same ancestral gene A1. Similarly, genes 
M2 and H2 are orthologous as well. Genes H1 and M2 are outparalogues, since gene M2 
arose from gene duplication before speciation. Genes M2 and M3 are inparalogues since 
gene M3 is a duplication of gene M2. Genes H2 and M3 are also orthologues since M3 
is a duplication of M2. 
 
 
1.3 MEASURING SELECTION PRESSURE ON A PROTEIN 
The availability of DNA sequence information from closely related organisms 
allows the direct comparison of their encoded protein sequences. Thus, 
nucleotide differences between homologous proteins can be used to infer the 
GENE A 
GENE A1 GENE A2 
Gene 
duplication 
in ancestor 
GENE H1 GENE M1 GENE M2 
 
GENE H2 
GENE M3 
Time 
Gene 
duplication 
in mouse 
Speciation 
event 
leading to 
human and 
mouse 
GENE H1 GENE M1 GENE M2 
 
GENE H2 
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number and type of mutations that have occurred between two species since they 
last shared a common ancestor. Nucleotide differences can be of two types: a 
nonsynonymous nucleotide change is one which results in an amino acid change 
in the protein sequence whereas a synonymous nucleotide substitution leads to 
no change in amino acid, due to the degeneracy of the genetic code (Figure 1.2). 
 
Figure 1.2   Examples of nonsynonymous and synonymous mutations 
 
 
 
Since synonymous mutations have no effect on protein sequence, they are not 
subject to natural selection acting on the protein. However, in mammals, 
synonymous mutations have been found to have an effect on fitness. Such 
mutations can, for example, disrupt splicing of alternatively spliced exons, can 
interfere with miRNA binding (Charmary, Parmley and Hurst, 2006). They have 
also been found to modify protein abundance most probably mediated by 
alteration in mRNA stability and modification of protein structure and activity 
probably mediated by translational pausing (Parmley and Hurst, 2007). 
 
 
Nonsynonymous (replacement) substitution: 
Original sequence:      UUU CAU CGU 
       Mutation:       UUU CAG CGU 
           Original protein sequence:        Phe   His    Arg                                                                       
                 New protein sequence:        Phe   Gln   Arg          
 
 
Synonymous (silent) substitution:  
Original sequence:      UUU CAU CGU 
                Mutation:      UUU CAC CGU 
Original protein sequence:        Phe   His   Arg                                                                       
                 New protein sequence:         Phe   His   Arg 
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The rate of fixation of nonsynonymous mutations is also monitored by selection. 
Thus, the comparison of the fixation rates of synonymous and nonsynonymous 
mutations can be used to understand the action of selective pressure on protein 
coding sequences. Selection pressure can be measured by contrasting the number 
of nonsynonymous substitutions per non-synonymous site (dN), with the number 
of synonymous substitutions per synonymous site (dS) (Miyata and Yasunaga, 
1980).  
 The dN/dS rate ratio is known as ω, and in this measure ω = 1 (dN = dS) 
indicates neutral evolution (Yang and Bielawski, 2000). If one or more amino 
acid substitutions reduce the fitness of the carrier, these changes are likely to be 
removed by negative selection. This results in the nonsynonymous substitution 
rate to be less than the synonymous substitution rate (dN < dS). Hence ω < 1 is 
indicative of negative selection. If amino acid substitutions confer fitness 
advantages, the nonsynonymous substitution rate will be greater than the 
synonymous substitution rate (dN > dS) leading to ω > 1, an indication of positive 
Darwinian selection. The resulting alterations in the protein sequence can lead to 
variations in the secondary structure of the protein as seen in human MHC class 
1 molecules or a change in protein conformation exemplified by positive 
selection in the insulin gene in caviomorph rodents (Opazo et al., 2005). Changes 
in protein sequence can also result in modifications in the substrate protein 
binding mechanism such as MRGX2, a G-protein coupled receptor (Yang S et 
al., 2005) or the means by which it interacts with other proteins as seen in genes 
in the HOX cluster.  
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1.4 ESTIMATION OF SYNONYMOUS AND 
NONSYNONYMOUS SUBSTITUTION RATES 
I will first describe the early counting methods which were used to estimate dN 
and dS between a pair of homologous, protein-coding sequences, and then the 
more realistic approach using maximum likelihood methods under a codon 
substitution model.  
 
1.4.1 Counting methods: pairwise methods 
Perler et al. (1980) developed a simple statistical method to estimate synonymous 
substitutions. Miyata and Yasunaga (1980) and Li et al. (1985) proposed 
methods to incorporate different weights for two or more possible evolutionary 
pathways between a pair of codons. Both these methods were fairly complicated 
so Nei and Gojobori (1986) devised a simpler method based on the Miyata-
Yasunaga method (1980) that gave essentially the same results. The Nei-
Gojobori method estimates dN and dS in three steps:  
Step One:  
The numbers of nonsynonymous sites (n) and synonymous sites (s) in each 
codon are calculated. For a codon, let i be the number of possible synonymous 
changes at this site. For example, the codon TTA can undergo two synonymous 
substitutions: one substitution at the first nucleotide T (T → C) and one 
substitution at the third nucleotide A (A → G). Therefore for codon TTA, i = 2. 
This site is then counted as having i/3 synonymous sites and (9-i)/3 
nonsynonymous sites, which gives s = 2/3 and n = 7/3 for codon TTA. The 
values of s and n from each codon in the sequence are summed to give S and N 
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for the sequence. To obtain S and N for two sequences which are being 
compared, the mean values of S and N of each sequence are used.  
Step Two: 
The numbers of nonsynonymous (Nd) and synonymous (Sd) differences between 
the two sequences are counted. This step is fairly straightforward if there is only 
one nucleotide difference between the two codons (e.g. there is one synonymous 
difference between the codons GTA (Val) and GTT (Val)). However, if the two 
codons differ by more than one nucleotide, all possible evolutionary pathways 
between the two codons will have to be evaluated. For example, in the 
comparison of codons TTT and GTA, the two pathways are: 
 
Pathway I:  TTT (Phe) ↔ GTT (Val) ↔ GTA (Val) 
Pathway II:  TTT (Phe) ↔ TTA (Leu) ↔ GTA (Val) 
 
Pathway I includes one nonsynonymous change and one synonymous change, 
whereas Pathway II includes two nonsynonymous changes. Pathways I and II can 
be assumed to occur with equal probability or be weighted for synonymous and 
nonsynonymous changes. If equal weights are assumed, Sd = 0.5 and Nd = 1.5 for 
this pair of codons. However, in almost all genes the synonymous substitution 
rate is higher than the nonsynonymous substitution rate so, to improve the model, 
a larger weight is given to synonymous substitutions than nonsynonymous 
substitutions. The weights are then multiplied by the number of differences to 
give Sd and Nd. Incorporating weights for different pathways was implemented 
by Li et al. (1985). 
Step Three: 
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The proportion of different sites at synonymous sites (pS) is now Sd /S and the 
proportion of different sites at the nonsynonymous sites (pN) is Nd /N (see Table 
of Definitions). pS and pN are actually underestimates of the distance between the 
two sequences (expected number of substitutions) because multiple substitutions 
could have occurred at the same site, not reflected in the observed sequences. 
Multiple hits include parallel substitutions, convergent substitutions, and back 
substitutions. The Jukes and Cantor distance formula (Jukes and Cantor, 1969) 
applies a correction to pS and pN to account for multiple substitutions which 
results in the number of synonymous substitutions per site (dS) and the 
nonsynonymous substitutions per site (dN) as:   
3 4
log(1 )
4 3
S sd p= − −  
 
    
3 4
log(1 )
4 3
NNd p= − −  
The estimates of dN and dS obtained by this method can be used to calculate 
ω = dN/dS. 
 The Nei-Gojobori method (Nei and Gojobori, 1986) was later improved 
by Ina (1995), which accounts for the transition/transversion bias in nucleotide 
substitutions. Transversions are substitutions for a purine for a pyrimidine or vice 
versa which changes the chemical structure of DNA dramatically. It is well 
known that nucleotide substitutions that are transitions (T ↔ C, and A ↔ G) are 
more common than transversions (T, C ↔ A, G). Ignoring the 
transition/transversion bias causes underestimation of S, overestimation of dS and 
underestimation of the dN/dS ratio (Li, 1993; Pamilo and Bianchi, 1993).  
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All of the counting methods to estimate the dN/dS are relatively simple. However 
there are several disadvantages: 
 
• The pairwise method averages dN/dS over all the sites of the protein and over 
time which leads to selection pressure being drastically underestimated. For 
example, Endo et al. (1996) performed a large-scale search of 3595 genes 
using the Nei and Gojobori method (1986) to estimate dN and dS, and only 
identified 17 proteins under positive selection, a very small proportion of 
0.47% probably due to the lack of power in the methods used. 
 
• Most proteins only have very few sites that have undergone positive 
selection, with most of the protein under strong purifying selection. Also, as 
adaptive evolution may occur over a very small period of evolutionary time, 
pairwise methods do not reliably infer the action of positive selection.  
 
• Use of the pairwise method cannot determine the particular codon that is 
under selection. 
 
• The pairwise method ignores the effects of codon usage bias and unequal 
nucleotide frequencies. In real data, base compositions and codon usage are 
quite biased, which implies that the substitution rates are not symmetrical and 
will affect the counting of sites and differences. Assuming codon frequency 
to be equal was shown to cause overestimation of S, underestimation of dS 
and overestimation of the dN/dS ratio by Yang and Nielsen (2000), who 
implemented a counting method that takes into account unequal nucleotide 
frequencies.  
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• Lastly, the Jukes and Cantor distance correction to account for multiple 
substitutions used in the third step of the pairwise method is not very accurate 
as the correction procedure is based on correction of multiple hits within 
nucleotide sequences, not codons. 
 
The last of the counting methods was formulated by Yang and Nielsen (2000). 
They devised a new approximate method incorporating the 
transition/transversion bias and unequal base frequencies in their algorithm 
assuming the HKY85 nucleotide substitution model (Hasegawa, 1985). This 
method was shown to produce estimates of dN and dS very close to the true values 
even for data with strong transition/transversion and codon biases.  
 
1.4.2 Maximum likelihood estimation methods based on a codon-
substitution model 
Maximum likelihood is a major statistical inference tool used in a variety of 
fields. The likelihood of a phylogenetic tree is the probability of observing the 
data under a given tree and a specific substitution model (such as a codon 
substitution model), P(data|tree) (Felsenstein, 1981). Nucleotide substitution 
models were already in existence so a natural extension was to create the slightly 
more complex codon-substitution model. Models that focus on detecting 
selection at the level of individual codons have been shown to fit data better and 
to produce more reliable estimates of dN/dS than nucleotide models (Goldman 
and Yang, 1994). Within the codon-substitution model, dN/dS is a parameter 
which is estimated along with other parameters by the maximum likelihood 
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method. Similar to pairwise methods the numbers of synonymous and 
nonsynonymous sites and the numbers of synonymous and nonsynonymous 
differences are calculated for each codon. Ancestral reconstruction allows these 
values to be computed across the entire tree generated from a multiple alignment 
instead of simply for two sequences as in pairwise methods. For any given codon 
site, dN = dS under the null hypothesis of neutrality. Each codon site in the 
alignment is taken in turn and positive selection inferred when the null 
hypothesis can be rejected (dN > dS).  
 Initial codon-substitution models were developed by Goldman and Yang 
(1994) and another, a slightly simpler version, by Muse and Gaut (1994). Later, a 
maximum parsimony method (Fitch, 1971) that required a phylogenetic tree to 
initially infer the ancestral codon for every node in the tree was developed.  
 The Goldman-Yang model (1994) is described below and modified 
versions used in the analyses in this study. The model specifies the probability 
that codon i changes to codon j during evolution along the segment of the tree of 
length t (in time units). A first-order Markov model, which assumes that the state 
at time t depends only on the previous state at time t-1, is used to model the 
substitutions within a codon. There are 61 states in the Markov model which 
correspond to the 61 sense codons in the Universal genetic code (stop codons are 
not considered). Each codon has a maximum of nine neighbours to which it may 
change to instantaneously (Figure 1.3). 
 
Codon substitution probabilities 
From the substitution model, the instantaneous substitution rate from codon i to 
codon j (i ≠ j) is qij and can be specified as follows:  
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The substitution rate is proportional to the equilibrium frequency (πj) of the 
codon being changed to (codon j), calculated using the observed frequencies in 
the data, which allows codon usage information to be incorporated into the 
analyses. Alternatively the equilibrium frequency of the codon can be calculated 
using the observed nucleotide frequencies at the three codon positions. 
Substitutions that are transitions are multiplied by κ, the transition/transversion 
rate ratio, and substitutions that result in a nonsynonymous substitution are 
multiplied by ω.  
 
Figure 1.3   A codon’s neighbours 
Example of other codons a codon (TCG) may instantaneously evolve into through a 
single nucleotide substitution. Black arrows represent transversions and red arrows 
represent transitions. Substitutions that result in no change in amino acid are marked 
with thicker arrows. Circle size represents the frequency (equilibrium) of that codon (in 
pooled α- and β-globin sequences). Adapted from Goldman and Yang, 1994. 
 
 
 
 
 
 
 
 
 
 
 
TTG 
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TCG 
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CCG 
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TCA 
(Ser) 
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Q = {qij} is the 61 x 61 rate matrix. The Markov process is reversible 
so Q Qi jij jiπ π= . The probability pij(t) that any codon i will become codon j after 
time t can be calculated from qij. A standard numerical algorithm is used to 
obtain the eigenvalues and eigenvectors of the rate matrix Q = {qij}, to calculate 
the transition probability matrix for a branch of length t:  
 
P(t) = {pij (t)} = e
Qt
 
 
When the parameter ω is different among branches in the tree (see Section 1.5.1), 
it is necessary to perform this calculation for each branch with a different ω.  
 
Advantages and disadvantages of the model 
The model assumes substitutions at the three positions occur independently, that 
is, only single-nucleotide substitutions can occur during an infinitely small time 
interval ∆t. The model ignores related changes that occur in more than one 
position and also multiple substitutions in a position as these would occur in time 
(∆t)2. The calculation of the transition probability from one codon to another 
eliminates the need to explicitly weight evolutionary pathways between codons. 
All of these factors enable the use of more realistic models in the estimation 
process. Since sites which contain gaps are ignored by the model, one of the 
disadvantages of this model is that it does not incorporate any processes for 
insertions or deletions. 
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Averaging over all possible ancestral sequences 
The model assumes that since the ancestral sequence separated into two 
descendent sequences when the species diverged, each sequence evolved 
independently of the other sequence, and each codon evolved according to the 
Markov model independent of other codons in the sequence. Since the ancestral 
sequence is unknown, the likelihood method averages over all possible ancestral 
sequences at each interior node in the tree. The probability of observing the two 
descendent codons at a site is given by summing over all ancestral codons in the 
common ancestor. First the probability at each site is calculated as described 
below. Then the probabilities are multiplied together to obtain the likelihood of 
all the sites in the alignment. 
 
Calculating probability at each site 
Given a set of aligned DNA sequences we can calculate the probability at each 
site separately. The process calculates the probability of each possible 
reconstruction, depending on assumptions made about the process of nucleotide 
substitution, branch lengths, rate of substitution and evolutionary time. For 
example, given a tree of four species (Figure 1.4), we have to sum over all 61x61 
combinations of ancestral states (j and k) at the two internal nodes, to calculate 
the probability of data at each site. 
 
Figure 1.4   An example of one site in an unrooted 4-taxon tree 
 
 
 
 
 
t2 t1  
j t4 
GAA GCA 
k 
GAG GAG 
t3 
t0 
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So the probability of observing data at site i (with codons GAG, GAG, GAA, 
GCA) is:  
 
0 1 2 3 4
0 1 2 3 4
prob({ , , , } | , , , , )
( ) ( ) ( ) ( ) ( )
i
k kj jGAG jGAG kGAA kGCA
k j
p GAG GAG GAA GCA t t t t t
p t p t p t p t p tπ
=
     =  ∑∑  
 
This averages over all possible values of the ancestral codons, j and k. The 
probability of observing data at site i is equal to the probability that the codon at 
the root is k, which is given by the equilibrium frequency πk, multiplied by the 
five transition probabilities along the five branches of the phylogeny.   
 
This calculation can be computationally intensive as an unrooted tree of n species 
has (n – 2) ancestral nodes, so the probability at each site will be a sum over 61(n 
– 2)
 possible ancestral reconstructions. The computation can be speeded up by the 
use of Felsenstein’s “pruning” algorithm (Felsenstein, 1981), by which 
conditional probabilities are calculated in a bottom-up manner. The probabilities 
for tips and daughter nodes are calculated before ancestral nodes with the 
probability for the root calculated last, hence reducing computation time.   
 
Likelihood of all sites in alignment 
The likelihood L, for the given set of sequences of length n codons, that is, the 
probability of the data across all the sites in the alignment, is the product of the 
probabilities across all the sites:  
  L = p1 × p2 × … × pi  × … × pn = 
1
n
i
i
p
=
  .∏  
As opposed to pairwise methods, the sequences from all the given species can be 
considered simultaneously. The values for the parameters (branch lengths in the 
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tree, t, κ, and ω) are estimated such that the likelihood value is maximised, using 
a numerical iteration algorithm. For ease of use, the log-likelihood (the log of the 
likelihood value) is calculated and is a sum over all sites: 
ℓ = log(L) = log(p1) + log(p2) + … log(pi) +…+ log(pn) = ∑
=
n
i
ip
1
)log( . 
 
 
Likelihood-ratio tests 
The log-likelihood value can be used as an optimality criterion to evaluate 
different models of evolution. The model with the highest likelihood value 
represents the model that best fits the data. Two models can be compared using a 
likelihood ratio test (LRT). However, both models must be nested with respect to 
each other, that is, one model must be a simpler form (H0, the null hypothesis) of 
the other model (H1, the alternate hypothesis).  
The test statistic from the LRT is 2∆ℓ = 2(ℓ1 – ℓ0) where ℓ1 is the  
log-likelihood from the complex alternative model H1 with p parameters and ℓ0 is 
the log-likelihood from the simpler null model H0, with q parameters. If H0 is 
true, then twice the log likelihood difference, 2∆ℓ = 2(ℓ1 – ℓ0), is approximately 
χ2 distributed with degree of freedom = p – q. If the observed value of the test 
statistic 2∆ℓ is greater than the χ2 critical value, we reject H0 and accept H1.  
 Computer simulations suggest that the maximum likelihood method has 
good power and accuracy in detecting positive selection over a wide range of 
parameter values (Wong et al., 2004). The type I error occurs if H0 is rejected 
when it is true. A test is accurate if the type I error rate is less than the 
significance threshold chosen for the test, α. The type II error of a test occurs if 
the test fails to reject H0 when it is false. The power of the LRT is defined as  
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1 – type II error rate and is equal to the probability of rejecting H0 given that H0 
is wrong and H1 is correct. Using computer simulations, Anisimova et al., (2001) 
showed that the power of the LRT increases with sequence length, sequence 
divergence and the strength of positive selection.  
 
1.5 MODELS IMPLEMENTED WITHIN THE MAXIMUM 
LIKELIHOOD FRAMEWORK 
The basic Goldman-Yang codon-substitution model (1994) for likelihood 
analysis can be modified to account for different levels of heterogeneity in the 
dN/dS ratio among lineages and among sites. The simplest model assumes the 
same ω for all branches in the phylogeny (model M0). The most general model 
assumes an independent ω for each branch in the phylogeny and is referred to as 
the “free-ratio” model (Yang, 1998). This model has as many ω parameters as 
the number of branches in the tree.  
 
1.5.1 Models of variable selective pressures among branches: 
branch models 
The first model assumed ω to be the same for all branches in the phylogeny. 
However for some genes, the evolutionary rate may be expected to be higher at 
specific points in the lineage i.e. along a particular branch. This branch is 
labelled as the foreground branch. Models that can accommodate a different ω 
value for a pre-specified branch were first illustrated by an analysis of the 
enzyme lysozyme (Yang, 1998). 
Lysozyme is a bacteriolytic enzyme that can cleave the glycosidic bonds 
in the cell wall peptidoglycans of bacteria. Due to its lytic activity, the enzyme is 
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part of the antibacterial defence mechanisms of many animals; it is found 
primarily in the tears and saliva of mammals and in the eggs of birds. In foregut 
fermenting animals, where ingested plant material is subject to bacterial 
fermentation, lysozyme is also secreted in the digestive system, permitting the 
retrieval of the nutrients from lysed bacterial cells. The ruminant artiodactyls 
(e.g. cow, deer) and the leaf-eating colobine monkeys (e.g. langur) have 
independently recruited lysozyme as a means of digesting bacteria. The 
difference between saliva and gastric lysozymes is that gastric lysozymes are 
active at low pH and are unusually resistant to cleavage by pepsin. In most 
mammals the omega values for lysozyme will be similar, other than in the 
artiodactyl ruminants, leaf-eating monkeys and a leaf-eating bird, where 
lysozyme is thought to have gone through positive selection followed by 
increased purifying selection.  
 Based on the phylogeny given, and from the above biological knowledge, 
we can formulate hypotheses that can be tested using maximum likelihood 
methods. Previous molecular work had demonstrated that the branch ancestral to 
the colobines and the branch ancestral to the hominids might be under positive 
selection or relaxed purifying selection (Messier and Stewart, 1997).  
 In the analysis by Yang (1998), the null hypothesis assumed the 
evolutionary rate (ω) of the branches of interest is equal to that of the 
background branches. Two alternative hypotheses were then formulated: one 
which assumed that ω was the same for all branches except the branch leading to 
the colobines; and the other which assumed ω was different only for the hominid 
branch. Both alternative hypotheses were tested against the null hypothesis in 
LRTs with 1 degree of freedom. LRTs to examine whether the foreground 
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branch ω (branch leading to colobines or the hominid branch) was greater than 1 
were also performed.  
 Maximum likelihood analyses found the background ω ratio was 
approximately 0.57 indicating negative selection for lysozyme during primate 
evolution. The LRTs resulted in the inferred omega of the lineage leading to the 
hominids to be significantly greater than 1, with approximately 9 
nonsynonymous substitutions and 0 synonymous substitutions occurring along 
this branch. The lack of synonymous substitutions results in the value of ω being 
infinity. The ω of the branch leading to the colobines was significantly greater 
than the background ω but the second LRT resulted in the inferred omega to not 
be significantly greater than 1, with 9 nonsynonymous substitutions and 1 
synonymous substitution having occurred along this branch. Therefore, it was 
concluded that lysozymes have evolved under positive selection possibly as an 
adaptation to the ruminant diet. 
 
1.5.2 Models of variable selective pressures among sites: site 
models 
The codon-based maximum likelihood model can also allow for categories of 
sites to evolve with different values of ω. This is a good model to detect adaptive 
evolution that affects only a few amino acids in functionally distinct regions of 
the gene. In almost all proteins where positive selection has been shown to 
operate, only a few amino acid sites were found to be responsible (Hughes and 
Nei, 1992). Averaging the estimates for ω across the entire sequence may result 
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in values less than 1, therefore failing to detect positive selection. Site models 
have higher power if positive selection had occurred over a long time period.  
 Site models allow different proportions of sites to be under purifying 
selection (ω < 1), neutral evolution (ω = 1) or positive selection (ω > 1). The 
neutral (M1) and selection (M2) models were described by Nielsen and Yang 
(1998), using the HIV-1 env gene as an example. These were later superseded by 
the nearly-neutral (M1a) and positive-selection models (M2a) (Yang et al., 
2000). The nearly-neutral model incorporates two categories of sites (Table 1.1). 
The first category of sites is of proportion p0 with 0 < ω0 < 1, and the second of 
proportion p1 (p1 = 1 - p0) with ω1 = 1 (Figure 1.5). The positive-selection model 
M2a has an extra category of sites of proportion p2 (p2 = 1- p0- p1). The inferred 
value of ω (ω2) for this category must be greater than 1 for positive selection to 
be inferred.  
 
Table 1.1 Models of ω ratio variation among sites used for analysis 
Model Parameters 
Number of free 
parameters 
Free 
parameters 
M1a (neutral) 
p0, p1(= 1 – p0) 
0 < ω0 < 1, ω1 = 1 
2 p0,  ω0 < 1 
M2a (positive 
selection) 
p0, p1, p2 (= 1 – p0 – 
p1) 
ω0 < 1, ω1 = 1,  ω2 > 1 
4 
p0, p1, 
ω0 < 1, ω2 > 1 
M7 (beta) p, q 2 p, q 
M8 (beta&ω) 
p0 (p1 = 1 – p0) 
p, q, ωs > 1 
4 p0, p, q, ωs > 1 
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Figure 1.5   Examples of nested site models used in likelihood ratio tests for  
         detecting positive selection 
 
 
 
 Two other models, the M7 (beta) and M8 (beta&ω) models use the beta 
distribution to accommodate the shape of the ω distribution that is likely to occur 
in real data (Yang et al., 2000). The null model M7 (beta) assumes a beta 
distribution for ω in the interval (0, 1). The alternative M8 (beta&ω) model adds 
an extra class of sites under positive selection with ωs > 1 (Figure 1.5).  
 If positive selection is detected, a Bayes empirical Bayes procedure 
(BEB) (Yang et al., 2005) is used to calculate the posterior probability of a site 
belonging to a particular category. The BEB method replaced the naïve empirical 
Bayes (NEB) method used in earlier models as NEB failed to account for 
sampling errors in the maximum likelihood estimates of the model parameters, 
such as the proportions and estimates of ω for the site classes. The BEB method 
resolves sampling errors by assigning a prior to the model parameters and 
integrating over their uncertainties.  
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 The human major histocompatibility complex (MHC) class 1 molecules 
is a good illustration of genes that have several sites that are extremely 
polymorphic within the antigen recognition site (ARS), whilst the immunoglobin 
domain is subject to purifying selection. It is advantageous for a population 
exposed to an array of pathogens to be polymorphic at the MHC loci, because a 
heterozygote will be able to detect a broader array of antigens, and thus resist a 
broader array of pathogens. Fixed-site models using a priori information to 
partition the sites in the MHC into two classes, those in the ARS and those 
outside, have been used to detect position selection. An analysis of 192 alleles of 
the A, B and C loci of human class I MHC demonstrated sites within the ARS 
were under positive selection, with an ω of 1.9, whereas non-ARS sites were 
under purifying selection with an ω of 0.23 (Yang and Swanson, 2002). The sites 
were scattered among the primary sequence but are clustered together at the ARS 
in the crystal structure of the protein. Many other convincing examples of 
positive selection have been detected in a variety of organisms and functional 
classes (Yang and Bielawski, 2000).  
 
1.5.3 Models of variable selective pressures among branches and  
sites: branch-site models 
The branch-site models are a composite of the branch and site models in that they 
allow ω to vary both among sites and among lineages (Yang and Nielsen, 2002). 
With this approach, positive selection can be identified for only a few sites in the 
protein along pre-specified lineages, which is likely to be a more effective 
method to detect positive selection as the evolutionary rate will have varied at 
different sites and at specific times in the gene’s evolution.  
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 After reports of false positives (Zhang, 2004), models were developed 
that were more robust against violations of model assumptions (Zhang et al., 
2005). The alternative branch-site model (also known as Model A) has four 
codon site categories. The first two classes are for sites evolving under purifying 
selection and neutral evolution on all the lineages and the additional two allow 
for sites under positive selection on the foreground branch and either purifying 
selection or neutral evolution on the background branches (Table 1.2). The null 
model restricts sites on the foreground lineage to be undergoing neutral 
evolution. The branch-site model has been shown to be very conservative with a 
low false positive rate and more sensitivity than a lineage model (Zhang et al., 
2005). The branch-site, site and branch models have been implemented in the 
PAML package (Yang, 1997; 2007). 
 
Table 1.2 Parameters in the branch-site model A 
  Branch-site alternative model Branch-site null model 
Site 
class 
Proportion Background Foreground Background Foreground 
0 p0 0 < ω0 < 1 0 < ω0 < 1 0 < ω0 < 1 0 < ω0 < 1 
1 p1 ω1 = 1 ω1 = 1 ω1 = 1 ω1 = 1 
2a 
(1-p0-p1)p0 
/(p0+p1) 
0 < ω0 < 1 ω2 ≥ 1 0 < ω0 < 1 ω2 = 1 
2b 
(1-p0-p1)p1 
/(p0+p1) 
ω1 = 1 ω2 ≥ 1 ω1 = 1 ω2 = 1 
 
 
1.6 GENOME SCANS FOR POSITIVE SELECTION 
The developments of the branch, site and branch-site models have facilitated the 
evolutionary analyses of many genes in numerous species. Genome-wide 
analyses to look for positive selection can provide great insights into the 
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underlying factors that contribute to biological differences between species. The 
action of positive selection pressure during orthologue evolution is indicative of 
divergence of gene function between species (Yang and Bielawski, 2000). 
Therefore researchers have been interested in comparing human genes with their 
close mammalian relatives to discover genes that have been subjected to positive 
selection during mammalian evolution.  
Another interesting aspect is the relationship between selective pressures 
affecting gene evolution and the genes involved in disease processes. Enrichment 
of positive selection signals in disease genes may be due to adaptive changes in 
response to the environment of early hominids which are maladaptive in the 
dramatically different conditions we live in today (Young et al., 2005). Another 
reason for positively selected disease genes is that perhaps highly derived 
functions that have developed since the separation of chimpanzees and humans 
cause higher rates of disease than functions that have been subject to purifying 
selection for millions of years. This poses questions such as whether humans are 
more susceptible to psychiatric disease than other animals due to our 
specialisation for higher cognitive function (Keller and Miller, 2006). 
 
1.6.1 Mammalian genome sequences 
The availability of genome sequences have made feasible large scale analyses 
such as genome scans for positively selected genes. Since the advent of whole 
genome shotgun sequencing and advances in BAC-based sequencing, the 
complete sequence for the human genome has become available along with 
increasing numbers of genomes of model organisms. The availability of 
sequence information from various organisms makes it possible to compare 
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precise nucleotide differences between genes to infer the number and types of 
changes that have occurred since they last shared a common ancestor (Miller et 
al., 2004). The comparative genomics study in this thesis compares human with 
four other mammalian species, mouse, rat, chimpanzee and dog, as they are 
common models for human disease studies and as complete, good quality 
genome sequences were available for these species.  
The more similar the genomes under comparison (for example, human and 
chimpanzee are thought to have separated 6 million years ago), the more fitting 
they are for finding major sequence differences that could account for differences 
between species (Hardison, 2003). Only homologous genes can be compared in 
this manner. In the four species selected for this study, over 80% of the protein-
coding genes have clear 1:1 orthologues in human (Table 1.3).  
 
Table 1.3 Numbers of genes and orthologues of human present in the 
species analysed in this study 
Genome 
Known and novel protein-
coding genes* 
Number of 1:1 
orthologues of human* 
Human 22740 - 
Chimp 20543 18133 
Rat 22503 13912 
Mouse 23493 15048 
Dog 19305 14700 
Note: *Data obtained from Ensembl (May 2008) 
 
 
1.6.2 Detection of adaptive evolution: a historical perspective 
Even prior to the availability of whole genome data, biologists have been 
interested in comparing the evolutionary parameters of protein-coding genes. A 
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very early study by Makalowski and Boguski (1998) defined 1880 unique 
human/rodent orthologue pairs using a phylogenetic approach. They found a 
strong relationship between substitution rates and the coding status of DNA, 
showing that non-coding sequences evolve approximately five times faster than 
coding sequences. 
 Since the availability of large scale genomic data many studies of 
evolution have been conducted. Here I provide a summary of some of the key 
studies in chronological order. Following the publication of the human and 
mouse genomes, Clark et al. (2003) conducted an in-depth analysis of 7645 
orthologues from human, chimpanzee and mouse. The authors categorized genes 
and pathways along the human lineage which had undergone positive selection. 
More importantly, when differences existed between human and chimpanzee, 
comparison with the mouse sequence allowed the inference of the primate 
ancestral state. Using maximum likelihood methods they tested their gene set 
with the branch-site models (Yang and Nielsen, 2002) and detected 125 human 
genes evolving with ω > 1 (p < 0.01).  
Certain functional classes of proteins had significant evidence of positive 
selection along the human lineage, including olfactory receptors and associated 
genes and genes involved in processes such as amino acid catabolism, 
developmental processes, reproduction, neurogenesis and hearing. The excess of 
positively selected genes (PSGs) in such functional categories are thought to be 
the result of the differing dietary habits and skeletal development of humans 
compared with chimpanzees. Genes associated with speech such as the FOXP2 
transcription factor, and hearing development were found to be subject to 
positive selection, consistent with the fact that speech is a human-specific 
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characteristic (White et al., 2006). Interestingly, they also found an over-
representation of PSGs within the Online Mendelian Inheritance in Man 
(OMIM), a repository of genes associated with human disease 
(www.ncbi.nlm.nih.gov/omim). One possible conclusion from this result is that 
genomic differences in humans (in comparison with our primate relatives) are 
associated with human specific diseases.  
 To investigate the hypothesis that there may be a relationship between 
disease genes and human diseases, Smith and Eyre-Walker (2003) compared 387 
human-rodent alignments for disease genes (defined as genes with mutations 
known to cause human disease) with 2,024 human-rodent alignments for non-
disease genes. They found that higher dN/dS ratios were detected for disease 
genes (p < 0.001) suggesting disease genes are either under weaker purifying 
selection compared to non-disease genes, or are often subject to positive 
selection.   
 Huang et al. (2004) also studied human-rodent alignments but found 
dN/dS ratios for their 844 disease genes were only modestly higher than those of 
non-disease genes (p = 0.035). They also found that genes implicated in different 
diseases had different evolutionary characteristics; in particular, genes involved 
in neurological disease were well conserved between primates and tend to exhibit 
low dN/dS ratios. However as this analysis was performed using pairwise 
counting methods and dN/dS ratios were estimated across the entire length of the 
coding sequence, it is possible that any positive selection on a subset of residues 
within the gene would not be detected as the signal would be swamped by the 
purifying selection acting on the majority of residues.   
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 Another study by Bustamante et al. (2005) also found that human genes 
subject to positive Darwinian selection, as a result of the McDonald-Kreitman 
test (McDonald and Kreitman, 1991), were over-represented in OMIM. Their 
study tested 11,624 loci and found 304 to be positively selected, many of which 
were involved in apoptosis, gametogenesis and immunity-defence. 
The availability of the chimpanzee genome sequence in 2005 (CSAC, 
2005) finally allowed DNA sequence comparisons with our closest relative. The 
analysis by the Chimpanzee Sequencing and Analysis Consortium (CSAC) of 
7,043 quartet orthologues found no significant difference in the mutation rates of 
disease genes in the human and chimpanzee lineages. Their functional analysis 
using GO categories revealed a wide range of processes including intracellular 
signaling, metabolism, neurogenesis and synaptic transmission, which were 
under strong purifying selection. They also found that the omega values of each 
of the GO categories that showed an over-representation of adaptive genes were 
highly correlated between hominid and murid orthologue pairs, suggesting that 
the positive selection acting on particular functional categories has been largely 
similar in hominid and murid evolution. The chimpanzee genome sequence 
(CSAC, 2005) also allowed the estimation of  the genome-wide nucleotide 
divergence between the human and chimpanzee genomes to be 1.23%, with the 
proportion of divergent sites to be less than 1.06%. This means that a small 
proportion of sites identified as being under positive selection can potentially be 
a polymorphic site in either genome.  
 Nielsen et al. (2005) investigated 8079 human-chimpanzee alignments. 
The outcome of a LRT using the branch models was 35 genes (p < 0.05) for 
which the null hypothesis (ω = 1) was rejected. This study also used the 
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PANTHER database (Thomas et al., 2003) to identify functional groups of genes 
that showed an over-representation of positively selected genes. Again groups 
that had the most candidates for positive selection were involved in immune-
defence and sensory perception. Genes involved in apoptosis and 
spermatogenesis were also under positive selection, probably due to genomic 
conflict caused by the natural process of elimination of germ cells by apoptosis 
during spermatogenesis. Cancer-related genes that function in tumour 
suppression, apoptosis and cell cycle control also had strong evidence for 
positive selection. An investigation of gene expression patterns for genes under 
positive selection found that genes maximally expressed in the brain showed 
little or no evidence of positive selection. In contrast, genes with maximal 
expression in the testis were enriched with positively selected genes. They also 
found that genes on the X chromosome also had an increased tendency to be 
under positive selection.  
 In an attempt to differentiate between positive selection and relaxed 
selective constraint, Arbiza et al. (2006) performed lineage-specific tests on the 
human, chimp and hominid branches of the phylogeny. They compared 9,674 
human, chimpanzee, mouse, rat and dog orthologues using the branch-site 
methods (Zhang et al., 2005). Using both Test 1 and Test II, they could 
distinguish between cases of positive selection as opposed to cases of relaxed 
selection constraint. The more stringent Test II generated 108 and 577 PSGs in 
the human and chimpanzee lineages respectively. These numbers are after 
correction for multiple testing, which was employed for all comparisons unlike 
other studies which only applied correction in some cases. Interestingly, the same 
sets of biological functions were over-represented by human and chimpanzee 
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PSGs but not due to an overlap of genes. GO terms such as G-protein coupled 
receptor (GPCR), sensory perception, electron transport, integrin-mediated 
signalling pathway and inflammatory response were augmented by human PSGs. 
Genes that were exclusively in Test I and not in Test II are likely cases of relaxed 
selective constraint (122 in human, 245 in chimpanzee and 287 hominid genes). 
Again G-protein coupled receptors were increased in representation in both the 
human and chimp lineages, which suggests that the process of relaxed selective 
constraint in G-protein coupled receptors occurred in both species. 
 From the above studies, it seems that some functional categories are 
consistently found enriched for positive selection. However, an analysis of 
10,376 human-chimpanzee-rhesus alignments by the Rhesus Macaque Genome 
Sequencing Consortium (Gibbs et al., 2007) found new categories such as iron 
ion binding and oxidoreductase activity which are encoded by keratin proteins to 
be enriched among human PSGs. These genes were proposed to have come 
under selection due to climate change or mate selection. The finding of new 
functional classes enhanced for PSGs perhaps indicates that the use of more 
primate species has the potential to uncover human specific neo-functionalisation 
in genes.  
 With this is mind, more recently, Bakewell et al. (2007) used the 
macaque sequence to root 13,888 human and chimpanzee orthologous pairs and 
investigated the evolution of disease genes since the separation of humans and 
chimpanzees. They found 9.7% of genes that are positively selected on the 
human lineage are represented in OMIM compared with 6.1% for the 
chimpanzee lineage. Therefore there seems to be evidence that disease-causing 
genes have been prone to positive selection pressure during human evolution.  
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1.6.3 Functional classification of positively selected genes 
Genome scans for selection pressure have attempted to identify molecular 
functions that are enriched for positively selected genes using the public domain 
Gene Ontology (Gene Ontology Consortium, 2008) or the PANTHER ontology 
(Thomas et al., 2003). The classes highlighted by seven recent reports are 
summarised in Holbrook and Sanseau (2007). Although all the studies used 
slightly different comparisons and methodologies, it can be seen that there is 
some consensus among the broad ontological categories identified as enriched 
for positively selected genes in human evolution, namely: defence/immunity, 
signal transduction, reproduction, apoptosis, nucleotide metabolism, sensory 
perception, transcription, subcellular transport, cellular structure, metabolism and 
development. It is not surprising that genes involved in immune defence are 
repeatedly identified as evolving by positive selection as the speed at which 
pathogens evolve has resulted in a co-evolutionary arms race between host cells 
and pathogens (e.g. MHC molecules).   
 All these studies have potentially high false positive error rate associated 
with the results, due to the difficulties of identifying orthologues and aligning 
sequences in a high throughput manner as well as the reliability of the positive 
selection detection methodologies. Also, analyses using genomic sequence 
encounter extra methodological problems, as predicting open reading frames is 
performed in an automated manner. Errors in any of these processes can impair 
the accurate detection of positive selection pressure. Despite these computational 
difficulties it is remarkable that most genome scans have found similar functional 
categories enriched for adaptive human genes. 
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1.6.4 Studies of functionally related genes 
Some analyses for positive selection focused on specific groups of genes. One 
such study was by Dorus et al. (2004) who selected 214 genes to cover nervous 
system biology as broadly as possible. On average these genes had substantially 
higher dN/dS ratios in primates than rodents (p < 0.0001) suggesting adaptive 
evolution in primates. Sub-classification of these genes showed that ones 
involved in nervous system development had a greater dN/dS disparity between 
primates (humans and macaques) and rodents (mice and rats) compared with 
house-keeping genes.  
Yu et al. (2006) performed an analysis on 2633 human genes with 
maximal expression in the brain, and gave evidence for the rhesus macaque as a 
better outgroup than mouse in identifying human selection. They identified 47 
candidate genes showing strong evidence of positive selection in the human 
lineage.  
Another study on a specific set of genes was performed on genes related 
to skin (Izagirre et al., 2006). Analyses for positive selection in 81 candidate loci 
for skin pigmentation using both population and phylogenetic methods found two 
genes, MYO7A and PGR as being under positive selection.  
 
1.7  WHY SELECTION PRESSURE MATTERS TO DRUG 
DISCOVERY 
The discovery of new drugs to treat human diseases is a difficult business with 
very low success rates. One reason for this is the transition from pre-clinical 
R&D to clinical trials in humans is reliant on successfully translating 
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experimental results in model organisms such as mice, rats, non-human primates 
and dogs, to humans. Animal models are used during the phases of target 
selection and validation (Pravenec and Kurtz, 2007), drug efficacy studies (Priest 
and Kaczorowski, 2007) and drug safety studies (Valentin et al., 2005). One of 
the major causes of the observed high levels of attrition in R&D pipelines is lack 
of human efficacy and safety since animal models of efficacy are notoriously 
unpredictive (Kola and Landis, 2004). The two therapeutic areas with very high 
attrition rates, oncology and the central nervous system, are also the areas in 
which animal models are often not predictive of true human pathophysiology. 
Difficulties lie in determining the different susceptibilities of various diseases in 
animal models, especially in studies of higher cognitive abilities. For example, 
some aspects of aging in humans (Alzheimer’s disease) do not develop naturally 
in nonhuman primates or do not follow the same course of natural development 
in monkeys (menopause), therefore it is necessary to use experimental models of 
these conditions for study. However, difficulties in the interpretation of animal 
experiments to predict human drug response can also be caused by biomedical 
differences between humans and model species in the biology of the drug target 
or proteins interacting with the drug target or in drug metabolism. On the 
molecular level, the complete absence of an evolutionary orthologue of the 
human drug target in a model species is an extreme example of this difficulty 
(Norgren, 2004; Holbrook and Sanseau, 2007). However a more likely cause is 
variations in drug target function between species as a result of positive selection 
acting on the gene in one of the species. Studying the evolutionary history of the 
genes encoding drug targets could help elucidate species differences prior to 
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choosing animal models for pre-clinical tests and allow better interpretation of 
experimental results from model species. 
 
1.8 PROJECT AIMS 
This thesis describes a comparative genomics project which applies maximum 
likelihood models of DNA sequence evolution to detect episodic periods of 
evolution along the human lineage and lineages of model organisms. This 
information can be used to identify the biological processes that have been 
subject to adaptive evolution in the species under investigation. I also explore 
whether genes under positive selection show significant associations with human 
disease. Detection of selective pressures which indicate functional shifts are also 
important in the pharmaceutical industry for establishing species differences that 
affect drug-discovery assays and the choice of animal models.  
 The study begins with the identification of strict 1:1 orthologues to 
human in the four mammalian species: chimpanzee, mouse, rat and dog. The 
resulting 3079 high-quality gene sets were scanned for positive selection signals 
during mammalian evolution comparing the five species together. In contrast to 
previous studies which have tended to focus on human evolution, the objective of 
this study was to determine genes which have undergone adaptive evolution in 
both humans and animal models. Chapter 2 describes the orthologue 
identification and alignment pipeline and use of the branch-site model to test all 
extent and ancestral lineages on the species phylogeny for evidence of positive 
selection.  
 Functional classes such as nucleic acid metabolism, neuronal activities, 
and immunity and defence were found to be the most enriched by primate genes 
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under positive selection, as explained in Chapter 3. I also provide evidence to 
support the hypothesis that genes under positive selection tend to interact more 
with each other than other genes.  
 The chimpanzee lineage was found to have more genes under positive 
selection than any of the other lineages. In Chapter 4, I show that positive 
selection in these genes is unique to the chimpanzee lineage, explore the effects 
of taxon sampling on the detection of positive selection and finally offer some 
hypotheses for the high number of divergent chimpanzee genes. 
 Chapter 5 illustrates how genes that have been subject to positive 
selection pressure during human evolution are implicated in diseases which have 
uniquely human pathogenic mechanisms. Epithelial cancers, schizophrenia, 
autoimmune diseases and Alzheimer’s disease are some diseases which differ in 
incidence or severity between humans and apes (Olson and Varki, 2003; Varki 
and Altheide, 2005). Biomedical differences between species could be due to 
functional shifts in gene involved in the molecular mechanisms of the disease 
and hence can be attributed to positively selected genes.  
Further work, covered in Chapter 6, explores selection pressure in 
transcription factors, such as nuclear receptors. An in-depth analysis of the 48 
human nuclear receptors and their mammalian orthologues using the site and 
branch-site models, demonstrates the variation of selection in functionally 
distinct regions of these genes. 
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The processes described in this chapter form the data sources and analyses for 
results described in Chapters 3, 4 and 5. Additional methods specific to a single 
chapter are described within that chapter. Methods pertaining to Chapter 6 are at 
the beginning of that chapter. 
 
The Bioinformatics groups at GSK designed and carried out some of the 
procedures described in this chapter. Simon Topp, Vinod Kumar, Mike Word 
and Mark Simmons designed and analysed the data collection processes and 
orthologue calling pipeline described in Sections 2.1 – 2.3. Samiul Hasan wrote 
the Perl programs and carried out the data analysis in Sections 2.6 and 2.8. Dilip 
Rajagoplan designed the co-evolution experiments in Section 2.12. 
 
2.1 SOURCES OF DATA FOR HUMAN AND MODEL SPECIES 
GENES 
The study of positive selection in orthologous genes is wholly dependent on 
careful collation of true orthologues of human in the species selected for analysis 
and their alignment. Human genes from NCBI Entrez Gene (accessed in 
September 2006) (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene) that had 
been annotated as protein coding and had an identified DNA transcript were 
selected for evaluation. The DNA transcripts and corresponding peptides were 
downloaded from GenBank (http://www.ncbi.nlm.nih.gov/Genbank/), RefSeq 
(http://www.ncbi.nlm.nih.gov/RefSeq/) and Ensembl (http://www.ensembl.org/) 
with the exception of RefSeq predicted transcripts and peptides (commonly 
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recognised by accession numbers prefixed by XM and XP), which were excluded 
from the analysis pipeline due to the potential for poor quality gene prediction.  
To produce a non-redundant list of peptides, the peptide sequence files for each 
locus were clustered based on identity and length via the blastclust program 
(blastclust -i sequence_file -p T -L 1 -b T -S 100) 
(http://www.ncbi.nlm.nih.gov/). For each cluster, DNA sequences were 
generated using the longest open reading frame of the longest peptide in each 
cluster. The transcript sequences were then named MELgeneID_clusterID where 
geneID was the EntrezGene ID and clusterID was the cluster number from the 
peptide cluster analysis. The mRNA and genomic sequences for the four model 
organisms (chimpanzee, mouse, rat and dog) and chicken (outgroup) were 
extracted from GenBank (accessed September 2006). 
 
2.2 ORTHOLOGUE CALLING PIPELINE 
The primary method employed to find orthologues is to establish homology 
using reciprocal tBlastx searches (Altschul et al., 1990) as this approach is 
known to be conservative. The premise of using this method is if two sequences 
within the two genomes are orthologues, the BLAST hit between the two 
sequences should have a lower p value from BLAST than to an outparalogue. 
Although the reciprocal BLAST hit method to find orthologues is not a 
phylogenetic method, it is less computationally intensive and is suitable to find 
1:1 orthologues. The tBlastx parameters used in the orthologue detection pipeline 
between the human and model organism sequence databases were B=50 V=50 
W=3 E=0.01 topcomboN=2 wordmask=xnu+seg maskextra=6 Z=3000000000 
progress=0 warnings cpus=1 matrix=blosum62 Q=30 R=2 and ctxfactor=36.0. 
 53 
The sequence representing each human gene cluster was used as the seed query 
to account for alternatively spliced variants. Reciprocal best hits between the 
starting human gene and model organism gene were marked as the main 
orthologue pair for that human transcript query. Each cluster was  Blast searches 
of human sequences against species databases that resulted in genomic sequence 
were processed further. Genewise (Birney et al., 2004) was used to identify a 
predicted cDNA using the human peptide as a template. The genomic sequences 
were masked for interspersed repeats and low complexity regions prior to 
analysis by Genewise, to increase specificity and improve gene predictions. The 
resulting cDNA sequence was then used as a query in the reciprocal tBlastX 
search against the human database. Highest scoring mRNA sequences were 
submitted to the reciprocal tBlastX search without modification. 
 Finding orthologues by reciprocal BLAST can result in erroneous pairs if 
genes have been modified by domain-shuffling and other forms of horizontal 
transfer. tBlastx versus genomic sequence is also susceptible to finding 
pseudogenes. To make orthology assignment more conservative, a human gene 
and a model organism gene were marked as the orthologue pair only if the 
negative log of the p value of the best hit of the human sequence against the 
model organism database was higher than 95% of the negative log of the p value 
of the best hit from the reciprocal step.  
 Incomplete genome sequencing will also contribute to error in orthologue 
calling. Reciprocal blasting is invalidated as a method for calling orthologues in 
these circumstances, as the absence of the true orthologue would cause a more 
divergent paralogue to be the top hit. To address this problem, a cut-off was 
added which required the p value of the putative orthologue for that species to be 
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less than that of the chicken orthologue for that gene. The chicken was chosen 
for two reasons: the complete draft genome sequence was available (International  
Chicken Genome Sequencing Consortium, 2004) at sufficient coverage, and a 
non-mammalian species was required to serve as an outgroup for the mammalian 
orthologue calls. For the 392 human genes for which a chicken orthologue was 
not found, the model species orthologues were kept and labelled as lower 
confidence orthologues.  
 The last three nucleotides were removed for any sequences terminating in 
a stop codon. All putative orthologue sequences were assessed for the optimal 
ORF, using the human sequence as a template. The human sequence contained 
only the CDS and hence was translated from nucleotide one. Each orthologue 
sequence was translated in the three forward frames. From each translation, 
every peptide sequence between stop codons (or between stop codons and the 
sequence termini) was assessed for length. If the sequence was less than 50% of 
the length of the human protein, the peptide was excluded. Sequences meeting 
the length cut-off were aligned to the human protein using the EmBoss ‘Needle’ 
Needleman-Wunsch (Rice et al., 2000) algorithm. The peptide with the highest-
scoring alignment was deemed to be the most appropriate ORF, and the encoding 
nucleotides were written to the output. If no peptides in any frame met the length 
criteria, the orthologue sequence was excluded from the output. All sequences 
resulting from the orthologue calling process were exported as fasta files labelled 
with the original accession number, the species name, and the human gene used 
as the starting query. 
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2.3 ALIGNMENT AND PAML INPUT FILES 
The resulting nucleotide sequences were aligned using the SIM-based codon-
centric algorithm implemented in SwissPDBviewer/Promod (Guex and Peitsch, 
1997). A custom version was used that included support for trimming unaligned 
N- and C-termini, searching for the initial Methionine (within the first 60 
residues and conserved in at least 50% of sequences), and alignment scoring 
based on a combined amino-acid matrix (Blosum70) plus codon identity penalty 
score, with gap=6 and gap_extension=4. Alignments were read out in PAML 
format. Unrooted tree files for each alignment were created using a standard 
mammalian species tree (Murphy et al, 2001) (Figure 2.1). 
 
Figure 2.1   Unrooted five-species tree used in branch-site analyses 
 
 
 
 
2.4 BRANCH-SITE ANALYSES 
2.4.1 Branch-site model 
The branch-site model (Yang and Nielsen, 2002; Zhang et al., 2005) 
implemented in the codeml program from the PAML package (Yang, 1997) was 
used to test for positive selection. Each of the seven branches on the species 
Human 
Chimpanzee 
Dog 
Rat 
Mouse 
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phylogeny was tested, treating each in turn as the foreground branch, with all the 
other branches specified as background branches. Each branch-site model was 
run three times. Since the model can have local maxima, the requirement was 
that at least two of three replicate runs of each model should converge at or 
within 0.001 of the same log-likelihood value for convergence to be established. 
Runs that did not converge were indicative of problems with the data and were 
re-done until convergence was obtained or else reported as a convergence 
problem.   
 
2.4.2 Optimisation of branch-site model parameters 
To determine the values of branch lengths for the subsequent branch-site model 
run, the M0 model was run on all of the data sets. The M0 model assumes the 
same dN/dS ratio for all branches in the tree and among all codon sites in the gene
 
(Goldman and Yang, 1994). To reduce complexity and computational time, 
branch lengths estimated by the M0 model were used as fixed values for the 
branch-site model (fix_blength = 2), as opposed to using them as initial values 
for the branch-site model (fix_blength = 1) (Yang, 2000). Two runs of the M0 
model were performed on each alignment to check that values for log-likelihood, 
κ and branch lengths were consistent between the two runs. Runs that were not 
consistent were repeated until the values converged.  
 281 alignments were used to investigate the effects of fixing branch 
lengths on the other parameter estimates. The number of genes that had a signal 
for positive selection (p < 0.05) decreased when branch lengths and the 
transition/transversion ratio (κ) were fixed (Table 2.1). Other parameters such as 
proportions of sites under different selection categories, background-ω and 
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foreground-ω remained consistent between the two analyses. The overall run 
times reduced by two-thirds as fixing the branch lengths reduced the number of 
parameters to estimate from 12 to 5. Fixing branch lengths therefore makes the 
branch-site test more conservative and should improve convergence problems. 
 
Table 2.1 Numbers of positively selected genes when branch lengths and  
κ were fixed and free to be estimated 
 No of PSGs (free parameters) No of PSGs (fixed parameters) 
 p<0.05 p<0.01 p<0.05 p<0.01 
Human  6 3 5 2 
Chimpanzee 106 106 107 106 
Hominid 3 2 1 0 
Mouse 18 15 15 11 
Rat 37 30 28 23 
Murid 21 10 6 2 
Dog 40 33 26 20 
 
 
2.4.3 Multiple hypothesis testing correction  
Likelihood-ratio tests were performed with the Bonferroni correction for multiple 
testing (Anisimova and Yang, 2007). If n hypotheses are tested on a set of data, 
the Bonferroni correction raises the statistical significance level by 1/n times 
what the significance level would be if only one hypothesis was being tested. 
Prior to correction, the critical values at p values of 0.05, 0.01 and 0.001 and 1 
degree of freedom for a chi-square distribution were 3.84, 6.63 and 10.83, 
respectively. After correction for seven tests, the critical values were raised to 
6.63, 10.55 and 13.83.  
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Perl programs were written to analyse and perform calculations on the 3079 
alignments in an automated manner. Descriptions of some of the major scripts 
can be found in Appendix 1.  
 
2.5 UPDATING ALIGNMENTS 
The initial analysis with the branch-site models resulted in a larger number of 
chimpanzee genes to be detected under positive selection than human (result set 
A) (see Section 3.2.1). Many of the positively selected chimpanzee genes were 
thought to be false positives. An investigation into the resulting branch lengths 
and manual inspection of alignments uncovered data problems with many 
sequences that had been designated as orthologues having single base deletions 
or substitutions when compared to the ‘golden path’ genomic sequence data in 
the UCSC Genome databases (http://genome.ucsc.edu/cgi-bin/hgGateway). Since 
the inception of this study, several updates to the NCBI genome databases had 
made the data used in this initial analysis out of date. In addition, a major update 
to the chimpanzee genome sequence increased the coverage from 4x (September 
2005) to 6x (March 2006), subsequently increasing sequence quality as well.  
 To select which sequences were outdated and were to be replaced, for 
each gene, the sequences in the current alignments were aligned against the 
species-specific mRNA RefSeq sequences using fasta34 (fasta34 –q –H –d 1 –b 
1 query library > results.txt’, where -H = no histogram, -b = best scores, -d = 
number of best alignments and -q = quiet and library = protein file e.g. 
chimpRefSeqGenes.txt) (Pearson, 2004). RefSeq sequences were chosen as 
opposed to Ensembl or UCSC mRNA libraries as they were the most updated 
sequences at the time. mRNA and protein library sequences were downloaded 
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from ftp://ftp:ncbi.nih.gov/genomes/H_sapiens/rna and 
ftp://ftp:ncbi.nih.gov/genomes/H_sapiens/protein  
The percentages of genes for each species that matched exactly to its RefSeq 
counterpart or had 90% identity are shown in Table 2.2.  
 
Table 2.2 Percentages of sequences from each species that matched its 
RefSeq counterpart 
Species 
RefSeq 
library size 
(no. of 
sequences) 
RefSeq library 
creation date 
Percentage of 
sequences with 100% 
identity to RefSeq 
Percentage of 
sequences with 
greater than 90% 
identity to RefSeq 
human 34180 05/09/2006 82.83 98.96 
chimpanzee 51947 25/09/2006 45.65 81.08 
dog 33651 01/09/2006 60.37 87.92 
mouse 46892 04/05/2006 80.82 98.48 
rat 36496 10/07/2006 78.55 94.31 
 
 
Sequences in the current alignments which had less than 100% identity and 
greater than 80% identity were replaced by their RefSeq equivalent and new 
protein alignments were created using Muscle (Edgar, 2004). Alignments that did 
not have any sequences replaced were also aligned with Muscle (muscle –in 
seqs.fasta –out seqs.fa.musc) to ensure consistency. Protein alignments were then 
converted to their corresponding DNA alignments and the ends trimmed to 
remove single sequence areas. Alignments were checked using a simple 
alignment scorer which assigns a mismatch score to each sequence in the 
alignment. The mismatch score is the number of bases in a sequence which do 
not match to any other base in the alignment slice, expressed as a percentage of 
the length of the sequence (not the length of the alignment). The higher the 
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mismatch score, the more problematic the sequence is in the alignment. RefSeq 
substituted sequences that made the mismatch score worse were reverted back to 
the original sequence.  
Chimpanzee and dog sequences which had a 100% match to a RefSeq 
sequence but still had a high percentage of mismatches in the alignment were 
updated with new gene predictions using updated versions of their respective 
genome sequences. 214 chimpanzee and 445 dog sequences were re-predicted by 
the same method described in Section 2.2.  
  
2.6 FRAMESHIFT CORRECTION 
It was noted that some model species sequences had frameshifts when compared 
to their human orthologue due to missing or additional bases possibly from 
sequencing errors. Nucleotide codon alignments were scanned for potential 
frameshift mutations using a frameshift correction script. All alignments were 
corrected for frameshifts in the sequences from the model organisms relative to 
human. Starting from the first position in the nucleotide alignment, an insert was 
placed at every position till the end of the sequence to create the new translated 
amino acid alignment. If sequence identity in the next 5 amino acid sites (relative 
to insert) improved over the current alignment, the modified nucleotide sequence 
replaced the original sequence in the alignment. 400 alignments were corrected 
by this method. 
 
2.7 G-BLOCKS CORRECTION 
The program G-blocks (Castresana, 2000) was used to examine alignments for 
regions of high divergence. This program masks regions in the alignment that are 
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poorly aligned and returns the remaining alignment. Alignments were scanned 
and categorised into two classes:  
Class A - returns more than ~70% of whole alignment  
Class B - returns less than ~70% of whole alignment.  
35 alignments were returned in class B. These were manually inspected and 
when alignment quality was high enough for these alignments to be deemed 
useable for the branch-site analysis. The branch-site models were re-run on the 
new alignments to generate result set B.  
When result set B, the product of the procedures described above, was 
examined closely some alignments had areas of ambiguous alignment or areas 
where sequences did not appear orthologous. A number of positively selected 
genes in all the tested lineages had many consecutive sites being reported by the 
Bayes Empirical Bayes method as having a high probability of being under 
positive selection. Upon closer inspection, it seemed that these sites 
corresponded to regions that were either misaligned or were non-orthologous. 
Therefore the data were subjected to further manual corrections detailed below. 
    
2.8 LOW SIMILARITY SEQUENCE MASKING  
To correct for regions of low similarity, all alignments were scanned to mask out 
parts of a sequence where more than 3 consecutive codons in that sequence were 
different to the other sequences in the alignment and these codons were flanked 
by gaps on one or both sides. These regions were then masked by Ns and the 
branch-site analysis re-run on the entire dataset.  
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2.9 MANUAL CURATION OF ALIGNMENTS 
After re-running PAML on the entire dataset, the alignments were manually 
examined for all significant results at p < 0.05. A result was discarded if the gene 
sequence belonging to the lineage that was identified as being under positive 
selection had a frameshift or was ambiguously aligned. We also manually 
examined alignments in which the chimpanzee branch length was higher than 1 
substitution per site (codon). A result was discarded if the gene sequence 
belonging to the lineage that was identified as being under positive selection had 
a frameshift, had many gaps or was misaligned. The set of significant genes 
remaining was termed result set C. Genes under positive selection along the 
hominid and murid lineages were not manually curated as a positive result in the 
hominid lineages arises if the human and chimpanzee sequences are similar to 
each other and different to the other sequences. Similarly, a positive result in the 
murid lineage arises if the mouse and rat sequences are the same and different to 
the other sequences. If an alignment had some sections which had good 
homology and also had sites under positive selection and other that looked 
misaligned, then the result for this alignment was not discarded because the gene 
would still come up as being under positive selection even if the misaligned area 
was corrected.  
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2.10 PHRED QUALITY VALUES OF CHIMPANZEE 
POSITIVELY SELECTED GENES 
As a further precaution, the quality values of the sequences for chimpanzee genes 
under positive selection were also checked. The 162 sequences in result set C 
were aligned against the dataset of chimpanzee chromosome sequences using 
BLAT to obtain their genome coordinates. Four of these (MEL640, MEL677, 
MEL9636 and MEL81099) had a few missing bases and did not produce a 
BLAT result with 100% identity. The alignments of these four genes were 
manually examined and the missing bases had resulted in incorrect amino acids 
which then caused significance to be inferred incorrectly. Of the sequences that 
generated a BLAT result with 100% identity, the quality values corresponding to 
the genome coordinates were obtained. Only 1 of these (MEL51368) had phred 
quality values less than 20 among the bases inferred to be under positive 
selection. The results for these five genes were discarded.  
 
2.11 CALCULATING RATE DIFFERENCES 
To calculate ω for each branch of the species phylogeny, the free-ratio model in 
the codeml program was run on each alignment. The median value was chosen as 
the representative value for that branch after exclusion of maximal values (999) 
of ω. The free-ratio model was also run on the concatenated set of alignments, 
after removal of sites with ambiguity gaps and alignment gaps, which left 81% of 
the concatenated alignment.    
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2.12 ANALYSIS OF INTERACTION DATA 
2.12.1  Interaction Data 
A network consisting of protein-protein interactions such as binding and 
phosphorylation, transcriptional control and post-translational modification was 
used to search if genes under positive selection from this study interact together 
significantly. Interaction data in the network was licensed from several 
commercial vendors including Ingenuity (www.ingenuity.com), Jubilant 
(www.jubilantbiosys.com), GeneGO (www.genego.com), NetPro 
(www.molecularconnections.com) and HPRD (www.hprd.org). Data from these 
products  is obtained from literature-derived information describing interactions 
of various kinds (binding, regulation, metabolic etc) between pairs of genes. In 
addition, high-quality, automatically extracted interactions licensed from the 
PRIME database (Koike and Takagi, 2005) were also included in the network. 
Interactions associated with transcriptional regulation were obtained from 
experimentally validated protein-DNA binding relationships licensed from the 
TransFac (Matys et al., 2003) and TRRD (Kolchanov et al., 2002) databases. No 
distinction is made between DNA, RNA and protein for a particular gene, and all 
three are represented as a single node in the network. Integrating data from all 
these sources that describe direct interactions between genes results in a network 
with 98, 095 unique interactions (edges) among 14781 genes and metabolites 
(nodes), of which 1035 are metabolites and the rest are genes.  
 
2.12.2  Biological clustering algorithm  
Searches of gene lists that resulted in a biological sub-network were conducted 
and scored as in Rajagopalan et al. (2005). Gene lists of PSGs from each lineage 
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and the associated p value (after Bonferroni correction) was used as the input 
dataset. A similarity metric of the square of the Pearson correlation coefficient 
was calculated for all pairs of genes in the input dataset. The list of all pairs of 
genes is then filtered using 0.81 as a cutoff to generate a set of significant pairs 
of genes (set S). Pairs of genes in set S that are not supported by the interaction 
network are removed from set S. If the pairs of genes being considered are 
neighbours on the interaction network or have one intermediate network node 
that is a metabolite, the pair is preserved.  
 A simple greedy search algorithm is then applied to set S to form clusters 
of genes. The process starts with the best remaining pairs of genes, as measured 
by the correlation coefficient. All genes that are connected to either of these first 
two genes via an edge in set S are added to the cluster. Next genes that are in set 
S that are connected to genes already in the cluster are added to the cluster. The 
process continues successively until no more genes can be added to the cluster. A 
new cluster is started based on the best remaining pair in S.  Clusters are then 
merged together if two clusters are separated by a node on the interaction 
network that is not contained in any cluster but  the node is adjacent to a node in 
each of the two clusters. The resulting clusters of genes are PSGs from the 
lineage being analysed and are also connected together by prior biological 
knowledge.  
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3.1 INTRODUCTION 
Direct comparisons of human genomic and transcriptomic information to that of 
other species reveal three major types of molecular genetic changes which have 
contributed to species differences. The most obvious mode is the presence or 
absence of genes in different species, including gene duplication and gene 
inactivation. Much attention has been paid to genes that are unique to humans or 
lost in the human lineage (Olson and Varki, 2003; CSAC, 2005; Varki and 
Altheide, 2005; Kehrer-Sawatzki and Cooper, 2007). However these probably 
represent the ‘tip of the iceberg’ of human genomic differences compared to 
other species. The second class of molecular genetic changes consists of 
nucleotide substitutions that may cause functional changes in both protein coding 
and non-coding RNAs. The third category of molecular changes consists of 
variations in the levels of gene expression between species and in the 
mechanisms regulating gene expression (Gilad et al., 2006; Kehrer-Sawatzki and 
Cooper, 2007). 
 In this study we investigate the second type of molecular differences and 
focus on coding changes in protein-coding orthologous genes. An estimated 70% 
to 80% of orthologous protein sequences are distinct between humans and 
chimpanzees (CSAC, 2005; Glazko et al., 2005). However, a substantial 
proportion of differences may have no functional impact on human-specific 
diseases. Positive selection analyses can determine which nucleotide changes 
contribute to biological differences between species. This follows from the 
premise that the action of positive selection pressure in orthologous genes during 
evolution is indicative of divergence of gene function between species (Yang, 
2005). Determining such genes on the human lineage is thus a rational and 
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promising way to reveal the molecular changes implicated in human-specific 
diseases.  
 Our initial dataset was aggressively filtered to eliminate paralogous 
alignments, spurious annotations, pseudogenes in one or more species, and poor 
exon prediction. Hence only quintets for which we could assign orthology with 
high confidence were used in our analysis for positive selection. Due to this strict 
screening it must be noted that our orthologue dataset may contain a bias towards 
orthologues of high levels of conservation, thereby underestimating the number 
of positively selected genes and underestimating the average levels of 
divergence. Results prior to multiple hypothesis correction should not be used for 
subsequent analysis as the family-wise error rate is unacceptably high 
(Anisimova and Yang, 2007). Here we report results following a Bonferroni 
correction for multiple testing which is known to be conservative and hence, 
prediction of positive selection is particularly robust. The corollary of such a 
strict approach is the potential generation of false negatives. 
 As demonstrated in the yeast protein interaction network, evolutionary 
rate is thought to be negatively correlated with protein connectivity (Fraser et al., 
2002; Fraser et al., 2003; Fraser and Hirsh, 2004). Hence, genes under positive 
selection are generally believed to be less promiscuous, that is, they interact with 
fewer genes compared to genes under neutral evolution or purifying selection. 
This may be because promiscuous genes are subject to functional constraints due 
to their pivotal or multiple roles in biological pathways. However, others 
analysing the same data claim that the results are inconclusive (Bloom and 
Adami, 2003; Jordan et al., 2003). We investigate whether genes under adaptive 
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evolution interact with fewer genes compared to genes not under positive 
selection but did not see a significant difference between the two gene groups.  
 We also investigated the hypothesis that a gene under adaptive evolution 
would drive complementary divergence of genes encoding interacting proteins. 
Many studies on the co-evolution of individual genes and the genes they interact 
with have been published. The most common examples are receptor-ligand 
couples that co-evolve to maintain or improve binding affinity and/or specificity. 
Examples of such genes include the prolactin (PRL) gene and its receptor 
(prolactin receptor, PRLR) in mammals (Li et al., 2005), primate killer cell 
immunoglobulin-like receptors (KIRs) that co-evolved with MHC class I 
molecules (Hao and Nei, 2005) and red and green visual pigment genes (Deeb et 
al., 1994). However, this phenomenon has never been investigated among 
mammalian genes on a genome-wide level. Here we present evidence that 
positively selected genes are significantly more likely to interact with other 
positively selected genes than genes evolving under neutral evolution or 
purifying selection.  
 
3.2 RESULTS 
3.2.1 Numbers of positively selected genes in result set A 
The five species orthologue identification procedure and alignment pipeline 
resulted in 3079 orthologue alignments corresponding to 16% of the human 
genome. 2689 of the genes also had a chicken homologue (representing genes 
conserved at least in the chordata) and 390 genes did not have a chicken 
homologue (representing potential mammalian specific genes or genes that were 
missing in the incomplete chicken genome sequence).  
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The branch-site model in the codeml program of PAML (Zhang et al., 2005) was 
used to investigate the evolutionary rate of each gene on each branch of the 
species phylogeny. This set of genes under positive selection that resulted from 
the initial analysis was termed result set A. This set showed an unusually high 
number of positive genes in the chimpanzee lineage (Table 3.1). Table 3.1 
includes the numbers of positively selected genes (PSGs) in result sets B and C 
which are discussed in turn below. Result set B is a subset of result set A and 
similarly, result set C is a subset of result sets A and B. 
 
Table 3.1 Numbers of genes detected to be under positive selection by 
the branch-site model  
 Human Chimpanzee Hominid Mouse Rat Murid Dog 
Result set A (data from pipeline) 
p < 0.05 111 814 41 145 229 48 232 
p < 0.01 76 756 18 110 191 16 177 
Result set B (before data curation) 
p < 0.05 69 354 49 121 155 86 162 
p < 0.01 46 325 24 94 126 41 127 
Result set C (after data curation) 
p < 0.05 54 162 56 65 89 81 97 
p < 0.01 32 137 56 47 64 81 62 
 
A close examination of the alignments which resulted in significant results 
reveals many alignments with high branch lengths in the foreground lineage. The 
number of genes which had a branch length greater than 1 (measured as the 
number of nucleotide substitutions per codon) and were not significant for 
positive selection were compared to PSGs with branch lengths greater than 1 
(Table 3.2). The branch length value of 1 substitution per codon was chosen 
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arbitrarily as a gene having a branch length of 1 is considered quite high. There 
does not seem to be a correlation between the large number of positive genes in 
the chimpanzee lineage and high branch length as there were many genes which 
were not significant for positive selection that also had high branch lengths. 
Whilst long branch lengths may mean accelerated evolutionary rates, excessively 
long branches can also indicate alignment problems. These alignment problems 
could be the cause of the high number of significant results that ensued. Errors in 
alignment could have resulted from errors in sequencing or incorrect regions in 
gene predictions.  
 
Table 3.2 Number of genes in each lineage with branch length greater 
than 1 
 Human Chimpanzee Hominid Mouse Rat Murid Dog 
No. of genes 1 41 5 24 62 27 69 
No. of PSGs 1 22 0 3 16 5 23 
 
 
The set of overall branch lengths was estimated by running the M0 model of the 
concatenated set of 3079 alignments. The resulting tree was: 
((Human: 0.017784, Chimpanzee: 0.072954): 0.169006, (Mouse: 0.130561, Rat: 
0.176092): 0.339659, Dog: 0.287177). 
The total tree length was 1.19323. It can be seen that the chimpanzee branch is 
approximately four times longer than the human branch length, implying a four-
fold acceleration of substitution rates in the chimpanzee lineage compared to the 
human lineage since they last shared a common ancestor. This is unusual as we 
would expect the distances to be somewhat similar for human and chimpanzee. 
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The M0 model was run again after removing alignments for which the 
chimpanzee branch length was greater than 1.0. The branch length of the 
chimpanzee branch decreased but only marginally. Hence the inclusion of more 
divergent chimpanzee genes does not contribute to overall branch length of the 
chimpanzee branch length.   
 Manual examination of some of the alignments showed that the current 
data problems were caused by sequencing errors of single base deletions or 
substitutions in many of the orthologous sequences when compared to the 
‘golden path’ genomic sequence data in the UCSC Genome databases 
(http://genome.ucsc.edu/). Recent data updates to many of the genome sequences 
have improved the quality and coverage of the sequence, in particular the 
chimpanzee genome sequence, for which the coverage had increased from 4x to 
6x. The low quality of some of the sequences in the current alignments could be 
the cause of false-positive results from the branch-site analysis.  
 
3.2.2 Number of positively selected genes after data curation: 
result set B 
Low quality sequences in the original alignments were replaced with NCBI 
RefSeq sequences and new chimpanzee and dog sequences from gene predictions 
on updated genome sequences. Automated frameshift correction was performed 
on the alignments and the branch-site analysis was performed again. The ensuing 
set of PSGs was named result set B. The analyses resulted in 69 PSGs (p < 0.05) 
along the human lineage (Table 3.1). The number of PSGs in the other lineages 
varied with the highest seen in the dog (162) and chimpanzee (354) lineages.  
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 The consequence of employing frameshift correction for genes in result 
set B is that although frameshift errors due to alignment are corrected, 
frameshifts that exist in nature would have been corrected as well. To check if 
true frameshifts had been corrected we compared our set of PSGs in result set B 
with the set of genes that had undergone pseudogenisation along the human 
lineage (Wang et al., 2006). We did not find any overlaps, suggesting that our 
frameshift correction has only rectified sequence errors and not modified genuine 
species differences. 
 Alignments were again examined to look for areas of high divergence. 
Some alignments had areas of ambiguous alignment or areas where sequences 
did not appear orthologous. Areas of non-orthology could result from incomplete 
gene predictions due to gaps in the genomic sequence or absent or variant exons.  
 
3.2.3 Number of genes under positive selection after manual  
curation: result set C 
The alignments were subjected to masking of regions of low homology (see 
Section 2.8). A portion of the following numbers of sequences was masked in 
each species: chimpanzee 1209, dog 1474, rat 1294, mouse 1169 and human 835. 
The branch-site analyses were re-run and all alignments which resulted in a 
significant result in one or more lineages were manually inspected for alignment 
errors. Results were discarded if sequences were misaligned or if sequences did 
not appear orthologous. The resulting set of PSGs was named result set C.  
 In this set we found 1222 genes to have evolved under positive selection 
in at least one of the seven mammalian lineages (1707 genes from all lineages as 
some genes were significant in more than one lineage) but after data curation, we 
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only considered 511 genes (604 genes from all lineages) for further analysis. 
Following Bonferroni corrections, all lineages tested showed significant (p < 
0.05) evidence of genes evolving under positive selection varying from 54 genes 
along the human lineage to 162 along the chimpanzee lineage (Table 3.1). The 
rat lineage also showed a slightly higher number of positive genes (89) compared 
to the mouse lineage (65). In comparison with result set B, the number of PSGs 
in result set C in all lineages except in hominids decreased. The number of PSGs 
along the hominid lineage increased from 49 to 56 after data correction because 
data curation increased the identity of human-chimpanzee sequences, resulting in 
an increase in the number of PSGs in the hominid lineage. A complete list of 
PSGs that were detected in each lineage is available in Appendix 2.  
 Subsequent analyses were performed on both result sets B and C. We 
found that in all cases the findings for the two sets were similar although result 
set B may contain some false positives resulting from alignment errors. 
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3.2.4 Overall evolutionary rates 
To obtain an overall perspective of the evolutionary rates of the genes in our 
dataset, the free-ratio model in the codeml program was run on each alignment 
(see Section 2.11). The median ω values for each lineage ranged from 0.14 in 
mouse and rat to 0.17 in human and 0.20 in chimpanzee (Figure 3.1).  
 
Figure 3.1   Five species tree with branch-specific dN/dS ratios 
The median ω value from free-ratio model estimates of evolutionary rates in 3079 genes 
for humans, chimpanzees, mouse, rat and dog. Branch lengths are proportional to 
absolute dN values (Table 3.3).  
    
 
 
 
Table 3.3 Estimates of branch lengths, dN, dS (free-ratio model) on the 
concatenated alignment of 3079 genes  
 Human Chimpanzee Hominid Mouse Rat Murid Dog 
Branch 
length 
0.017 ± 
0.00017 
0.060 ± 
0.00027 
0.159 ± 
0.00053 
0.125 ± 
0.00048 
0.155 ± 
0.00044 
0.346 ± 
0.00073 
0.275 ± 
0.00064 
dN 0.0038 0.0176 0.0249 0.0197 0.0249 0.0461 0.0444 
dS 0.0109 0.0268 0.1323 0.1032 0.1265 0.3095 0.2239 
Note: Branch lengths are measured as the number of nucleotide substitutions per codon ± 
standard error calculated by the curvature method (Yang, 2007). 
Mouse 
Rat 
Murid 
Dog 
Human 
Chimpanzee 
Hominid 
0.1688 
0.2029 
0.1677 
0.1945 
0.1533 
0.1387 
0.1429 
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3.2.5 Functional processes affected by positive selection  
A one-sided binomial test was used to test if the PSGs from each lineage were 
over-represented among the PANTHER Biological Process (BP) and Molecular 
Function (MF) ontology terms (Thomas et al., 2003). Each process was tested 
individually as a separate test. The overlaps between the PSGs from each lineage 
were very small so multiple testing corrections were not applied. None of the 
tests were expected to be significant so an FDR was not applied. The ontology 
terms that showed enrichment were then grouped by the BP family (Figure 3.2) 
and MF family (Figure 3.3) they belonged to, as defined by the PANTHER 
classification system (Thomas et al., 2003). Twenty-six BP ontology terms 
which belonged to fourteen BP families were enriched for PSGs (p < 0.05, 
binomial test). The ontologies that had the most representation by PSGs from the 
primate lineages were nucleic acid metabolism (RBM16, RDM1, REPIN1, 
RKHD1 and ZRSR2) and transport (CACNA1S, CNGA4, KCNK5, SLC5A9 and 
SRL). Categories of genes that can be associated with species-specific differences 
such as reproductive processes (ARID2, INPP5B), signal transduction 
(CEACAM20, GPR111 and GPRC6A, NR5A1, PDE6A, EMB, PIK3C2G, 
INPP5B, GIPC2) and development (IFRD2, MICALCL, MOV10, MYF5, 
ST8SIA3 and TRIM67) also showed enrichment. PSGs from the murid lineages 
showed over-representation mostly in the functional categories of immunity, 
defence and signal transduction. The same was done for each gene using the 
Molecular Function terms (Figure 3.3). Hydrolases and cell adhesion classes 
were also seen to have an excess of genes under positive selection across all 
species.  
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Figure 3.2   Biological Process ontologies over-represented by PSGs 
Biological Process ontology terms which had an over-representation of PSGs (p < 0.05). 
Ontology terms are grouped by functional protein PANTHER Biological Process 
families. 
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Figure 3.3   Molecular Functions ontologies over-represented by PSGs 
Molecular Function ontology terms which had an over-representation of PSGs (p < 
0.05). Ontology terms are grouped by functional protein PANTHER Molecular Function 
families.  
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3.2.6 Positively selected genes on all lineages show evidence of 
co-evolution 
To test if PSGs or proteins encoded by PSGs interact with fewer genes or 
proteins compared to genes that are not under positive selection, we queried a 
meta-database of biological interactions (see Section 2.12, (Rajagopalan and 
Agarwal, 2005)) with the list of all PSGs. The median number of interactors for 
1) the genes subject to positive selection, and 2) the genes that were tested but for 
which no signal of positive selection was found, were calculated. For the 511 
PSGs along all lineages, 155 (30%) did not have any annotated interactions with 
any other proteins and the median number of interactions was 5. For the 2568 
genes in the test set with no evidence of positive selection, 783 (31%) did not 
have any interactors and the median number of interactors was also 5. Therefore 
it was concluded that PSGs do not have a lower median number of interactors 
than genes not under positive selection in the test set (p = 0.815; two-tailed 
Wilcoxon rank sum test), which suggests that the number of interactors is not a 
determinant for PSGs.  
 To determine if any of the PSGs interact with each other and form 
smaller clusters of sub-networks, we queried the same database with the lists of 
PSGs from each lineage. PSGs from all lineages except the human lineage 
formed clusters. For example, among the 162 chimpanzee PSGs, 9 clusters were 
found, consisting of 2 clusters of 3 genes and 7 clusters of 2 genes. We applied a 
permutation test to determine whether the number and size of the clusters formed 
was more than would be expected by chance. For example, for a random set of 
162 genes (picked from the 3079 test set) would we expect the 9
th
 cluster to be 2 
nodes in size, given there are 8 other clusters of size 2 nodes or above? 1000 
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permutations were run. The overlaps between the PSGs from each lineage were 
very small so multiple testing corrections were not applied. For PSGs in both the 
chimpanzee and hominid lineages, the size of the smallest two clusters 
(chimpanzee clusters 8 (PEX12, PEX19) and 9 (NRP1, MSI1) and hominid clusters 3 
(DRD2, TH) and 4 (ITGAV, AZGP1)) exceeded what would be expected by chance 
(p < 0.05) (Table 3.4) and in the dog lineage the third cluster (containing genes 
SNTA1, DAG1 and MUSK) was significant. Therefore there is some evidence that 
PSGs are likely to interact and form sub networks. No interconnectivity was 
found between the genes positively selected within the human lineage and this 
statistic was not significant for the mouse, rat and murid lineages.   
We also tested each cluster to determine whether the size of the cluster 
was more than that expected by chance given the number of interactors for each 
individual gene in the cluster. Again a permutation test was run to answer the 
question: would a random group of genes (from the 3079 test set) with the same 
number of interactors as those in the cluster, be expected to interact with each 
other? Multiple testing corrections were not applied as the PSGs from each 
lineage did not contain many overlapping genes. All 28 clusters were found to be 
significant (p < 0.05; permutation test) (Table 3.4). Therefore there is a highly 
significant phenomenon of PSGs interacting with other PSGs. To confirm this 
observation, further analysis was performed on the genes that interact with the 
beta 2 integrin gene (ITGB2) which showed evidence of positive selection along 
the rat (p < 0.001) and murid (p < 0.05) lineages. Three of its four known 
interacting alpha subunits (Ewan et al., 2005) showed positive selection either on 
the murid branch (ITGAL, p < 0.01; ITGAX, p < 0.05) or on the mouse branch 
(ITGAD, p < 0.001).  
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One of the sites (M165Q) under positive selection in the ITGAL gene was 
found to be in the metal ion-dependent adhesion site (MIDAS) motif. This motif 
functions to mediate ligand binding in a metal ion-dependent manner. Positively 
selected residues in the ITGB2 gene included one in the linker region between 
the PSI (plexin/semaphorin/integrin) domain and the I-like domain, prior to the 
MIDAS motif in this protein.  
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Table 3.4 Interacting clusters formed between PSGs on each lineage 
Cluster 
number 
Genes in cluster 
p value of cluster size given 
previous clusters 
p value of cluster given 
number of interactions 
per gene**  
Chimpanzee 
1 PCSK5, BMP4, PHOX2A 0.981 0.0013 
2 LHB, OTX1, JUB 0.391 0.0001 
3 XPC, RAD23A 0.519 0.0035 
4 NUCB1, PTGS1 0.346 0.0046 
5 ITGB6, ALOX12 0.227 0.0030 
6 MYO18A, TRADD 0.131 0.0028 
7 GSTP1, MAP2K4 0.075 0.0442 
8 PEX12, PEX19 0.036* 0.0003 
9 NRP1, MSI1 0.019* 0.0008 
Dog 
1 
CFP, TAL1, SERPINB1, MMP12, PRF1, 
BCL2, HRG, ITGA5, COMP 0.385 < 0.0001 
2 CD79A, HCLS1, LCP2 0.209 0.0012 
3 SNTA1, DAG1, MUSK 0.036* 0.0002 
4 LRP5, SLC2A2 0.171 0.0026 
5 ALB, MCAM 0.082 0.0123 
Hominid 
1 CCL19, CD86, MADCAM1 0.335 0.0015 
2 MRC2, COL4A4 0.186 0.0028 
3 DRD2, TH 0.045* 0.0488 
4 ITGAV, AZGP1 0.008* 0.0080 
Mouse 
1 HLA-DRB1, HLA-DQA2 0.755 0.0123 
2 C1R, C1QA 0.288 0.0030 
Murid 
1 TLR5, CD86, PTGIR 0.678 0.0001 
2 SCNN1G, SPTA1, HECW1 0.432 0.0021 
3 CNR1, RAPGEF1 0.190 0.0110 
4 F5, GP1BA 0.064 0.0032 
Rat 
1 
CDKN2D, TRIM21, CDKN1B, CAST, 
ICAM1, CFD, ITGB2, C3 0.360 < 0.0001 
2 KCNA4, ACTN2, PIK3R5 0.526 0.0016 
3 PIM1, RP9 0.280 0.0063 
4 ASPH, HDAC4 0.118 0.0053 
*p < 0.05 
**All tests to investigate whether the size of the cluster would be more than that expected by 
chance, given the number of interactors for each individual gene in that cluster, were significant 
(p < 0.05). 
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3.2.7 Are malleable genes common targets of positive selection 
pressure? 
There were several genes that showed signatures of selection in multiple 
lineages. We found that 17 genes overlap between the human and chimpanzee 
PSGs, 8 genes overlap between the mouse and rat PSGs and 8 genes intersect 
between the hominid and murid PSGs, all significantly greater than that expected 
by chance (2.8; p < 7 x 10-10, 1.9; p < 5 x 10-04, 1.5; p < 8 x 10-05, Fisher’s exact 
test of proportions) (Table 3.5).  
These genes suggest the presence of some common targets of positive 
selection in each of the pairs of species and may represent malleable genes that 
are involved in adapting to changing external environments, like sensory 
perception and dietary content. Some examples of such genes are the olfactory 
receptor OR4F17, a PSG in both the human and chimpanzee lineages, which 
illustrates what is known about both humans and chimpanzees showing extensive 
evidence of olfactory adaptation (Gilad et al., 2005). DHDH, a PSG in both the 
mouse and rat lineages, is involved in carbohydrate metabolism.  
The hominid and murid lineages share PSGs involved in cell 
differentiation (FZD2) and reproduction (TXNDC3). The TXDNC3 protein 
(Sptrx-2) participates in the final stages of sperm tail maturation in the testis 
and/or epididymis and is a structural component of the mature fibrous sheath of 
spermatozoa (Miranda-Vizuete et al., 2004). Proteins involved in reproduction 
tend to have evolved under positive selection (Wyckoff et al., 2000; Swanson 
and Vacquier, 2002).  
 
 84 
Table 3.5 Positively selected genes common in adjacent lineages 
Lineages p value Gene Symbol 
Human and 
Chimpanzee 
p < 7 x 10-10 
ABCF1, ALPPL2, CNGA4, PIK3C2G, ZRSR2, 
KIAA0372, C8ORF42, ANGEL1, MICALCL, 
OR4F17, ZNF324B, ANKRD35, GIPC2, 
RUFY4, RBM16, MGC50722, INPP5B 
Mouse and Rat p < 5 x 10-04 
SYT4, STS, CA6, CDC14B, TARP, RRAGA, 
DHDH, C19ORF16 
Hominid and 
Murid 
p < 8 x 10-05 
TXNDC3, ITGAV, MRC2, CLSTN2, ZNF665, 
CD86, FZD2, F5 
Note: The p value is from Fisher’s exact test of proportions to test for significance.  
 
 
We combined some of the common murid and hominid PSGs with PSGs only in 
the hominid or murid lineage. We then used this dataset to query the previously 
described database of biological interactions to find significant networks and 
found three networks of genes involved in inflammation processes (Figure 3.4). 
All the functional processes concerned with inflammation are represented by the 
genes that appear in these networks: genes such as F5, GP1BA, VWF, PTGIR are 
involved in blood coagulation, cell-adhesion genes such as MADCAM1, ITGAV, 
genes that participate in inflammatory response (TLR5, CXCL13, CCL19, 
CCL21) and immune defence (CD86, AZGP1) as well as other related transport 
proteins. As the challenges to the immune system are constantly evolving and 
changing, we would expect immune system genes to be constantly under positive 
selection pressure to adapt to new incoming challenges. This can be seen with the 
MHC molecules (Bernatchez and Landry, 2003) and may also be true of the 
genes in our network. 
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Figure 3.4   Positively selected genes along the hominid and murid lineages 
cluster to form networks involved in inflammatory processes 
MADCAM1
CCL19 CXCL13
PTGIR
TLR5 CD86
CCL21
RGS1
ADRB3
AZGP1
ITGAV
F5GP1BA
VWF
MRC2 COL4A4
Key:
Murid PSG
Hominid PSG
Hominid and murid PSG
Gene not analysed
 
 
 
3.3 DISCUSSION 
This comprehensive evolutionary study offers the first genome scan for the 
action of positive selection pressure influencing human genes, their orthologues 
in model organisms and the two ancestral lineages. Having generated a robust set 
of genes that have undergone positive selection in many closely-related species, 
we have the opportunity to ask a wide array of fascinating scientific questions on 
the relationships between these genes. 
 As seen in other studies as well (Arbiza et al., 2006; Bakewell et al., 
2007), the number of PSGs in chimpanzee was much higher than in human. We 
considered the elevation in chimpanzee PSGs to be artefactual, perhaps caused 
by sequencing errors in the unfinished chimpanzee genome sequence. The rat 
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lineage also shows a slightly higher number of PSGs (89) compared to the mouse 
lineage (65). 
 We noticed that the second release of the chimpanzee genome (6x, 
Pan_troglodytes-2.1) was a radical improvement to the 4x sequence 
(Pan_troglodytes-1.0 (CSAC, 2005)). We had used the 4x sequence, which was 
also used in previous genome scans (CSAC, 2005; Arbiza et al., 2006; Bakewell 
et al., 2007), in prior analyses (result set A) and encountered unusually large 
numbers of chimpanzee PSGs, and accordingly re-ran with the 6x sequence 
anticipating fewer PSGs. 
 Since use of the 6x genome sequence also resulted in large numbers of 
chimpanzee PSGs (result set B), we considered that perhaps errors were also 
present in the 6x genome sequence. However, one would expect the number of 
sequencing errors in the chimpanzee and dog genomes to be approximately the 
same as both genomes have comparable coverage (chimpanzee at 6x; dog at 
7.6x) but at lower sequence coverage than the human genome sequence (CSAC, 
2005). On this basis the number of PSGs in the dog lineage would be elevated as 
well, but perhaps we observe more chimpanzee PSGs because low sequence 
quality would have a bigger impact on lineages with short branches in the species 
phylogeny. The dog branch is much longer than the chimpanzee branch and thus 
the dog branch is able to accommodate more nucleotide substitutions, masking 
the detrimental impact of sequencing errors on selection results along the dog 
lineage.  
 Any analysis of positive selection must first ascertain complete 
confidence in the homology between genes used for inference of positive 
selection and the robust identification of their open reading frames and alignment 
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of their sequences. Hence another source of error, particularly under automation, 
would be incorrect or incomplete gene predictions that may result in frameshifts 
in open reading frames or alignment errors. Ambiguous orthologue calls or 
misalignment may cause sequences to appear more divergent than they are and 
hence generate false positive results.  
 To correct for errors in genome sequence and errors in gene prediction 
and alignment, we applied conservative filters and complete manual checking to 
ensure that our results set was robust. We applied stringent cut-offs during the 
orthologue calling procedure to ensure we studied only truly orthologous sets and 
also controlled sequencing errors by masking out the divergent ends of partial 
sequences. We manually inspected alignments, discarding orthologous sequences 
which contained frameshifts relative to the human sequence or those that 
included regions of very low similarity (see Section 2.9). It is believed that any 
automated process of orthologue calling, open reading frame prediction and 
sequence alignment is prone to errors and it is suggested that manual 
examination and adjustment is the only way to prevent the possibility of false 
positives. The impact of this manual adjustment is indicated by the 392 positive 
selection results that were disregarded from results set B during our data curation 
steps. The high level of quality control is also the reason that we have identified 
comparatively fewer PSGs than some other studies (Clark et al., 2003; Arbiza et 
al., 2006), despite the increased power associated with the inclusion of more 
species.  
 The overall ω values that we obtained from the free-ratios model for each 
lineage (Figure 3.1) were comparable to the median ω values published by the 
Chimpanzee Sequencing and Analysis Consortium (CSAC, 2005) (mouse 0.142, 
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rat 0.137, human 0.208, chimp 0.194) but were more similar to those from 
Rhesus Macaque Genome Sequencing and Analysis Consortium (Gibbs et al., 
2007) (human 0.169, chimpanzee 0.175, mouse 0.104). This suggests that the 
strict criteria used to select our input gene set have not introduced a bias for 
genes with high ω values in humans and chimpanzees. The higher median values 
observed in the chimpanzee lineage suggest that overall nonsynonymous 
mutations were fixed much faster along the chimpanzee lineage than along the 
human lineage since the separation of the two species. 
 The functional categories enriched for PSGs in this study were found to 
closely correlate with those detected in previous genome scans (Holbrook and 
Sanseau, 2007). The consensus is compelling given the different techniques used 
in each study and the risk of false positives inherent in these large-scale studies. 
It is interesting to note that among the five species analysed, protein families 
with distinct functions could be identified as evolving under positive selection 
for each species. Techniques to connect positive selection with function are still 
in the early stages of development, but gradual progress is being made. As more 
data becomes available on the function of each individual amino acid, from 
structural or mutagenesis studies, it will become possible to connect function and 
positive selection. Data, such as that generated by this study, provides a 
preliminary starting point for experimental follow-up.  
 Positive selection pressure would be expected to act not just on one gene 
at a time but on pathways of genes, but evidence has been scant so far. We found 
that genes that were subjected to positive selection along the same lineage were 
significantly more likely to interact with each other than with genes not under 
selection, the first evidence for co-evolution of genes as a widespread 
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phenomenon in mammals. We suggest that the high level of connectivity 
between PSGs is caused by compensatory change of a protein’s interaction 
partners when a protein undergoes change in response to selection. This was 
exemplified by the evidence of positive selection pressure in ITGB2 and its 
interacting alpha subunits, ITGAL, ITGAX and ITGAD. This suggests that the 
major participants of integrin-signalling have co-adaptively evolved in the rodent 
species.
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4.1 INTRODUCTION 
Comparative analyses of the genomes of mammalian model organisms can 
provide insight into human adaptation as the availability of high quality 
functional annotation allows prediction of the likely consequences of adaptive 
evolution in particular genes. Such analyses can also indicate the numbers of 
genes that have undergone positive selection in other species such as 
chimpanzees, which we commonly believe to be fewer in number than in human 
(Hawks et al., 2007). 
 In result set C the number of PSGs detected on the human lineage was 54 
(p < 0.05) whilst the number of PSGs was still highest along the chimpanzee 
lineage (162, p < 0.05), having many more genes than any of the other lineages 
and approximately three times more than along the human lineage. This was 
surprising despite the findings of other reports which mention that a high number 
of genes underwent positive selection during chimpanzee evolution (Arbiza et 
al., 2006; Bakewell et al., 2007). Bakewell et al. (using a wholly different 
methodology to this study) identified 21 positive chimpanzee genes and 2 
positive human genes from an initial data set of 13,888 genes. Elevated numbers 
of PSGs along the chimpanzee lineage were also found by Arbiza et al. (2006) 
who obtained 1.12% of genes under positive selection in the human genome and 
5.96% in the chimpanzee genome, which is in close accordance with 1.75% 
(human) and 5.26% (chimpanzee) obtained here.  
 In the following discussion, evidence is presented to argue against the 
possibilities that this result is due to artefacts introduced by genome sequence 
coverage, gene sample selection or algorithmic sensitivity to errors in sequence 
data or alignments. Instead, it is concluded that the elevated number of 
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chimpanzee positively selected genes is a true reflection of evolutionary history 
and is most likely due to positive selection being more effective in the large 
populations of chimpanzees in the past or possibly remarkable adaptation in the 
chimpanzee lineage. 
 
4.2 RESULTS AND DISCUSSION 
4.2.1 Taxon sampling does not affect detection of positive 
selection 
This study included five species exemplars whilst previous studies have been 
more restricted (Nielsen et al., 2005; Bakewell et al., 2007). However, the effect 
of taxon sampling on the detection of positive selection is largely unknown. To 
address this question we conducted permutation analyses of the original five-
species alignments to determine if the exclusion of each non-human species in 
turn affects the results obtained.  
Both alignments from results sets B and C were used in this analysis to 
ensure that the manual curation step performed to generate results set C did not 
skew our results. For the first permutation test, after the sequence was removed 
from the alignment, the remaining sequences were not re-aligned prior to 
analysis with the branch-site model. For the second permutation test, the 
sequences remaining after a sequence was excluded were re-aligned. The number 
of PSGs each analysis had in common with result sets B (Table 4.1) and C (Table 
4.2) was calculated. The common set of PSGs in the five- and four-species 
analyses number includes genes that were identified as being under positive 
selection in both tests. The difference in p value for a particular gene to be under 
positive selection in the five- and four-species analyses is simply an outcome of 
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the value of the test statistic and does not reflect a disparity in the significance of 
the result. This is also emphasised by the fact that although the p values might be 
different between the two analyses, in the majority of cases, the same residues 
were being reported as having high probabilities of being under positive selection 
(data not shown).  
 The number of genes reported in the permutation tests was very similar to 
the number of PSGs in result sets B and C. For example, in result set B, the 
mouse lineage had 65 PSGs and in the permutation test without re-alignment, 
there were 74 mouse PSGs when the chimpanzee sequence was removed and 67 
PSGs when the dog sequence was removed. However, this does not represent a 
complete overlap as some genes that were not significant for positive selection in 
the test using the five-species alignment became non-significant in the test using 
the four species alignment, probably due to loss of power when fewer species 
were used in the analysis.   
 Counter-intuitively, many genes that were not significant in the five-
species analyses became significant in the four-species analysis. It would be 
expected that as the number of species included in the analysis was decreased, 
the number of positive genes found would also decrease. This could be because if 
a divergent sequence caused ambiguity in the five-species alignment, then re-
aligning the data after removal of the divergent sequence results in a more 
conservative alignment.   
 The numbers of PSGs in each lineage after sequence exclusion without 
re-alignment were almost the same as the numbers of PSGs after sequence 
exclusion and with re-alignment. For example, from results set C, the number of 
human PSGs when the dog sequence was removed was 54 in permutation test 1 
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and 50 in permutation test 2. The two tests also had a significant number of PSGs 
in common (Table 4.3), which indicated that re-aligning the data did not make a 
significant difference to the results for positive selection.  
 
 
Table 4.1 Number of PSGs after sequence exclusion (result set B) 
Taxon 
removed 
Human Chimpanzee Hominid Mouse Rat Murid Dog 
Number of PSGs after taxon exclusion and no re-alignment (permutation test 1) 
Chimpanzee    134 (94) 176 (96) 101 (85) 199 (96) 
Dog 73 (71) 368 (94)  115 (74) 149 (79)   
Rat 74 (90) 364 (97) 63 (71)    175 (89) 
Mouse 67 (80) 369 (98) 51 (61)    161 (85) 
Number of PSGs after taxon exclusion followed by re-alignment (permutation test 2) 
Chimpanzee    133 (80) 183 (88) 99 (69) 200 (85) 
Dog 63 (61) 372 (87)  100 (65) 155 (70)   
Rat 71 (77) 364 (90) 69 (55)    170 (77) 
Mouse 71 (72) 361 (90) 39 (43)    153 (72) 
Note: Numbers (p < 0.05) are only shown for lineages for which there were no changes in 
topology when the taxon in question was removed from the tree.  
In parentheses are the numbers of common genes in the analyses with the sequence excluded and 
the five-species alignment as a percentage of the number of PSGs in the five-species alignment.   
 
 
 
Table 4.2 Number of PSGs after sequence exclusion (result set C) 
Taxon 
removed ↓ 
Human Chimpanzee Hominid Mouse Rat Murid Dog 
Number of PSGs after taxon exclusion and no re-alignment (permutation test 1) 
Chimpanzee    74 (88) 87 (75) 80 (70) 113 (79) 
Dog 54 (67) 174 (89)  67 (74) 77 (58)   
Rat 54 (83) 162 (92) 53 (57)    89 (72) 
Mouse 59 (80) 163 (90) 50 (54)    79 (81) 
Number of PSGs after taxon exclusion followed by re-alignment (permutation test 2) 
Chimpanzee    72 (77) 100 (70) 72 (56) 123 (75) 
Dog 50 (50) 200 (86)  66 (65) 87 (54)   
Rat 48 (57) 188 (86) 58 (52)    98 (68) 
Mouse 62 (67) 189 (86) 46 (46)    92 (64) 
Note: Numbers (p < 0.05) are only shown for lineages for which there were no changes in 
topology when the taxon in question was removed from the tree.  
In parentheses are the number of PSGs that were common to the four-species analyses and the 
original five-species alignment (result set C) as a percentage of the number of PSGs in the five-
species alignment.   
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Table 4.3 Number of PSGs common to permutation tests 1 and 2  
 
Taxon 
removed ↓ 
Human Chimpanzee Hominid Mouse Rat Murid Dog 
Chimpanzee        
Result set B    108 154 80 167 
Result set C    60 74 61 101 
Dog        
Result set B 49 324  88 124   
Result set C 38 164  55 64   
Rat        
Result set B 57 328 45    139 
Result set C  36 152 40    77 
Mouse        
Result set B 54 325 30    128 
Result set C 46 149 37    74 
 
 
It should be noted that the percentages of PSGs the analysis with five species had 
in common with the permutation tests using four species were lower for result set 
C compared to result set B (Tables 4.1 and 4.2). This is due to the smaller overall 
size of the result set C; the raw numbers of genes in common were similar.  
 Comparison of the same branches in both the re-aligned and non-re-
aligned analyses shows that the effect of taxon elimination on the number of 
PSGs was most pronounced on the ancestral lineages, resulting in the most 
severe loss in the number of detected PSGs. This could be because there are no 
direct observations to obtain data for the internal branches; instead the sequence 
is inferred by ancestral reconstruction. If more species were used in the analysis, 
sequence reconstruction can be performed more accurately. Hence, in this case, 
the removal of one sequence influences reconstruction and can considerably 
affect the number of positive genes detected.  
 Among the extant lineages, removal of the dog sequence seems to have 
had the most severe effect (percentages of overlapping genes range from 50-
89%). This is probably because dog is an outgroup in the species phylogeny and 
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hence removal of this branch substantially decreases the power to detect positive 
selection. The exclusion of a sequence from the remaining three taxa has slightly 
lesser effects (percentages range from 57% to 92%) but an assessment of the 
number of genes that were positive in all three analyses (see Table 4.4 for 
comparison with result set B and Table 4.5 for comparison with result set C) 
shows that detection of positive selection in a substantial portion of genes is 
robust to all manipulations and species exclusions. 
 
 
Table 4.4 Number of PSGs common to both permutation tests and the 
five-species analysis (result set B) 
Taxon 
removed 
Human Chimpanzee Hominid Mouse Rat Murid Dog 
Chimpanzee    96 (79) 143 (92) 68 (79) 143 (88) 
Dog 40 (58) 302 (85)  77 (64) 110 (71)   
Rat 51 (74) 315 (89) 28 (57)    128 (79) 
Mouse 45 (65) 315 (89) 22 (45)    121 (75) 
Note: In parentheses are the numbers of genes that the three analyses had in common, shown as a 
percentage of the number of PSGs in the five-species alignment. 
 
 
 
Table 4.5 Number of PSGs common to both permutation tests and the 
five-species analysis (result set C) 
Taxon 
removed 
Human Chimpanzee Hominid Mouse Rat Murid Dog 
Chimpanzee    50 (77) 60 (67) 45 (56) 73 (75) 
Dog 26 (48) 138 (85)  42 (65) 46 (52)   
Rat 30 (56) 140 (86) 28 (50)    64 (66) 
Mouse 34 (63) 138 (85) 25 (45)    59 (61) 
Note: In parentheses are the numbers of genes that the three analyses had in common, shown as a 
percentage of the number of PSGs in the five-species alignment.   
 
 
When we compare our two most divergent species (Figure 4.1), it can be seen 
that the numbers of mouse and rat genes that were under positive selection when 
the chimpanzee sequence was excluded were approximately the same as when 
the dog sequence was excluded. Similarly the number of human and chimpanzee 
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genes under selection were quite similar when the mouse sequence was excluded 
and when the dog sequence was excluded.  
 
Figure 4.1   Summary of results from taxon exclusion studies  
Circle A: Five-species alignment  
Circle B: Species exclusion and no re-alignment 
Circle C: Species exclusion and re-alignment 
The exclusion of the chimpanzee sequence and the mouse sequence are compared to the 
exclusion of the dog sequence. The dog lineage, as the outgroup, had the most impact on 
the number of PSGs on the other lineages.   
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The high numbers seen are a reflection of the stability of the results regardless of 
changes in the number of taxa used, changes in tree topology and also changes in 
the alignment. We conclude that once rigorous orthologues are established the 
results are fairly consistent regardless of the species being removed. We can 
conclude that PAML is robust to the effects of taxon sampling and the 
determination of PSGs reported in this study is accurate and not an effect of 
taxon sampling. In particular, the inclusion of chimpanzee sequences in our study 
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did not affect the inference of positive in the other four species, nor in the 
ancestral lineages. 
 
4.2.2 Chimpanzee PSGs are lineage specific 
To determine whether the PSGs seen in the chimpanzee lineage were also under 
positive selection in other non-human primates, we performed a pilot study with 
other primate sequences, whose draft assemblies were available (macaque, 
orangutan and marmoset) at the same coverage (5-6x) as the chimpanzee 
genome. Marmoset (6x coverage), orangutan (6x coverage) and macaque (5.2x 
coverage) supercontigs were downloaded from the Washington University 
Genome Sequencing Center (http://genome.wustl.edu/).  
 Eleven of the 162 chimpanzee PSGs were selected as they had the most 
number of residues predicted to be under positive selection. For these genes, 
orthologous sequences in the three primate genomes were obtained by gene 
prediction using GeneWise (Birney et al., 2004). The protein sequences for these 
orthologous sequences were added to the original alignment of the five species 
used in the genome scan analysis.  
 We then performed positive selection analyses under the branch-site 
model on the resulting new alignments. All primate branches and branches 
leading to primates were tested as the foreground lineage in turn. The tree 
topology used for all the analyses was (((((Human, Chimp), Orangutan), 
Macaque), Marmoset), (Mouse, Rat), Dog). The addition of these three primate 
sequences to the original 5-species alignment did not change the length of the 
alignment as these genes were approximately the same length in all these 
mammalian species. 
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Table 4.6 Test statistic (2x ∆lnL) from chimpanzee lineage branch-site  
analyses with and without orangutan, marmoset and macaque 
sequences 
Gene 
Chimpanzee 
(original 
analysis) 
Chimpanzee 
(with primate 
sequences) Orangutan Macaque Marmoset 
Ancestor 
to HCOM 
AQP2 87.08** 77.41**     
EEF1G 40.88** 36.23**   131.94** 8.54* 
ELF4 78.34** 64.28**  166.93** 28.11**  
HCRTR1 49.61** 53.64**     
TKTL1 25.85** 24.84**   19.74**  
DYRK2 78.86** 85.44**   8.74*  
PIGV 127.93** 134.6**     
PSD2 150.79** 139.6** 216.47**  66.84**  
CCDC97 90.45** 100.5**     
CXorf38 52.64** 57.87**     
GIYD1 47.88** 33.88**     
* p < 0.05; ** p < 0.001 
 
 
All eleven genes remained subject to positive selection along the chimpanzee 
lineage (Table 4.6). The sites predicted to be under selection in the chimpanzee 
lineage were also the same in the analysis before and after addition of the primate 
sequences. Some of the genes were under positive selection along the other 
primate lineages, with five of the genes under positive selection in the marmoset 
lineage (a New World monkey). The amino acid differences observed in the 
eleven chimpanzee sequences are specific to the chimpanzee, with the other 
primate sequences having the same state as the human sequence. This suggests 
that the human state is the ancestral state and the chimpanzee state is the derived 
change with the adaptation observed in the chimpanzee being lineage specific. 
 
4.2.3 Functional analysis of chimpanzee PSGs 
It is also important to identify as far as possible the functional significance or 
biological grouping of these chimpanzee genes under positive selection. 
Classification of PSGs using the PANTHER Biological Process (BP) and 
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Molecular Function (MF) ontology terms (Thomas et al., 2003) showed that 
biological processes that were over-represented by chimpanzee PSGs included 
DNA repair, metabolism of cyclic nucleotides, peroxisome transport and the 
serine/threonine kinase signalling pathway. Each BP and MF ontology term was 
tested separately so multiple testing correction was not applied. 
 Interestingly, approximately a third (52 out of 162) of the chimpanzee 
PSGs are orthologues of human genes that are of unknown biological function. 
This proportion of 52 genes is significantly high (p < 0.036; Fisher’s exact test of 
proportions) compared to the number of genes with unknown function among the 
human PSGs (p < 0.053). Of these, 13 genes were identified to contain the IMP 
dehydrogenase/GMP reductase domains. This family is involved in the 
biosynthesis of guanosine nucleotide. IMP dehydrogenase catalyses the rate-
limiting reaction of de novo GTP biosynthesis, the NAD-dependent reduction of 
IMP into XMP. GMP reductase converts nucleobase, nucleoside and nucleotide 
derivatives of G to A nucleotides, and maintains the intracellular balance of A 
and G nucleotides. IMP dehydrogenase is associated with cell proliferation and 
genes that contain this domain are considered to be possible targets for cancer 
chemotherapy. Nielsen et al. (2005) also found many genes with unknown 
biological functions in both their set of chimpanzee and human PSGs but showed 
sequence similarity to known transcription factors.  
There is the possibility that these genes of unknown function might 
contain incorrectly predicted open-reading frames and hence might be falsely 
detected to be under positive selection when compared to the other mammalian 
species in our analyses. Current gene sets are mostly built by gene-prediction 
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software of which the error rate can only be determined by manual annotation of 
genes and their alternately-spliced variants.   
 
4.2.4 No correlation with genes under selection in human 
populations 
The number of PSGs from result set B was compared with genes shown to be 
under positive selection pressure within human populations (Voight et al., 2006; 
Tang et al., 2007). We did not see any evidence of a relationship between a gene 
being positively selected within human populations and in our mammalian 
species. In fact, there seems to be a trend that suggests that genes are less likely 
to have been selected along the hominid branch if they were under selection in 
recent human history. This is evident in the lower proportion of genes that were 
both under recent positive selection and positively selected along the hominid 
branch (0.0011) compared to the proportion of genes under positive selection 
along the hominid branch alone (0.0149). 
 
4.2.5 Hypotheses to explain the high number of PSGs on the 
chimpanzee lineage 
Our results after data curation and from investigating the effects of taxon 
sampling exclude the possibility that taxon sampling have affected the results. 
However there is still the possibility that sequence errors in the genes from a 
species might affect the number of PSGs and could perhaps cause the relatively 
high numbers of PSGs in the chimpanzee lineage. Other likely explanations for 
the elevation in PSGs along the chimpanzee lineage include: 
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1. High chimpanzee polymorphism: the individual chimpanzee sequence has 
been reported to have many high quality, single-nucleotide polymorphisms 
(SNPs) with a heterozygosity rate of 9.5 x 10-4. This rate is slightly higher 
than what was seen among West African chimpanzees (8.0 x 10-4) (CSAC, 
2005) which have similar diversity levels to human populations 
(Sachidanandam et al., 2001).   
2. Population structure: one of the factors affecting the strength of selection is 
population size. Since selection must be greater than 1/4Ne (where Ne is the 
effective population size) to reach fixation, it follows that genes are under 
stronger purifying selection in larger populations. Chimpanzees are noted to 
be more polymorphic indicating that they had larger (22,400 to 27,900) (Won 
and Hey, 2005) long-term populations than humans (10,000). Comparison of 
human sequences with great ape sequences revealed humans have reduced 
nucleotide diversity and a signal of population expansion (Kaessmann et al., 
2001). Thus positive selection may have reduced efficacy in humans than in 
chimpanzees which may explain some of the elevation in chimpanzee PSGs. 
3. Positive selection may have acted on the human and chimpanzees lineages 
during different periods of evolutionary time. In humans many selective 
events are relatively recent and are thought to be a result of adaptation to 
migration and domesticity (Tishkoff and Verrelli, 2003; Voight et al., 2006; 
Balaresque et al., 2007; Tang et al., 2007). This recent positive selection 
pressure is not amenable to detection by PAML and is more likely to be 
discerned by study of human population data (e.g. (Tang et al., 2007)). 
Comparison of our results with data from Tang et al. (2007) did not show a 
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large overlap of genes. This suggests that different sets of genes were subject 
to positive selection after the separation of the human and chimpanzee 
lineages than those sets of genes subject to recent positive selection within 
human populations.   
 
We observe many chimpanzee genes and possibly genes in other primates have 
been subject to positive selection during the evolution of their anthropoid 
ancestor. Since medical research and the vast majority of biological research 
have focussed on discovering more about human biology, we know a lot less 
about chimpanzee-specific characteristics. The number of PSGs on the 
chimpanzee lineage that are not false positives due to sequence errors or false 
gene predictions, would suggest that these chimpanzee adaptations are at least as 
striking as our much-vaunted human-specificities.  
 
4.2.6 Summary 
The comparative study of mammals offers many fascinating questions for 
researchers. In this study molecular evolutionary signals were used to predict 
how mammalian species have evolved. The approach taken in this study has 
confirmed an uncharacterised set of positively selected genes in the chimpanzee 
lineage. This adaptation could be in previously unrecognised aspects of 
chimpanzee biology, even for instance, in sensory or cognitive systems. Many of 
the chimpanzee PSGs have unknown functions which might suggest they belong 
to pathways that researchers have not focussed on as being relevant to human 
biology. It is anticipated that as more primate genome sequences become 
available, we will be able to determine whether other primates also have high 
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numbers of genes under positive selection, as seen in the chimpanzee lineage. It 
is also hoped that the study of these groups will yield answers to the questions of 
what is “humanness” and “chimpness” at a genetic level.  
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Chapter 5 
Positively Selected Genes and Associations with Human 
Diseases 
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5.1 INTRODUCTION 
Much scientific and medical progress has depended on experimental findings in 
model organisms being extrapolated to humans because it is very often the case 
that diseases shared between humans and other mammals mirror each other in 
molecular processes. However, even species that are evolutionarily close to each 
other, such as humans and chimpanzees, often experience the same medical 
condition with varying symptomatology, as seen in the cases of Alzheimer’s 
disease or AIDS. In addition, many diseases are far more prevalent in humans 
than in other primates (Olson and Varki, 2003; Varki and Altheide, 2005).  
 Comparison of disease prevalence and symptomatology across species is 
complicated by the fact that modern human lifestyles, very far from the 
conditions of early human evolution, may reveal susceptibilities to disease that 
were not evident in the early history of the human species (Young et al., 2005). 
However, there are biomedical differences between humans and other animals 
that cannot be wholly explained by lifestyle (Olson and Varki, 2003; Varki and 
Altheide, 2005).  
 Genetic disease can occur as a by-product of an adaptation which confers 
a large selective advantage (Nesse and Williams, 1995). For instance, the 
seemingly human-specific disease of schizophrenia (Crespi et al., 2007) and the 
greater human susceptibility to Alzheimer’s disease compared with primates 
(Gearing et al., 1994) may be a by-product of the human specialisation for higher 
cognitive function (Keller and Miller, 2006). Genes that have evolved different 
functions since the divergence of humans from other primates may be involved 
in this adaptation and therefore in diseases that affect the adaptation. 
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Besides Alzheimer’s disease and schizophrenia, many other diseases also 
differ in frequency and symptomatology between humans and other mammals. 
Olson and Varki (2003) and Varki and Altheide (2005) list some of these 
diseases with the emphasis on differences between humans and non-human 
primates, indicating that for these diseases chimpanzees are not good models 
despite their close evolutionary relationship with humans. Comparative 
evolutionary genomics may offer insights into these disease mechanisms as 
correlations between molecular differences that arose during species evolution 
and phenotypic differences in diseases between species may throw light on 
disease-causative genes and pathways. Consistent with this rationale, genes 
included in the Online Mendelian Inheritance in Man (OMIM) database 
(http://www.ncbi.nlm.nih.gov/Omim) have been found to be enriched for signals 
of positive selection pressure ((Clark et al., 2003; Smith and Eyre-Walker, 2003; 
Huang et al., 2004; Bustamante et al., 2005; Bakewell et al., 2007); but see 
(CSAC, 2005)).  
 
5.1.1 Gene products that are common drug targets 
Some genes that were reported to have demonstrated evidence of positive 
selection in the genome scan described in this thesis are currently being pursued 
as drug targets in the pharmaceutical industry. However these genes are not 
represented in the OMIM database as they are involved with substance abuse and 
addiction.  
 One example is the cannabinoid receptor, CNR1, a G-protein coupled 
receptor. The cannabinoid receptor binds cannabinoids, the psychoactive 
ingredients of marijuana, mainly delta-9-tetrahydrocannabinol, as well as other 
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synthetic analogs. This gene is the target for marketed drugs such as Nabilone 
and Marinol with indications for anorexia and emesis. Although the endogenous 
ligand that binds to the cannabinoid receptor has not yet been characterised, the 
well known psychoactive effects and other CNS actions caused by the binding of 
marijuana such as hallucinations, memory deficits, altered time and space 
perception, CNS depression and appetite stimulation, have been extensively 
studied. The cannabinoid receptors are also believed to play a role in 
neurogenesis during development (Julian et al., 2003). In comparisons between 
primates and rodents, it appears that the distribution in the forebrain of the 
cannabinoid receptor has altered during evolution (Harkany et al., 2005), but so 
far there have been no reports of positive selection pressure. The genome scan in 
this thesis found positive selection pressure in the murid lineage suggesting 
divergence between human and rodent species. 
 Another drug target is the dopamine receptor 2, DRD2, which has been 
associated with alcohol and tobacco dependence, substance abuse and myoclonic 
dystonia (Klein et al., 2000). D2 receptors are also known targets of 
antipsychotic drugs, such as Levodopa, Haloperidol and Promazine. These drugs 
are used to treat many neuropsychiatric disorders including schizophrenia, 
bipolar disorder, Parkinson's disease, anxiety and Tourette's disorder. Signalling 
through dopamine D2 receptors governs physiologic functions related to 
locomotion, hormone production, and drug abuse. DRD2 is also associated with 
the melanin pathway and shows large differences in SNP occurrences within the 
European, Asian and African populations, having undergone recent positive 
selection for skin pigmentation (Wang et al., 2004; Lao et al., 2007) but has not 
been reported as being under positive selection along the human or hominid 
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lineages. In our analysis, the DRD2 gene displayed a signal for positive selection 
along the hominid branch (p < 0.05) suggesting divergence between human and 
animal models, with an ω of 8.9 for 0.8% of the sites along the protein.  
 The serotonin receptor 1D, encoded by the gene HTR1D, is also a target 
for many marketed drugs such as Rizatriptan, Tegaserod, Almotriptan and 
Naratriptan among others, with indications for migraine, schizophrenia and 
inflammatory bowel disorder. Serotonin is also one of the neurotransmitters 
involved in the aetiology of attention-deficit hyperactivity disorder and autism, 
with the release of serotonin in the brain being regulated by serotonin 1D 
autoreceptors (Coutinho et al., 2007). Positive selection detected along the 
hominid lineage in the HTR1D gene maybe linked with increased cognition in 
primates compared to rodents.  
 In this chapter, I relate genes predicted to have changed function during 
mammalian evolution from the genome scan to the diseases known to show 
biomedical differences between humans and model organisms. These genes may 
be causative of the phenotypic disease differences between species and are 
promising targets for therapeutic intervention. I also attempt to confirm and 
pinpoint the lineage in which positive selection signal occurred in the three 
known drug targets, CNR1, DRD2 and HTR1D. These genes were investigated 
further in order to identify residues under positive selection that play a role in 
ligand-binding or activity modulation. 
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5.2 METHODS 
5.2.1 Comparison with OMIM genes 
Data from the Online Mendelian Inheritance in Man (OMIM) database 
(http://www.ncbi.nlm.nih.gov/omim), a catalogue of genetic diseases, was used 
to investigate whether genes under positive selection were over-represented 
among genes associated with disease. The OMIM Morbid map, an alphabetical 
list of disorders and their cytogenetic locations, was downloaded on 2
nd
 May 
2007. Gene names were mapped to Entrez Gene IDs using ENSEMBL BioMart 
(http://www.ensembl.org/biomart/) and batch searching of NCBI 
(http://www.ncbi.nlm.nih.gov/).   
 
5.2.2 Comparison with disease categories 
To investigate if genes from my dataset of PSGs were enriched among genes of a 
particular disease category, an ontology of major disease groups was created. 
Each gene in OMIM and its related medical term were placed in one of 19 
specific groups based on the anatomical system affected by that disease. OMIM 
disease terms were mapped to MeSH terms (Medical Subject Headings), with 
identical terms being used whenever possible. When an identical term was not 
available a higher MeSH term which superseded the OMIM term was used. The 
MeSH terms were then mapped to the MeSH ontology to find a higher MeSH 
term. These were finally collapsed into one of 19 broad categories 
(Cardiovascular Diseases; Congenital, Hereditary, and Neonatal Diseases and 
Abnormalities; Digestive System Diseases; Endocrine System Diseases; Hemic 
and Lymphatic Diseases; Immune System Diseases; Metabolic Diseases; 
Muscular Diseases; Neoplasms; Nervous System Diseases; Psychiatric Disease; 
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Reproductive and Sexual Disease; Respiratory Tract Diseases; Skeletal Diseases; 
Sensory Disease; Skin Diseases; Tooth Diseases; Trait; Urologic Diseases). 
When a MeSH term was not available for a particular OMIM disease term, the 
ontological term was assigned by manual judgement after inspection of the 
OMIM record or another online resource (Pubmed, eMedicine, Encyclopaedia of 
Genetic Diseases or The Office of Rare Diseases). For an OMIM term, if 
abnormalities were seen in multiple systems (e.g. Down syndrome), the higher 
term, Congenital, was used. When a term did not seem to be a disease or disorder 
(e.g. blood group, hair colour) the higher term Trait was used. Terms describing 
oncology were mapped to neoplasms. When several classifications were 
available the one likely to be affected by selection pressure was used. For 
example, a failure of metabolism that had a neurological clinical presentation 
was categorised as a neurological disorder. 
 
5.2.3 Site model analyses 
To confirm and isolate the location of positive selection in the genes that are 
commonly employed as drugs targets, CNR1, DRD2 and HTR1D, two likelihood 
ratio tests were performed using the site models described in Section 1.5.2. In the 
first test, the null model M1a (nearly neutral) was compared with the M2a model 
(selection). The second test compares the model M7 (beta) with the model M8 
(beta & ω) (Yang and Swanson, 2002). As described for the branch-site model 
analyses (see Section 2.4.2) for both tests values for branch-lengths and kappa 
are estimated from the M0 model. The test statistics obtained for each gene were 
compared to a chi square distribution with 2 degrees of freedom using critical 
values of 5.99, 9.21 and 13.82 at p values of 0.05, 0.01 and 0.001, respectively.  
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 Orthologous sequences from other species were downloaded from 
GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) for each gene. The accession 
numbers of the CNR1 sequences used were AAG37763.1 (crested gibbon), 
AAG37762.1 (macaque), AAG37761.1 (spider monkey), AAG37760.1 (Western 
tarsier), AAG37764.1 (Goeldi's marmoset) and AAG37759.1 (lemur). These 
sequences were added to the CNR1 alignment and an unrooted tree files were 
created using a standard mammalian species tree (Murphy et al., 2001) 
(((((Human, Chimpanzee), Gibbon), Macaque), (((Spider monkey, Western 
tarsier), Marmoset), Lemur)), (Mouse, Rat), Dog). 
 The accession numbers for the DRD2 sequences used were 
XP_001085449.1 (macaque), ABA62305.1 (gorilla), ABA62309.1 (bonobo), 
ABA62306.1 (orangutan) and ABA62304.1 (gibbon). The tree topology based on 
a standard mammalian species tree was (((((((Human, Chimpanzee), Bonobo), 
Gorilla), Orangutan), Gibbon), Macaque), (Mouse, Rat), Dog). 
 The accession numbers for the HTR1D sequences used were 
XM_001102386.1 (macaque) and NM_214158.1 (pig) and the tree used with the 
additional two species was (((Human, Chimpanzee), Macaque), (Mouse, Rat), 
Dog, Pig). 
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5.3 RESULTS 
5.3.1 OMIM is enriched for positively selected genes 
In order to determine if our dataset of PSGs was significantly enriched for 
disease genes, we examined genes that caused or were linked to human diseases 
as defined by OMIM. Of the 3079 genes used in our analysis, 469 genes were 
associated with a disease term in OMIM. Of the 511 PSGs from result set C from 
all seven lineages, 99 genes were coupled with a disease term in OMIM (Table 
5.1). The numbers were slightly higher for result set B as 146 genes were 
associated with a disease term in OMIM. A test based on the binomial 
distribution showed that there was a significant link between PSGs and disease (p 
= 0.0067). Multiple testing corrections were not applied as the PSGs from each 
lineage showed little data overlap. While PSGs along the murid lineage were 
significantly over-represented in OMIM (p = 0.0087), PSGs along the human, 
chimp or hominid lineages did not display any over-representation (p < 0.05). 
The enrichment could be due to how the 3079 were chosen was we have only 
selected genes that have 1:1 orthology to human in the other four species. 
 
 
Table 5.1 Correlation of positively selected genes with genes in OMIM 
Result set B 
 No. of PSGs 
No. of PSGs in 
OMIM 
Expected p value 
Human 69 12 11 0.3572 
Chimp 354 61 54 0.1650 
Hominid 49 10 8 0.2043 
Mouse 121 16 18 - 
Rat 155 33 27 0.0272* 
Murid 86 24 13 0.0019* 
Dog 162 30 25 0.1462 
All 775 146 118 0.0037* 
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Result set C 
 
No. of PSGs 
No. of PSGs in 
OMIM 
Expected p value 
Human 54 8 8 0.5919 
Chimp 162 26 25 0.4190 
Hominid 56 13 9 0.0753 
Mouse 65 11 10 0.4032 
Rat 89 18 14 0.1242 
Murid 81 21 12 0.0087* 
Dog 97 21 15 0.0577 
All 511 99 78 0.0067* 
 
Note: The p value is from a binomial test to look for over-representation of PSGs within OMIM, 
using a probability of a gene being in OMIM as 469/3079. The mouse lineage in result set B was 
not analysed as the observed value was less than the expected value.   
*, p < 0.01 
 
 
5.3.2 Comparison of PSGs with major disease categories 
Since the OMIM database contains information for a large variety of diseases, 
each disease was placed in one of 19 groups based on the anatomical system 
affected (see Methods). 408 genes were associated with one or more higher 
disease terms, giving 515 gene-disease terms. Table 5.2 presents the numbers of 
PSGs from result set C from each lineage found in each disease category. PSGs 
in each lineage had very few genes in common, nor did genes in each disease 
category show much overlap so multiple testing correction was not carried out. 
In the mouse, rat, murid and dog lineages, PSGs showed enrichment in some of 
the disease categories (Figure 5.1). For example, genes that cause or are involved 
in skin diseases were over-represented in both the mouse and murid lineages. 
Moreover, mouse PSGs and PSGs from all seven lineages were augmented 
among genes associated with reproductive/sexual diseases (p = 0.026 and 0.0357, 
respectively). The individual genes found in each of the over-represented disease 
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categories are described in Table 5.3. In contrast, PSGs along the chimpanzee 
and human lineages were not enriched in any of the specific disease categories. 
 
 
Figure 5.1   Correlations of PSGs with Disease Ontologies 
Tree depicting lineages which had an excess of PSGs in the 19 major disease categories. 
Only genes from non-primate species were over-represented in specific disease classes.   
 
Mouse 
Rat 
Murid 
Dog 
Human 
Chimpanzee 
Hominid 
Congenital/Hereditary (p = 0.383) 
   Immune System (p = 0.022) 
Skin (p = 0.010) 
Metabolic (p = 0.042) 
Hemic/Lymphatic (p = 
0.011) 
Neoplasms (p = 0.029) 
         Skin (p = 0.030) 
   Reproductive/Sexual (p = 0.026) 
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Table 5.2 p values from binomial test to look for over-representation of  
positively selected genes in 19 major disease categories 
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n 16 32 4 26 37 47 10 10 38 12 6 44 50 47 8 18 37 28 33 12 
Human 
m 1 1 0 1 1 1 0 1 2 1 0 2 0 1 0 0 0 1 0 1 
p 0.25 0.43   0.36 0.5 0.56   0.16 0.14 0.19   0.18   0.56       0.40   0.19 
Chimp  
m  1 2 0 2 3 2 0 0 2 1 0 3 2 2 0 1 2 2 2 1 
p 0.58 0.50   0.40 
0.3
1 
      0.60 0.48   0.41       0.62 0.59 0.44 0.52 0.48 
Hominid  
m  0 0 0 0 1 1 1 0 1 0 1 2 1 1 0 1 2 1 1 1 
p         0.5 0.58 0.17   0.50   0.10 0.19 0.60 0.58   0.28 0.15 0.40 0.45 0.20 
Mouse 
m  0 3 1 0 0 1 0 0 0 2 0 0 2 1 0 0 1 1 0 0 
p   0.02 0.08     0.63       0.03     0.29 0.63     0.55 0.45    
Rat 
m 0 2 0 3 1 2 0 0 1 1 0 3 0 1 1 1 4 0 1 0 
p   0.23   0.04   0.40       0.30   0.13     0.21 0.41 0.02   0.62  
Murid 
m 0 4 1 0 0 1 1 0 1 1 1 1 4 3 0 0 1 0 4 0 
p   0.01 0.10     0.71 0.23   0.64 0.27 0.15 0.70 0.04 0.12     0.63   0.01  
Dog 
m 2 0 1 0 4 2 1 0 2 0 0 3 3 0 0 1 1 2 3 0 
p 0.09   0.12   0.1 0.44 0.27   0.34     0.16 0.21     0.44   0.22 0.09  
Note: Number of genes in 3079 genes in disease category (n), number of PSGs from each lineage 
in disease category (m) and p values from a binomial test to look for over-representation of genes 
under selection in these disease categories.  
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Table 5.3 Disease categories over-represented by PSGs 
Lineage Gene Name 
Chromosomal 
Location 
Disease Biological Process 
MOUSE     
 Skin Diseases 
 STS Xp22.32 Ichthyosis, X-linked  
Phospholipid metabolism; Sulfur 
metabolism 
 HLA-DRB1 6p21.3 Pemphigoid, susceptibility to  MHCII-mediated immunity 
 KRT2 12q11-q13 Ichthyosis bullosa of Siemens 
Ectoderm development; Cell 
structure 
 Reproductive Diseases 
 STS Xp22.32 Placental steroid sulfatase deficiency  
Phospholipid metabolism; Sulfur 
metabolism 
 SYCP3 12q 
Azoospermia due to perturbations of 
meiosis 
Meiosis 
RAT      
 Congenital, Hereditary, and Neonatal Diseases and Abnormalities 
 ATRX Xq13.1-q21.1 Smith-Fineman-Myers syndrome mRNA transcription regulation 
 PRSS1 7q32-qter Trypsinogen deficiency  Proteolysis 
 UBR1 15q13 Johanson-Blizzard syndrome Proteolysis 
 Immune System Diseases 
 C3 19p13.3-p13.2 C3 deficiency  Complement-mediated immunity 
 C8B 1p32 C8 deficiency, type II  Complement-mediated immunity 
 CFD 19p13.3 Complement factor D deficiency  
Proteolysis; Complement-mediated 
immunity 
 ITGB2 21q22.3 Leukocyte adhesion deficiency 
Cell adhesion-mediated signalling; 
Extracellular matrix protein-
mediated signalling; Cell adhesion 
MURID      
 Skin Diseases     
 HLA-C 6p21.3 Psoriasis, early onset, susceptibility to MHCI-mediated immunity 
 KRT2 12q11-q13 Ichthyosis bullosa of Siemens 
Ectoderm development; Cell 
structure 
 LAMC2 1q25-q31 
Epidermolysis bullosa, generalized 
atrophic benign; Epidermolysis bullosa, 
Herlitz junctional  
Cell adhesion-mediated signalling; 
Extracellular matrix protein-
mediated signalling; Cell adhesion 
 ENAM  4q13.3 Hypoplastic enamel pitting, localized Developmental processes 
 
Metabolic 
Diseases  
    
 LYZ 12q15 Amyloidosis, renal 
Carbohydrate metabolism; Stress 
response 
 PNLIP 10q26.1 Pancreatic lipase deficiency  Lipid metabolism 
 SCNN1G 16p12 Pseudohypoaldosteronism, type I 
Cation transport; Taste; Regulation 
of vasoconstriction, dilation 
 SLC34A3 9q34 
Hypophosphatemic rickets with 
hypercalciuria 
Phosphate transport; Cation 
transport; Other homeostasis 
activities 
 Hemic and Lymphatic Diseases  
 F5 1q23 
Hemorrhagic diathesis due to factor V 
deficiency  
Proteolysis; Signal transduction; 
Blood clotting 
 GP1BA 17pter-p12 von Willebrand disease, platelet-type 
Other receptor mediated signalling 
pathway; Developmental processes 
 HBD 11p15.5 Thalassemia due to Hb Lepore  
Transport; Blood circulation and gas 
exchange 
 SPTA1 1q21 Elliptocytosis Biological process unclassified 
DOG      
 Neoplasms 
 BCL3 19q13.1-q13.2 Leukemia/lymphoma, B-cell mRNA transcription regulation 
 118 
 SLC22A18 11p15.5 Rhabdomyosarcoma 
Small molecule transport; Other 
transport 
 PRF1 10q22 Lymphoma, non-Hodgkin Immunity and defence 
 TAL1 1p32 Leukemia, T-cell acute lymphocytic  
mRNA transcription regulation; 
Oncogene 
 
  
 
5.3.3 Confirmation of selection in genes involved in drug 
discovery 
Cannabinoid receptor 1 
To further confirm the presence of positive selection along the rodent lineage and 
identify residues in the protein inferred to be under positive selection pressure, 
six primate sequences (crested gibbon, macaque, spider monkey, Western tarsier, 
Goeldi’s marmoset, and lemur) were added to the alignment (see Section 5.2.3). 
An 11-species tree was created and the branch-site model analysis rerun. Even 
with the addition of more primate sequences, the test of the murid branch 
resulted in a strong signal for positive selection. The Bayes empirical Bayes 
analysis inferred the residues 76 and 77, both of which code for threonine, to be 
under positive selection with posterior probabilities greater than 0.95.  
A site model analysis was also performed to consider if selection pressure 
had occurred over the entire evolutionary history of the gene. Of the two 
likelihood-ratio tests which were performed, only the test of M8 versus M7 was 
significant (p < 0.05). The Bayes empirical Bayes procedure again inferred 
residues 76 and 77 to be under positive selection. The residues 76 and 77 are 
glutamine and valine in the primate lineages. Glutamine is a hydrophilic, polar 
amino acid and valine is a hydrophobic, aliphatic residue whereas threonine is a 
hydrophobic polar residue.  
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Dopamine receptor 2 
In order to identify the exact split in the hominid lineage which had been subject 
to positive selection in the evolution of the DRD2 gene and also to ascertain 
positively selected sites within the open reading frame, DRD2 sequences from 
five other primates (see Section 5.2.3 for accession numbers for macaque, 
gibbon, orangutan, gorilla and bonobo sequences) were added to the existing 
alignment and the branch-site analysis repeated.  
All the lineages leading to the primates and primate ancestors were tested 
in turn to determine which branches were under positive selection. The branch 
representing the root of the primate lineage (Figure 5.2) was significant at p < 
0.05, with an ω of 13.8. Residue 46 in the alignment was significant with a 
posterior probability of 0.892. Two likelihood-ratio tests using the site models, 
M2a-M1a and M8-M7 did not result in any significant signals for positive 
selection.  
Serotonin receptor 1D 
The HTR1D gene was also found to be under positive selection along the 
hominid branch suggesting divergence between human and animal models. To 
investigate the selection signal from the gene HTR1D, orthologues from 
macaque, marmoset, orangutan and pig sequences were added to the existing 
alignment. However, the branch-site analysis with the additional sequences 
resulted in the alternate model failing to converge. Several permutations of the 
run parameters including fix_blength = 1 and method = 0 and numerous 
repetitions of the branch-site run did not facilitate the alternate model to 
converge. Use of the gene tree as opposed to the standard species tree resulted in 
the runs converging but the test for positive selection of the HTR1D gene along 
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the hominid lineage was no longer significant. The gene tree differed from the 
species tree in that in the gene tree the dog and pig lineages were in the same 
clade whereas in the species tree they were in separate clades. The gene tree is 
incorrect in having the pig and dog lineages in the same clade: the pig and dog 
belong to different orders in mammalian phylogeny. The site model analysis did 
not generate any significant results either. 
 
Figure 5.2   Tree showing selection along primate ancestor in DRD2 
 
 
 
 
 
5.4 DISCUSSION 
Overall, I observed that PSGs from all lineages were over-represented among 
genes found in OMIM. Yet in contrast to the findings of Clark et al. (2003) along 
the human lineage, PSGs were not seen to display any over-representation in 
Dog 
Macaque 
Human 
Gorilla 
Bonobo 
Gibbon 
Orangutan 
Chimpanzee 
Rat 
Mouse 
0.1 
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OMIM, nor in any of the disease categories (p < 0.05). However the set of genes 
they found to be significant were the results of a branch test (model 2) and not all 
of these genes had ω > 1. A branch test tends to average ω values across the gene 
and across the lineage, so genes that show episodic changes in ω at particular 
sites along the gene will not be found to be significant. The initial set of 7645 
genes tested by Clark et al. and our primary data set of 3079 genes share only 
851 genes and since the type of analyses done by both groups are different, the 
results cannot be directly compared. 
My findings, however, were consistent with other recent studies that found no 
significant associations (CSAC, 2005) or only marginal associations (Bakewell et 
al., 2007) between PSGs and human diseases. Note that the OMIM database only 
contains genes exhibiting direct Mendelian disease inheritance but not the genes 
involved in the much more common, polygenic human disorders.  
 
PSGs implicated in diseases with biomedical differences between mammals 
Initial examination of the individual PSGs along the human and hominid lineages 
(Table 5.4) that had disease associations in OMIM did not reveal any patterns or 
major disease implications. However a closer look at specific diseases that show 
biomedical differences between mammals revealed positively selected genes that 
are implicated in such diseases (Table 5.5). These are diseases that show 
differences in severity and frequency between humans and great apes, as 
experienced by primate centres and zoos over the last century. 
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Table 5.4 Human and hominid PSGs associated with disease in OMIM  
Gene Name 
Chromosomal 
Location 
Disease Disease Type Biological Process 
Human      
CACNA1A 19p13.2-p13.1 Cerebellar ataxia Nervous System 
Cation transport; 
Neurotransmitter release; Muscle 
contraction 
CACNA1S 1q32 Thyrotoxic periodic paralysis Muscular 
Cation transport; 
Neurotransmitter release; Muscle 
contraction 
  Malignant hyperthermia  none  
COL11A1 1p21 Marshall syndrome Skeletal Mesoderm development 
EDNRB 13q22 ABCD syndrome 
Congenital, Hereditary, and 
Neonatal 
G-protein mediated signalling; 
Calcium mediated signalling; 
Muscle contraction;  
  Hirschsprung disease Digestive System  
NR5A1 9q33 
Adrenocortical insufficiency without 
ovarian defect  
Endocrine System 
mRNA transcription regulation; 
Signal transduction; 
Developmental processes 
  Sex reversal, XY, with adrenal failure  Reproductive and Sexual   
MC1R 16q24.3 Melanoma Neoplasms 
G-protein mediated signalling; 
Vision 
  
Analgesia from kappa-opioid receptor 
agonist, female-specific  
none  
  
Oculocutaneous albinism, type II, 
modifier of 
Sensory  
  UV-induced skin damage,  Skin  
  Blond/light brown hair and/or fair skin Trait  
UMPS 3q13 Orotica aciduria  Skeletal Biological process unclassified 
     
Hominid     
ADRB2 5q31-q32 Asthma, nocturnal Immune System 
G-protein mediated signalling; 
Calcium mediated signalling;  
  Beta-adrenoreceptor agonist none  
APOE 19q13.2 Myocardial infarction Cardiovascular 
Lipid and fatty acid transport; 
Transport 
  Sea-blue histiocyte disease Metabolic  
  Macular degeneration, age-related Sensory  
C1QA 1p36.3-p34.1 C1q deficiency, type A  Immune System Complement-mediated immunity 
COL4A4 2q35-q37 Alport syndrome Urologic Biological process unclassified 
COL11A1 1p21 Marshall syndrome Skeletal Mesoderm development 
COMP 19p13.1 Pseudoachondroplasia Endocrine System 
Blood clotting; Other 
developmental process 
  Epiphyseal dysplasia Skeletal  
F5 1q23 Hemorrhagic diathesis Hemic and Lymphatic 
Proteolysis; Signal transduction; 
Blood clotting 
MSH2 2p22-p21 
Cafe-au-lait spots, multiple, with 
leukaemia 
Neoplasms DNA repair; Meiosis 
TH 11p15.5 Segawa syndrome Nervous System  
Other amino acid metabolism; 
Signal transduction 
TXNDC3 7p14.1 Ciliary dyskinesia Respiratory Tract Pyrimidine metabolism 
ABCC11 16q12.1 Earwax, wet/dry Trait 
Small molecule transport; 
Extracellular transport and 
import; Detoxification 
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Table 5.5 Differences between humans and apes in incidence or severity  
of medical conditions and PSGs associated with them 
Medical condition Humans Great apes PSG 
    
Definite    
HIV progression to AIDS Common Very rare   HIVEP3 
Hepatitis B/C late 
complications   
Moderate to severe    Mild NR5A1 
P. falciparum malaria       Susceptible Resistant  
Myocardial infarction   Common   Very rare    
Endemic infectious 
retroviruses   
Rare Common  
Influenza A 
symptomatology   
Moderate to severe    Mild  
    
Probable    
Menopause Universal   Rare?   NR5A1 
Alzheimer's disease 
pathology   
Complete No neurofibrillary 
tangles   
APOE 
Epithelial cancers   Common Rare? MC1R, 
EDNRB, 
ALPPL2, 
GIPC2, 
MSH2, 
ABCC11 
TFPT, 
ZNF384 
Atherosclerotic strokes   Common Rare?  
Hydatiform molar 
pregnancy   
Common Rare?  
    
Possible    
Rheumatoid arthritis   Common Rare?  
Endometriosis Common Rare? NR5A1 
Toxemia of pregnancy   Common Rare?  
Early fetal wastage 
(aneuploidy)   
Common Rare?   UMPS 
Bronchial asthma Common Rare? ADRB2, 
TXNDC3 
Autoimmune diseases   Common   Rare?   CENP-B 
Major psychoses Common  Rare? PIK3C2G, 
XRCC1, 
GFRalpha3 
Note: Adapted from Varki and Altheide, 2005 
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Below we illustrate how some of the human and hominid PSGs identified in our 
study are linked to medical conditions described as being more prevalent or 
having increasing severity in humans compared to apes (Olson and Varki, 2003; 
Varki and Altheide, 2005).  
Epithelial cancers 
Human cancers are thought to be the cause of over 20% of deaths in modern 
human populations whereas among non-human primates, the rates are as low as 
2-4% (Varki, 2000). Although this may be partly attributed to carcinogenic 
factors in the lifestyles of modern humans and differences in life expectancy, 
there are many intriguing lines of evidence to suggest that another overwhelming 
factor is the presence of susceptibility genes in human (McClure, 1973; Seibold 
and Wolf, 1973; Beniashvili, 1989; Crespi and Summers, 2006; Puente et al., 
2006; Coggins, 2007; Kehrer-Sawatzki and Cooper, 2007). Among the human 
lineage PSGs, a number of genes have been implicated in the development of 
epithelial cancers: 
• MC1R (melanocortin-1 receptor) modulates the quantity and type of melanin 
synthesised in melanocytes by acting as the receptor protein for the 
melanocyte-stimulating hormone (MSH). With mutations in this gene 
associated with melanomas (Valverde et al., 1996), this receptor is a major 
determining factor in sun sensitivity. In other species, mutations in this gene 
have been associated with coat colour variation, with changes being driven 
by positive selection (Mundy and Kelly, 2003). Residue 186 (threonine in 
human, valine in other species), which showed a high posterior probability 
for being under positive selection, is part of an extracellular loop in the 
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transmembrane protein so it could potentially be involved in ligand 
recognition or binding.    
• The G-protein coupled receptor EDNRB (endothelin type-B receptor) and its 
physiological ligand, endothelin 3, are thought to play key roles in the 
development of melanocytes and other neural crest lineages (McCallion and 
Chakravarti, 2001). EDNRB promotes early expansion and migration of 
melanocyte precursors and delays their differentiation. EDNRB is greatly 
enhanced during the transformation of normal melanocytes to melanoma 
cells where it is thought to play a role in the associated loss of differentiation 
seen in melanoma cells (Lahav, 2005).    
• The presence of the ALPPL2 gene product, an alkaline phosphatase 
isoenzyme, has been shown to increase the potential of premeiotic male germ 
cells to malignant transformation. Increased promoter activity of this gene 
was seen in the process of tumour progression. ALPPL2 has now been 
confirmed as a marker for testicular germ cell tumours (Tascou et al., 2001).  
• GIPC2 mRNAs is expressed in cells derived from a diffuse-type of gastric 
cancer, and also shows increased expression in several cases of primary 
gastric cancer (Katoh, 2002). The PDZ domain of the GIPC2 protein interacts 
with several genes that are involved in modulation of growth factor signalling 
and cell adhesion (e.g. FZD3, IGF-1 and NTRK1). Thus GIPC2 may play 
key roles in carcinogenesis and embryogenesis.  
 
In the hominid lineage, several PSGs have also been implicated in epithelial 
cancer development suggesting differences in cancer disease processes between 
hominids and other mammals: 
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• MSH2 is a DNA mismatch-repair gene that was identified as a common 
locus in which germline mutations cause hereditary nonpolyposis colon 
cancer (HNPCC) (Yoon et al., 2008). As deficiencies in any DNA repair 
gene would potentially increase cancer risk, the whole group is of interest in 
investigation of species differences in cancer prevalence. I found that genes 
that are involved in DNA repair and nucleotide metabolism were over-
represented for PSGs along the chimpanzee and human lineages respectively 
(Figure 3.2). Enrichment of PSGs within the nucleotide metabolism category 
has also been reported previously (Holbrook and Sanseau, 2007).   
• The ABCC11 (ABC-binding cassette, subfamily C, member 11) gene product 
is highly expressed in breast cancer compared to normal tissue. ABCC11 is 
regulated by ERα, which mediates the tumour promoting effects of estrogens 
in breast cancer (Laganiere et al., 2005). The allele with Arg-184 is 
responsible for the dry earwax phenotype in some human populations. This 
gene participates in physiological processes involving bile acids, conjugated 
steroids and cyclic nucleotides and enhances the cellular extrusion of cAMP 
and cGMP. 
• TFPT (TCF3 (E2A) fusion partner (in childhood Leukaemia)) and ZNF384 
(zinc finger protein 384) are listed in Futreal et al. (2004) as genes that are 
mutated in cancer and causally implicated in oncogenesis. 
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Alzheimer’s disease 
A gene APOE, implicated in Alzheimer’s disease (Hanlon and Rubinsztein, 
1995; Mahley and Huang, 1999), was under positive selection along the hominid 
lineage. Selection for functional changes of the APOE gene in the hominid 
lineage could be related to either its role in neurological development or in lipid 
metabolism. Of the eight amino acids found to be under positive selection in this 
study, four are present in the lipid-binding carboxyl terminus.  
 Suggestion that there are species differences in Alzheimer’s disease 
between humans and other mammalian species comes from the observation that 
the complete pathological lesions including the neurofibrillary tangles associated 
with human Alzheimer’s disease have never been observed in the brains
 
of 
elderly chimpanzees or rhesus monkeys (Gearing et al., 1994; Gearing et al., 
1996) or elephants (Cole and Neal, 1990). Also, transgenic mouse models of 
Alzheimer's disease that presented β-amyloid neuropathology do not exhibit the 
cognitive decline at the first appearance of amyloid plaques seen in humans 
(Howlett et al., 2004). Finally and intriguingly, mammals other than humans 
seem to have just one allelic form of APOE, the E4 allele, which in humans 
predisposes carriers to a much higher risk of Alzheimer’s disease (Strittmatter et 
al., 1993). In humans, polymorphisms at two sites within the APOE gene result 
in three isoforms: E2, E3, and E4. The most common isoform, E3, has a cysteine 
at position 112 and arginine at position 158; isoform E2 has cysteines at both 
sites, whereas E4 has arginines at both sites (Hanlon and Rubinsztein, 1995). The 
APOE4 allele is highly associated with late-onset Alzheimer’s disease 
(Strittmatter et al., 1993) and also with relatively elevated LDL-cholesterol levels 
compared to other genotypes (Mahley, 1988). 
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Schizophrenia 
Neurological studies have shown that brain areas differentially dysregulated in 
schizophrenia are also subject to the most evolutionary change in the human 
lineage (Brune, 2004). A number of PSGs along the human lineage are 
associated with schizophrenia:   
• SNPs in the gene PIK3C2G (phosphoinositide-3-kinase) have recently been 
shown to be associated with schizophrenia (Jungerius et al., 2007). This gene 
is related to the phosphatidylinositol signalling pathway, and thus is a 
probable candidate for schizophrenia and bipolar disorder (Stopkova et al., 
2003).  
• Another candidate for chronic schizophrenia is the Q399 allele of the 
XRCC1 protein, which plays a role in base excision repair (Saadat et al., 
2008). The pathophysiology of schizophrenia is associated with an increased 
susceptibility to apoptosis. Mutations in XRCC1 may cause DNA damage, 
which, if detected, cause apoptosis regulators to arrest cell cycle progression.  
 
Other cognitive disorders 
Equally detected under positive selection pressure along the human lineage was 
the gene GFRalpha3, a receptor for artemin. Artemin is a member of the glial 
cell line-derived neurotrophic factor (GDNF) family of ligands. This gene acts as 
a signalling factor regulating the development and maintenance of many 
sympathetic neuronal populations (Wang et al., 2006). In particular, along with 
other GDNF family members, artemin plays a role in synaptic plasticity, a 
mechanism thought to be central to memory (Kim and Linden, 2007).  
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Autoimmune diseases 
Autoimmune diseases are rare in non-human primates whereas they are relatively 
common in humans (Varki, 2000). CENP-B is one of three centromere DNA 
binding proteins that are present in centromere heterochromatin throughout the 
cell cycle. Autoantibodies to these proteins are often seen in patients with 
autoimmune diseases, such as limited systemic sclerosis, systemic lupus 
erythematosus, and rheumatoid arthritis (Russo et al., 2000). The positive 
selection pressure acting on this gene during human evolution is consistent with 
experimental results that antigenic specificity in the C-terminus of this protein is 
species-specific (Sugimoto et al., 1992).  
  
Recurrent Miscarriage 
Varki (2000) postulates that the high rate of early foetal wastage seen in humans 
could be caused by fertilisation of deteriorating eggs which contain gross 
chromosomal and genetic abnormalities. This occurs when fertilisation takes 
place at sub-optimal times as a result of the absence of external signs of 
ovulation in human females. It has long been known that in cattle a deficiency in 
uridine monophosphate synthetase (DUMPS) is a mono-genic autosomal 
recessive disorder that results in early embryogenic death of homozygous 
offspring (Schwenger et al., 1993; Ghanem et al., 2006). In humans, recessive 
mutations in the orthologous gene, UMPS, are known to cause a rare disorder 
called orotic aciduria which is linked to congenital abnormality in progeny 
(Harden and Robinson, 1987; Bensen et al., 1991). This gene has undergone 
selection only in the human lineage and further experimental evidence needs to 
be obtained to ascertain whether this can be related to embryonic death in 
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humans and hence contribute to a higher rate of human foetal wastage in 
comparison with non-human primates. 
 
Bronchial asthma 
Two genes that were positively selected along the hominid lineage are associated 
with respiratory diseases. These genes were: 
• The β2-adrenergic receptor gene, ADRB2 mediates bronchodilatation in 
response to exogenous and endogenous beta-adrenoceptor agonists. Point 
mutations and various polymorphic forms of this gene have been linked to 
nocturnal asthma, obesity and type 2 diabetes as well as individual 
differences to therapeutic drug responses. Residue 92 of the protein (alanine 
in hominids, serine in other species) is part of the second transmembrane 
subunit of the protein and was identified as being under positive selection.  
• The other gene TXNDC3 encodes a thioredoxin–nucleoside diphosphate 
kinase and is implicated in primary ciliary dyskinesia (PCD), a genetic 
condition characterized by chronic respiratory tract infections, left–right 
asymmetry randomization, and male infertility. This gene was positively 
selected on both the hominid and murid lineages.  
 
Ataxia and Migraine 
The calcium channel gene of type P/Q, CACNA1A, was found to be under 
positive selection along the human lineage. CACNA1A is predominantly 
expressed in neuronal tissue, with Purkinje neurons in the cerebellum containing 
predominantly P-type voltage-sensitive calcium channels and the Q-type being 
the prominent calcium current in cerebellar granule cells. Within this gene, 
 131 
residue 27 (serine in human, alanine in other species) was shown to be under 
positive selection, and is in the cytoplasmic region, N-terminal to the first 
transmembrane domain. In humans, mutations in CACNA1A are associated with 
channelopathies, such as spinocerebellar ataxia 6 and episodic ataxia type 2 (Jen 
et al., 2007) as well as with more prevalent conditions such as familial 
hemiplegic migraine, dystonia, epilepsy, myasthenia and even intermittent coma 
(Jouvenceau et al., 2001). The benefits of enhanced CNS excitability may 
outweigh the risk of severe headache and disability, the symptoms of migraines 
(Loder, 2002). It could also be an artefact of design constraints in the brain 
resulting from imperfect interconnections between older and more recently 
evolved brain structures (Nesse and Williams, 1995). 
 
Positive selection in genes affecting the regulation of other genes  
Selection events on coding sequences may also have effects on gene expression 
regulation. One such gene is NR5A1, the transcriptional regulator SF1 
(steroidogenic factor 1), which had evolved under positive selection along the 
human lineage. The implications of functional divergence in human NR5A1 are 
considerable as SF1 is an orphan nuclear receptor that plays an essential role in 
the development of the adrenal gland, testis, ovary, pituitary gonadotropes, and 
hypothalamus (Luo et al., 1999). Examination of gene interaction data suggests 
that this gene is involved in regulation of about 900 genes in the human genome 
(Kolchanov et al., 2002). Some examples of genes regulated by SF1 and 
implicated in diseases with biomedical differences between species are:  
• Aromatase P450 is a gene which is expressed at very high levels in 
endometriosis (Yang et al., 2002), an estrogen-dependent disease affecting 
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females of reproductive age. Endometriosis seems to be less common in non-
human primates than in humans (Varki and Altheide, 2005). The regulation 
of aromatase P450 also has implications for menopause, a condition that is 
only seen in humans but has not been observed in long-lived captive non-
human primates (Bellino and Wise, 2003).  
• SCARB1 (scavenger receptor B1) is associated with entry and progression of 
hepatitis B and C viruses (Grove et al., 2007). In humans, both hepatitis B 
and C trigger complications that are not seen as frequently in experimentally 
induced viral infections in chimpanzees (Makuwa et al., 2006). 
 
Another transcription factor that showed signs of positive selection along the 
human lineage was HIVEP3 (immunodeficiency virus type I enhancer binding 
protein 3). This gene belongs to a family of zinc-finger proteins whose functions 
include activating HIV gene expression by binding to the NF-kappaB motif of 
the HIV-1 long terminal repeat (Seeler et al., 1994). It is commonly known that 
HIV infection in chimpanzees does not progress to the level of medical 
complexity that is seen in human AIDS (Varki, 2000), where the virus proceeds 
to infect and destroy helper T-cells. In chimpanzees however, the virus lives in a 
benign relationship within the immune system.  
 Some regulatory elements of gene expression also showed evidence of 
positive selection along the human lineage. One is the MOV10 gene (Moloney 
leukaemia virus 10, homolog), an RNA helicase contained in a multiprotein 
complex along with proteins of the 60S ribosome subunit. MOV10 is associated 
with human RISC (RNA-induced silencing complex) (Chendrimada et al., 2007). 
RNA silencing or interference (RNAi) has been recently described as an 
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important therapeutic application for modulating gene expression at the transcript 
level or for silencing disease-causing genes (Barnes et al., 2007; Federici and 
Boulis, 2007). Any functional changes in the MOV10 gene due to selection may 
affect transcriptional control of multiple genes. 
  
Genes associated with major disease categories 
The total number of PSGs from all lineages was over-represented in the diseases 
involved in reproductive processes. The enhancement in this category might be 
expected because alleles of genes involved in reproduction are likely to be 
positively selected during speciation events and hence cause reproductive 
isolation between the two new species. PSGs along the human lineage do not 
show any over-representation in any individual category possibly because they 
are evenly distributed across all categories of diseases.  
 PSGs on all the non-primate lineages show an association with one or 
more disease categories perhaps because genes that have undergone positive 
selection in other lineages are prone to disease in humans (since we are only 
looking at human diseases). The correlation between PSGs along the murid 
lineage and disease genes has implications for rodent models in drug discovery. 
If genes have undergone positive selection along the murid lineage, and in the 
process have acquired new, different or additional functions, then their use as 
drug targets in animal models might not accurately predict drug responses in 
humans. An illustration of this is seen in the KLF11 gene which codes for a 
pancreas-enriched Sp1-like transcription factor, which in my study had 
undergone positive selection in the mouse lineage. This gene does not cause any 
disease in mouse when mutated (Eppig et al., 2005) but in humans mutations in 
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this gene causes maturity-onset diabetes of the young, type VII. The reverse 
hypothesis is that genes that have selective advantages in humans might be 
linked to murine diseases but this is harder to prove as data on the subject of 
naturally occurring murine diseases are scarce.  
 I found that PSGs from the mouse, rat and murid lineages were associated 
with human diseases (Figure 5.1, Table 5.3) but genes that had undergone 
positive selection in the primate lineages were not associated with disease. The 
skin disease genes which were enhanced among PSGs from the mouse and murid 
lineages are linked to several types of skin disorders. The skin is known for its 
functional integrity (Wehrli et al., 2000) since skin cells are generally more 
tolerant of mutations. Mutations which might be lethal in other organs cause 
severe skin diseases which are tolerated in humans. 
Examples of such diseases include X-linked ichthyosis (continual and 
widespread scaling of the skin) which is associated with the gene STS (steroid 
sulfatase (microsomal), isozyme S). STS, which underwent adaptive evolution in 
the mouse lineage, is known to be pseudoautosomal in mouse (Keitges et al., 
1985) and X-linked in man. The STS locus is in the pseudoautosomal segment of 
the X and Y mouse chromosomes but not in human. (Yen, 1998) suggested that a 
pericentric inversion of the Y chromosome occurred during primate evolution, 
disrupting the former pseudoautosomal arrangement of these genes. Several 
attempts to clone the mouse homolog of the STS gene have failed, suggesting a 
substantial divergence between these genes (Salido et al., 1996). This is evident 
in the positive selection result I observed for the STS gene along the mouse and 
murid lineages.  
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Another example of a serious but tolerable skin disease is ichthyosis 
bullosa of Siemens which is caused by mutations in the gene KRT2 (keratin 1) 
(Kremer et al., 1994). Ichthyosis bullosa of Siemens is characterised by 
generalized reddening of the skin and widespread blistering. KRT2, which 
underwent positive selection along the mouse and murid lineages, is expressed in 
terminally differentiated epidermis and it is known that even conserved 
substitutions in the keratin gene affect the structure of the protein (Schweizer et 
al., 2006). Another murid PSG is HLA-C (major histocompatibility complex, 
class I, C) which has been implicated with psoriasis, a T cell-mediated 
autoimmune disorder, which affects a large proportion (2%) of the human 
population (Tiilikainen, 1980). 
PSGs along the rat lineage also showed a strong link to human disease 
genes including several genes (C3, C8B, CFD and ITGB2) linked to immune 
diseases. A deficiency of the C8 protein causes recurrent neisserial infections, 
predominantly with meningococcus infection of rare serotypes, which suggests 
that this protein plays a role in immune system signalling (Stark et al., 1980). 
The protein product of the complement factor D gene (CFD) is part of the 
alternative complement pathway and converts complement factor B to its end 
product. Moreover it is also secreted by adipocytes into the bloodstream as a 
serine protease, adipsin, and has been found to be deficient in several animal 
models of obesity. The deficiency in adipsin was not seen in mouse models 
which were obese due to overfeeding (Flier et al., 1987).  
 
 
 
 136 
Genes products utilised as common drug targets 
Analysis of the gene CNR1 revealed two residues, 76 and 77, to have evolved 
under positive selection pressure. These two residues are not known to be 
involved in ligand binding. However, the adjacent residue 78 is understood to be 
a potential attachment site for oligosaccharide N-acetylglucosamine (Andersson 
et al., 2003) and could, therefore, be an important target for post-translational 
modification. The two amino acids lie in the N-terminal region preceding the 
first transmembrane domain that begins at residue 118. It can be hypothesized 
that the substitution of residue 76 from a glutamine in primates, to a threonine (in 
murids), might have caused the protein to lose some binding power as glutamines 
are frequently involved in protein active or binding sites (Betts and Russell, 
2003). Glutamines contain a polar side-chain which is suited for interactions with 
other polar or charged atoms as well as a hydroxyl group which can form 
hydrogen bonds with a variety of polar substrates. Additionally, the N-terminal 
region of the protein CB1 plays a key role in the efficiency at which the N-tail is 
translocated across the endoplasmic reticulum membrane and hence contributes 
to the stability of the protein in the cytosol (Andersson et al., 2003). This is turn 
would affect the amount of tissue and cell distribution of the CB1 protein. 
 The DRD2 gene showed significant evidence of positive selection along 
the branch representing the root of the primate lineage (Figure 5.2). Residue 46 
(alanine in primates, phenylalanine in non-primate species) is present in the first 
of seven transmembrane domains (http://www.expasy.org/uniprot/P14416; PDB 
id = 1I15) but is not known to be a ligand binding site. Interestingly, the gene 
that regulates the synthesis of dopamine, tyrosine hydroxylase (TH), was also 
found to have undergone positive selection in hominids in this study. When 
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dopamine D2 receptors are activated, dopamine release is inhibited through 
regulation by TH (Lindgren et al., 2001). Pathway databases show that DRD2 
and TH interact together, confirming our previous finding (see Section 3.2.6) that 
positively selected genes have a tendency to interact together, as functional 
changes in one gene will drive adaptation in the other.  
Furthermore, CB1 cannabinoid (CB1) and D2 dopamine (D2) receptors are 
known to couple to the G protein Gαi/o. The concurrent
 activation of D2 receptors 
and CB1 receptors promotes functional CB1 receptor coupling
 
to Gαs resulting in 
elevation of intracellular cyclic AMP levels, presumably through Gαs (Jarrahian 
et al., 2004). The co-expression of the D2 receptor with the CB1 receptor is 
sufficient to switch the
 
coupling of the CB1 receptors from Gαi/o to Gαs, thus 
providing another example of positively selected genes interacting together.  
 
Summary: The utility of comparative methods in studies of human disease 
I conclude that comparative evolutionary genomics has an important contribution 
to make to the study of mammalian disease, enabling identification of candidate 
genes for further in vivo investigation. Researchers traditionally see the 
biomedical differences between humans and model organisms as an obstacle to 
progress. However, I have shown that these differences also provide an 
opportunity when studied at the codon level. To take advantage of this 
opportunity, we need powerful computational evolutionary algorithms (such as 
those used in this study) and a robust approach to utilise the ever-expanding 
genomic sequence data. However, it is also necessary to obtain detailed accounts 
of the physiological differences in disease occurrence and symptomatology 
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between species. Such data are currently sparse and thus it is important to collect 
observations on biomedical differences between species. 
 Understanding the evolutionary history of disease genes can also 
significantly impact the choice of pre-clinical animal models in the drug 
discovery process (Searls, 2003). The success rate in pharmaceutical pipelines 
remains low, one reason being the difficulties in successfully translating safety 
and efficacy studies from animal models to humans. Pre-clinical studies assume 
that drug targets in the experimental species and in humans are functionally 
equivalent, which is not always the case (Holbrook and Sanseau, 2007). In 
particular, animal models of neurodegenerative diseases have been shown not to 
have predictive validity in humans (Heemskerk et al., 2002). Studies of selection 
pressure during gene evolution can provide valuable information for the choice 
of animal models for drug target validation. Our results of PSGs in the five 
mammalian species serve as an informative resource that can be consulted prior 
to selecting appropriate animal models during drug target validation in the 
pharmaceutical industry. 
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Chapter 6 
Analysis of Positive Selection in Nuclear Receptors 
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6.1 MOTIVATION AND OBJECTIVES 
The previous chapter discussed a number of genes that regulate gene expression 
being under positive selection. Genes that are involved in transcription regulation 
and which respond to a wide variety of ligands are particularly interesting to 
study as functional changes in them would significantly impact the phenotype of 
the organism. One such superfamily is the nuclear receptors (NRs), which in 
humans consists of 48 genes with various roles in metabolic homeostasis, 
embryonic development, cell differentiation and detoxification (Laudet and 
Gronemeyer, 2002).  
The genome scan described in Chapters 2 to 5 identified nuclear receptor 
genes subject to positive selection in the five species studied. These included the 
nuclear receptor, NR5A1, which was under positive selection in both the human 
and chimpanzee lineages. NR5A1 regulates the expression of many genes that are 
involved in diseases with biomedical differences between species (see Section 
5.4). Another NR of particular interest and one that warrants this further 
investigation is the pregnane X receptor (NR1I2) which was found to be under 
selection along the murid lineage in this work. Nuclear receptors, NR2F2 and 
NR2F6 were also found to be under positive selection along the chimpanzee and 
dog lineages, respectively. Other genes, NR2F1, NR0B1 and NR0B2 were also 
analysed but were not found to be under positive selection.  
 This chapter extends the analysis of variation in selection pressure in 
functionally distinct regions of transcription factors by an in-depth analysis of the 
48 human nuclear receptors and their mammalian orthologues. The site and 
branch-site models were used to detect positive selection in the conserved DNA-
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binding domain and a variable ligand-binding domain present in these nuclear 
receptors.  
 
6.2 BACKGROUND TO NUCLEAR RECEPTORS 
The nuclear receptor family consists of hormone receptors for thyroid hormones, 
retinoic acids, sex steroids (estrogen, progesterone and androgen), 
glucocorticoids, mineralcorticoids, vitamin D3, leukotrienes, prostaglandins 
(Escriva et al., 2000) and ‘orphan’ nuclear receptors, for which ligands have not 
yet been identified (Giguere, 1999). They are present in varying numbers in 
arthropods, vertebrates and nematodes as a result of periods of gene duplication 
and lineage-specific gene loss (Bertrand et al., 2004). Some examples of nuclear 
receptors are the peroxisome proliferator-activated receptors (PPARs) which 
exert direct effects on fat and carbohydrate metabolism and are major targets for 
therapeutic agents in diseases such as cholesterol disorders, diabetes mellitus and 
hyperlipidaemia. The peroxisome proliferator-activated receptor gamma 
(PPARG) receptor plays a role in adipogenesis and this receptor targets genes 
that mediate insulin sensitisation (Rosen and Spiegelman, 2001). The liver X 
receptor (LXR) functions as a cholesterol sensor and its close relative, the 
farnesoid X receptor (FXR), acts as a bile acid sensor and regulates an array of 
genes involved in bile acid metabolism. 
 
6.2.1 Structure 
All nuclear receptors share a common structure (Figure 6.1), consisting of a 
variable N-terminal A/B domain which contains at least one constitutively active 
transactivation region (AF-1). The A/B domain is followed by a well conserved 
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DNA-binding region (DBD, C-domain) (Olefsky, 2001). The DBD contains the 
P-box, a motif that binds DNA sequences containing the AGGTCA motif 
(Robinson-Rechavi et al., 2003), and is involved in the dimerisation of nuclear 
receptors. Adjacent to the DBD is a non-conserved hinge-like D domain which 
contains the nuclear localisation signal that sits posterior to the E-domain or 
ligand-binding domain (LBD). The LBD recognises specific hormonal and non-
hormonal ligands. It has a conserved secondary structure of 12 alpha-helices and 
also contains another transactivation region (AF-2). A variable length F-domain 
whose function is not known lies at the C-terminus. The F-domain is absent in 
some NRs.  
 
Figure 6.1   Schematic view of the functional domains in a nuclear receptor 
Adapted from Olefsky, 2001. 
 
 
 
 
 
6.2.2 Function 
Nuclear receptors can act as homodimers and/or heterodimers and are thought to 
act in three steps (Figure 6.2) (Robinson-Rechavi et al., 2003): 
1) Repression – apo (unliganded)-nuclear receptor recruits corepressor complex 
with histone deacetylase activity (HDAC). 
DBD (C domain)  
LBD (E domain) 
D domain 
A/B domain 
F domain 
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2) Depression – occurs after ligand binding which dissociates this complex and 
recruits a first coactivator complex with histone acetyltransferase (HAT) activity, 
which results in chromatin decondensation. The receptor translocates into the 
nucleus. 
3) Transcription activation – the HAT complex dissociates and a second 
coactivator complex is assembled which establishes contact with the basal 
transcription machinery and results in transcription activation of the target gene 
(Moras and Gronemeyer, 1998).  
The precise order of events is still debated and the mechanism varies among 
receptors.  
 
Figure 6.2   Mechanism by which nuclear receptors bind to their co- 
        activators 
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6.2.3 Evolutionary history 
It is thought that the first NR was an ‘orphan’ receptor and the ability to bind to 
ligands was a function that was acquired during evolution (Escriva et al., 1997). 
Phylogenetic studies have shown that the first steroid receptor was an estrogen 
receptor, followed by a progesterone receptor (Thornton, 2001). The full 
complement of mammalian nuclear receptors evolved from these ancestral 
receptors by two large-scale genome duplications, one before the emergence of 
jawed vertebrates and one after (Escriva Garcia et al., 2003). Novel receptor-
hormone pairs are created by gene duplication of receptors. The duplicated gene 
may gain a new function (neo-functionalisation) during a time of relaxed 
selection (Hurles, 2004). New receptors have been shown to evolve affinity for 
intermediates in a biosynthetic pathway in which the terminal ligand was the 
ligand of the parent receptor (Escriva et al., 1997). The human genome has been 
found to contain 48 nuclear receptors (chosen for analysis in this study), 47 
nuclear receptors have been identified in the rat genome and 49 in mouse (Figure 
6.3). It is also known that genome duplication events at the origin of ray-finned 
fishes gave rise to the expanded family (68 genes) found in the pufferfish 
genome.  
 
6.2.4 Nomenclature 
Nuclear receptors fall into 7 subfamilies (NR0-6) (Nuclear Receptors 
Nomenclature Committee, 1999) (Table 6.1).The two members of the NR0 
family, DAX-1 (NR0B1; dosage-sensitive sex and AHC critical region on the X-
chromosome) and SHP (NR0B2; small heterodimer partner) lack a DBD.  
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Figure 6.3   Known members of the nuclear receptor superfamily  
Adapted from (Mangelsdorf et al., 1995). 
 
 
 
E78
CeF16H9.1
ER
FTZ-F1
ROR
DHR3
Rev-Erb
RAR
TR2-11
COUP
CeB0280.3
LXR
PR
GR
MR
AR
EcR
FXR
VDR
xONR
MB67
CeF11A1.3
TR
CeC2B4.2
RXR
HNF-4
TLL
CeF21D12.4
PPAR
GCNF
CNR14
E75A
NGFI-B
CeE2H1.6
ERR
CeZK418.1
KNIRPS
CeF43C1.4
CeK06A1.4
CeODR7
CeF11C1.6
 
 
 146 
Table 6.1 Human nuclear receptors, nomenclature and family name 
 
External 
Gene ID 
HGNC symbol Common Name Project ID Ensembl Gene ID 
Entrez Gene 
ID 
Known 
ligands? 
NR0B1 NR0B1 DAX1 9 ENSG00000169297 190 orphan 
NR0B2 NR0B2 SHP 10 ENSG00000131910 8431 orphan 
NR1A1 THRA THRA 46 ENSG00000126351 7067 yes 
NR1A2 THRB THRB 47 ENSG00000151090 7068 yes 
NR1B1 RARA RARA 37 ENSG00000131759 5914 yes 
NR1B2 RARB RARB 38 ENSG00000077092 5915 yes 
NR1B3 RARG RARG 39 ENSG00000172819 5916 yes 
NR1C1 PPARA PPARA 34 ENSG00000186951 5465 orphan 
NR1C2 PPARD PPARD 35 ENSG00000112033 5467 orphan 
NR1C3 PPARG PPARG 36 ENSG00000132170 5468 orphan 
NR1D1 NR1D1 REVERBA 11 ENSG00000126368 9572 orphan 
NR1D2 NR1D2 REVERBB 12 ENSG00000174738 9975 orphan 
NR1F1 RORA RORA 40 ENSG00000069667 6095 orphan 
NR1F2 RORB RORB 41 ENSG00000198963 6096 orphan 
NR1F3 RORC RORC 42 ENSG00000143365 6097 orphan 
NR1H2 NR1H2 LXRB 13 ENSG00000131408 7376 orphan 
NR1H3 NR1H3 LXRA 14 ENSG00000025434 10062 orphan 
NR1H4 NR1H4 FXR 15 ENSG00000012504 9971 orphan 
NR1I1 VDR VDR 48 ENSG00000111424 7421 yes 
NR1I2 NR1I2 PXR 16 ENSG00000144852 8856 orphan 
NR1I3 NR1I3 CAR 17 ENSG00000143257 9970 orphan 
NR2A1 HNF4A HNF4A 7 ENSG00000101076 3172 orphan 
NR2A2 HNF4G HNF4G 8 ENSG00000164749 3174 orphan 
NR2B1 RXRA RXRA 43 ENSG00000186350 6256 orphan 
NR2B2 RXRB RXRB 44 ENSG00000206218 6257 orphan 
NR2B3 RXRG RXRG 45 ENSG00000143171 6258 orphan 
NR2C1 NR2C1 TR2 18 ENSG00000120798 7181 orphan 
NR2C2 NR2C2 TR4 19 ENSG00000177463 7182 orphan 
NR2E1 NR2E1 TLL 20 ENSG00000112333 7101 orphan 
NR2E3 NR2E3 Tailless 21 ENSG00000031544 10002 yes 
NR2F1 NR2F1 SVP40 22 ENSG00000175745 7025 orphan 
NR2F2 NR2F2 SVP44 23 ENSG00000185551 7026 orphan 
NR2F6 NR2F6 EAR2 24 ENSG00000160113 2063 orphan 
NR3A1 ESR1 ESR1 2 ENSG00000091831 2099 yes 
NR3A2 ESR2 ESR2 3 ENSG00000140009 2100 yes 
NR3B1 ESRRA ESRRA 4 ENSG00000173153 2101 orphan 
NR3B2 ESRRB ESRRB 5 ENSG00000119715 2103 orphan 
NR3B3 ESRRG ESRRG 6 ENSG00000196482 2104 orphan 
NR3C1 NR3C1 GR 25 ENSG00000113580 2908 yes 
NR3C2 NR3C2 MR 26 ENSG00000151623 4306 yes 
NR3C3 PGR PGR (PR) 33 ENSG00000082175 5241 yes 
NR3C4 AR AR 1 ENSG00000169083 367 yes 
NR4A1 NR4A1 HMR 27 ENSG00000123358 3164 orphan 
NR4A2 NR4A2 NURR1 28 ENSG00000153234 4929 orphan 
NR4A3 NR4A3 NOR-1 29 ENSG00000119508 8013 orphan 
NR5A1 NR5A1 SF1 30 ENSG00000136931 2516 orphan 
NR5A2 NR5A2 LRH1 31 ENSG00000116833 2494 orphan 
NR6A1 NR6A1 RTR 32 ENSG00000148200 2649 orphan 
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6.2.5 Previous studies of positive selection 
Following the completion of the rat genome sequence, Zhang et al. (2004) 
performed a phylogenetic analysis on the entire set of NRs in human, mouse and 
rat and found that by comparison of dN/dS ratios of the LBDs, NRs were subject 
to strong purifying selection. However, they found the pairwise dN/dS ratios of 
the PXR (pregnane X receptor) and CAR (constitutive androstane receptor) genes 
to be 4-6 times higher than the average. The biological functions of the PXR and 
CAR genes could form a basis to explain the positive selection result. The orphan 
genes, CAR and PXR, are found only in mammals and mediate transcription of a 
variety of detoxifying enzymes that are members of cytochrome P450 molecules 
in response to xenobiotic compounds. The cytochrome P450 molecules have 
been extensively studied and are known to be subject to diversifying evolution by 
gene duplication in mammals (Waterston et al., 2002; Emes et al., 2003; Gibbs et 
al., 2004). It is also known that PXR orthologues in mouse and human display 
differential sensitivity to various xenobiotic agents, providing a basis for species 
specificity of xenobiotic responses (Xie and Evans, 2001). 
 A more in-depth analysis was carried out by Krasowski et al. (2005), who 
analysed the entire set of NRs in vertebrates. Their analysis used the PAML site 
models (Yang and Swanson, 2002) in two likelihood-ratio tests (LRTs). The first 
LRT, which compared the model M0 with the more complex model M3, found 
that 41 of 48 nuclear receptors had an ω greater than 0.5 in the LBD and only 1 
(PPARG) had an ω greater than 0.5 in the DBD. The second LRT, which 
compared model M7 against model M8, resulted in 10 of 132 receptors being 
identified as being significant for positive selection across all vertebrates, but 
only 3 of them were present in mammals. None of the M8 full-length analyses 
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identified any residues to have ω exceeding 1. Only the LBD of the PXR gene 
had a sub-population of codons (5%) with an inferred value of ω to be greater 
than 1. They concluded that nuclear receptors were subject to strong purifying 
selection, especially within the DBD. 
 The nuclear receptors play a wide role in the aetiology of many human 
diseases (cancer, diabetes or hormone-resistant syndromes) and are important as 
therapeutic agents in the pharmaceutical industry. Thus, a comprehensive 
understanding of their evolution is required to aid in the development of new 
drug treatments (Chen, 2008). These receptors also control various metabolites 
and detoxifying enzymes, including the cytochrome P450s. The cytochrome 
P450 family is one of most duplicated gene families in mammalian genomes with 
at least 58 members in human and 102 in mouse (Nelson et al., 2004).  
 Earlier studies to investigate positive selection in nuclear receptors used 
site models that were later found to be inaccurate in inferring positive selection. 
The work described in this chapter will also use more sensitive methods than 
previous studies which have the potential to detect positive selection that affect 
only a few residues in genes in which most residues are under purifying 
selection. In addition, with the availability of more mammalian genomes, the use 
of new orthologous sequences can greatly improve the power of maximum 
likelihood techniques to detect positive selection. 
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6.3 METHODS 
Coding DNA sequences and their corresponding protein sequences of the 48 
nuclear receptors in human and their available orthologues in 28 mammalian 
genomes were downloaded from the Ensembl database using Ensembl Biomart 
(http://www.ensembl.org/biomart/martview/). The accession numbers of the 
human genes used are given in Table 6.1. 
The protein sequences were aligned with DiALIGN (Morgenstern, 2007), 
Clustaw (Larkin et al., 2007) and Muscle (Edgar, 2004). The alignments 
generated by DiALIGN were chosen as manual curation based on the number of 
gaps and alignment length showed that it produced the most accurate local 
alignments (data not shown). Since nuclear receptors vary in the number of 
insertions and deletions between species, it is important that the homologous 
regions are aligned correctly. A cDNA alignment based on the corresponding 
protein alignment was generated by revtrans (Wernersson and Pedersen, 2003) 
and the files were converted to PAML (Yang, 1997) format.  
Two trees were produced for each alignment, one a species tree based on 
the standard mammalian species tree (Murphy et al., 2001) (Figure 6.4a) and the 
other a gene tree (Figure 6.4b). The standard mammalian species tree was 
trimmed to only include the species in the alignment using prunetree (Ziheng 
Yang, unpublished). The gene trees were created from the nucleotide alignment 
using phyml (Guindon et al., 2005) with model TN93 (Tamura and Nei, 1993) 
and 4 rate categories in the discrete gamma models of rate variation among sites 
(Yang, 1994). 
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Figure 6.4   Example of a species tree (A) and a gene tree (B) based on the 
VDR gene 
Species Abbreviations: LAF: Elephant, ETE: Tenrec, MIC: Mouse Lemur, OGA: 
Bushbaby, HUM: Human, PTR: Chimpanzee, MMU: Macaque, RNO: Rat, 
MUS: Mouse, CPO: Guinea Pig, STO: Squirrel, OPR: Pika, OCU: Rabbit, TBE: 
Tree Shrew, SAR: Common Shrew, EEU: Hedgehog, FCA: Cat, CAF: Dog, 
EQC: Horse, BTA: Cow, SUS: Pig, MLU: Bat, DNO: Armadillo, MOD: 
Opossum, OAN: Platypus 
 
Tree A 
 
Tree B 
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The branch-site model analysis was run on the 48 alignments as described in 
Section 2.4 except that only external branches were tested. The analysis was 
performed first with the species tree and then repeated with the gene tree. A site 
model analysis was also carried out with two likelihood ratio tests in the same 
manner as in Section 5.2.3. 
 To test if different domains were subject to differing selective pressures, 
the sequences were partitioned into functional domains. To determine the 
location of each domain in the alignment, a local version of the Pfam HMM 
library (Pfam_ls - downloaded March 2008) (Bateman et al., 2002) was used to 
search all sequences using the HMMER software. The resulting co-ordinates 
were then used to split the alignments into sub-alignments constituting of the A-
B, C, D, E and F domains. The search against the Pfam HMM library found that 
the F domain was absent in 29 nuclear receptors. The DBD (C domain) was 
missing in the two genes of the NR0 family, as expected. The AB domain of 
NR2C2 and the D domain of the NR1H4 gene did not pass the length cut-off of 
100 codons to be analysed so these were omitted from the analysis.  
 
6.4 RESULTS 
6.4.1 Comparisons of analyses using species trees and gene trees  
Analyses were performed using both species trees and gene trees to observe the 
effect of tree topology on the inference of the positive selection. The site model 
analyses using gene trees resulted in 8 genes under positive selection (p < 0.05) 
in the M1a-M2a comparison and 27 genes in the M7-M8 comparison (Table 6.3). 
Eight genes were significant by both tests. When the species trees were used in 
the analysis, 12 genes were under positive selection (p < 0.05) with the M1a-M2 
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model, 28 genes were significant under the M7-M8 model and 8 genes were 
significant under both models (Tables 6.2 and 6.3). When the test resulted in a 
significant result, the sites inferred to be under positive selection by the Bayes 
empirical Bayes procedure were identical in the analyses between the two tree 
topologies. The branch-site model analysis using gene trees was less 
conservative. Eleven of the genes analysed using gene trees resulted in more 
lineages under positive selection compared to the same analysis performed using 
species trees. Eight of the genes analysed had more lineages under positive 
selection with species trees compared to the same analysis performed using gene 
trees.  
In 41 of the 48 genes, the site model analyses gave the same results using 
species trees as those obtained with gene trees. The differences in the results of 
the remaining 7 genes were caused by differences in tree topology between the 
species tree and the gene tree. Such differences often arise after a gene 
duplication event from each gene copy having its own history (Hahn, 2007). 
Since use of the species trees resulted in more conservative results with the 
branch-site models and the mammalian species tree has been well studied, to 
allow comparisons between analyses, the results presented below are from 
analyses performed using the species tree.  
 
Table 6.2 Number of genes in each species that were under positive 
selection (p < 0.05) using site models and the species tree 
 
 Full 
sequence 
AB C (DBD) D E (LBD) F 
M2a vs M1a 12 4 2 2 0 3  
M8 vs M7 28 12 3 6 5 3 
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Table 6.3 Nuclear receptors under positive selection using site models 
Key: M2a – significant in the M1a-M2a comparison; M8 – significant in the M7-M8 
comparison. The domain specific results are from analyses with species trees. 
Gene 
Name 
Full 
sequence 
(Species 
Tree) 
AB domain 
C (DBD) 
domain 
D domain 
E (LBD) 
domain 
F domain 
Full 
sequence 
(Gene 
tree) 
AR M2a/M8 M2a/M8     M2a/M8 
ESR1  M8      
ESR2     M8 absent  
ESRRA M8       
ESRRB M2a/M8 M8     M2a/M8 
ESRRG M8   M2a/M8  absent M8 
HNF4A M2a/M8      M2a/M8 
HNF4G  M8      
NR0B1 M8 absent absent M8 M8 absent M8 
NR0B2  absent absent   absent  
NR1D1 M8    M8 absent M8 
NR1D2      absent  
NR1H2 M8   M8 M8 absent M8 
NR1H3        
NR1H4 M8 M8  absent  absent M8 
NR1I2 M2a/M8 M2a/M8   M8  M2a/M8 
NR1I3 M8  M8 M8  absent M8 
NR2C1 M8      M8 
NR2C2  absent    absent  
NR2E1 M2a/M8      M2a/M8 
NR2E3      absent  
NR2F1      absent  
NR2F2        
NR2F6 M8     absent M8 
NR3C1 M8 M8 M8   absent M8 
NR3C2 M8 M8     M8 
NR4A1 M8 M2a/M8    absent M8 
NR4A2      absent  
NR4A3      absent  
NR5A1 M8      M8 
NR5A2        
NR6A1        
PGR      absent  
PPARA M8   M8  absent M8 
PPARD M8     absent M8 
PPARG M8     absent M8 
RARA M2a/M8     M2a/M8 M2a/M8 
RARB M2a/M8     M2a/M8 M8 
RARG M2a/M8 M8    absent M8 
RORA M2a/M8  M2a/M8   absent M2a/M8 
RORB  M2a/M8    absent M8 
RORC      absent  
RXRA      absent  
RXRB   M2a     
RXRG      absent  
THRA M2a/M8     M2a/M8 M2a/M8 
THRB M2a/M8     absent  
VDR M2a/M8 M8  M2a/M8   M8 
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6.4.2 Results from site analyses 
The site model analysis conducted in this study inferred 12 of the 48 genes to be 
under positive selection in both the M1a-M2a and M7-M8 analyses (p < 0.05). 
An additional 16 genes were significant under the M7-M8 analysis alone. The 
number of genes expected to under positive selection by chance cannot be truly 
known in analyses involving maximum likelihood techniques, however at 
significance level 5%, there should be less than 5% significant tests if no genes 
were under positive selection.  
The genes in the NR superfamily generally show nucleotide variation 
across species consistent with strong purifying selection, particularly in the 
DBDs. The LBD domain might be more partial to positive selection pressure 
particularly in gene products that detect endogenous and xenobiotic compounds, 
that likely differ between species. The investigation into the constituent domains 
of each nuclear receptor under the M1a-M2a models also found 1 or more 
domains in 25 genes to be under positive selection (Table 6.3) including the 
DBD domain, which is thought to be highly conserved. Most genes showed 
signals of positive selection in the AB domain and the D (hinge) domain with site 
class patterns as seen in Figure 6.5. The genes PXR (gene 16) and CAR (gene 17) 
were both found to be under positive selection and also surprisingly, their close 
relative VDR (Figure 6.5), which had not been found to be under positive 
selection previously.  
 The PXR gene also had many residues that were predicted to be under 
positive selection by the Bayes empirical Bayes method by both the M1a-M2a 
and M7-M8 models: 
M2a: 6* 10* 17P 69* 101D 108L** 338V 380G 
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M8: 2E 6* 10** 17P 19M 66L 69* 70* 73* 75* 101D 106L 108L** 115S 253* 
329* 334G 338V 380G 459* 510G (sites marked with one asterisk had a 
posterior probability of 0.95 and those reaching 0.99 are marked with a double 
asterisk). The protein structure of the ligand-binding domain of PXR (1M13.pdb) 
was used to map the 5 positively selected sites within this region (Figure 6.6).  
 
Figure 6.6   Crystal structure of the PXR ligand-binding domain 
Positively-selected sites (329, 334, 338, 380 and 459) are marked in red. 
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6.4.3 Results under branch-site models 
The branch-site analyses detected 3 genes under positive selection along the human 
lineage (Table 6.4). The numbers in the other species ranged from 2 in mouse, 
chimpanzee, pig and pika to 18 and 21 in the bushbaby and platypus, respectively, 
which are novel findings. The number of species that were under positive selection 
for each gene when the full length sequence was used is listed in Table 6.5. The 
results from the analysis of individual domains can be found in Appendix 3. The 
LBD was under positive selection in 43 of the 48 genes in one or more species. The 
number of genes under positive selection for the other domains varied from 32 for 
the AB domain, 22 for the DBD domain and 31 for the D domain. Once again, the 
platypus had several genes and domains that had faster rates of evolution compared 
with other species.  
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Table 6.4 Number of genes in each species that were under positive 
selection under the branch-site models (p < 0.05) 
 
Ensembl code Species Name 
Full 
length AB C (DBD) D E (LBD) F 
Afrotheria        
LAF Elephant 7 2 5 0 3 1 
ETE Tenrec 7 6 0 2 1 0 
Primates       
MIC Mouse Lemur 9 6 1 2 5 2 
OGA Bushbaby 18 6 1 5 10 1 
HUM Human 3 2 0 1 0 0 
PTR Chimpanzee 2 4 0 1 1 0 
MMU Macaque 8 3 4 1 5 0 
Rodents       
RNO Rat 3 0 0 0 4 2 
MUS Mouse 2 3 0 0 1 0 
CPO Guinea Pig 3 1 1 3 3 0 
STO Squirrel 11 5 4 4 6 2 
Lagomorpha 
OPR Pika 2 5 0 2 1 1 
OCU Rabbit 8 6 2 3 2 0 
Scandentia 
TBE Tree Shrew 7 4 2 2 3 1 
Laurasiatheria       
SAR Common Shrew 6 3 1 2 2 1 
EEU Hedgehog 6 4 4 0 2 1 
FCA Cat 5 1 0 3 4 0 
CAF Dog 13 8 3 5 6 0 
EQC Horse 6 3 0 0 1 1 
BTA Cow 7 4 1 0 5 1 
SUS Pig 2 1 0 0 0 0 
MLU Bat 7 5 2 4 2 0 
Xenarthra        
DNO Armadillo 7 2 2 1 4 1 
Monotremes and Marsupials       
MOD Opossum 12 5 0 4 6 1 
OAN Platypus 21 4 1 5 12 1 
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Table 6.5 Results of branch-site analyses by species full length sequences 
Gene 
Name 
No. of 
species 
analysed 
No. of 
species 
under 
selection 
         
AR 22 4 MOD STO HUM ETE      
ESR1 23 6 OAN MLU BTA STO RNO OGA    
ESR2 26 2 EQC LAF        
ESRRA 18 3 CAF OCU TBE       
ESRRB 21 5 MOD STO MMU ETE LAF     
ESRRG 23 3 OAN OCU OGA       
HNF4A 19 5 DNO EEU STO CPO PTR     
HNF4G 21 3 OAN EEU RNO       
NR0B1 19 1 OCU         
NR0B2 20 2 OAN MIC        
NR1D1 22 3 MOD SAR MMU       
NR1D2 20 6 OAN MOD MLU CAF STO CPO    
NR1H2 19 3 MLU BTA STO       
NR1H3 24 3 OAN MOD FCA       
NR1H4 24 1 SAR         
NR1I2 20 1 SUS         
NR1I3 22 4 MLU CAF MUS OGA      
NR2C1 22 4 DNO MLU OGA MIC      
NR2C2 22 6 OAN FCA OCU MMU OGA LAF    
NR2E1 24 4 OAN STO OCU MIC      
NR2E3 17 3 OAN MOD OGA       
NR2F1 19 4 BTA EEU SAR TBE      
NR2F2 13 1 OGA         
NR2F6 15 1 CAF         
NR3C1 24 6 DNO FCA STO MMU OGA MIC    
NR3C2 22 9 MOD EQC STO RNO OCU TBE MMU MIC ETE 
NR4A1 21 1 OCU         
NR4A2 23 5 DNO MLU SAR OCU LAF     
NR4A3 21 6 OAN MOD BTA CAF EEU MIC    
NR5A1 18 3 OAN SUS STO       
NR5A2 23 4 EQC TBE OGA MIC      
NR6A1 21 5 MOD DNO EQC CAF HUM     
PGR 18 6 BTA CAF OPR TBE OGA MIC    
PPARA 22 2 OAN OGA        
PPARD 22 4 CAF TBE MMU OGA      
PPARG 22 3 OAN CAF SAR       
RARA 22 8 OAN DNO MLU EEU SAR STO TBE OGA  
RARB 23 8 OAN EQC FCA MUS MMU MIC ETE LAF  
RARG 19 1 OAN         
RORA 21 3 OAN DNO OGA       
RORB 22 5 OAN MOD CAF OPR LAF     
RORC 9 3 OAN MOD HUM       
RXRA 9 3 CAF MMU OGA       
RXRB 21 6 MOD EQC CAF OGA ETE LAF    
RXRG 20 2 FCA OGA        
THRA 20 6 OAN BTA CAF EEU OGA ETE    
THRB 23 2 BTA ETE        
VDR 18 3 OAN CPO PTR       
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The genes detected to be under positive selection in the human lineage were: 
AR (androgen receptor) 
Analysis of the full sequence of the androgen receptor resulted in a significant result 
for the test for positive selection along the human lineage. The AB domain of the AR 
gene was also under positive selection when each domain was analysed separately. 
In both the analyses of full length sequence and the AB domain, one residue, 233 
(asparagine in human, serine in other mammals) was inferred to be under positive 
selection by the Bayes empirical Bayes method (Yang et al., 2005). This residue is 
within the AF-1 region and adjacent to conserved hydrophobic residues that are 
important for receptor-dependent gene transcription (Betney and McEwan, 2003). 
The AB domain of the AR gene was also under positive selection in opossum, rabbit, 
mouse lemur and the tenrec but the positively selected sites in these four species 
were different from that in human.  
NR6A1 (retinoid-related, testis-associated receptor (RTR))  
Within the RTR gene, the residue 241, which is glutamine, a polar molecule in 
humans and proline (non-polar) in other mammals, was reported as having had faster 
evolution rates. This residue is within the DBD of this protein. The structure of the 
RTR protein is not yet available.  
NR1H2 (liver X receptor B)  
The NR1H2 gene did not give a significant result when the full length sequence was 
used but the D domain (hinge region) when tested independently, gave a significant 
result along the human lineage (p < 0.001). The sites under positive selection were 
consecutive from, residues 177 to 181 (ESQSQ). 
 161 
6.5 DISCUSSION 
Analysis of the full complement of nuclear receptors in the human genome and their 
mammalian orthologues clearly shows that nuclear receptors are under more positive 
selective pressure than previously thought. The most recent study by Krasowski et 
al. (2005) found only 3 NRs to be under positive selection under the M7-M8 models 
with none of the M8 full length analyses identifying residues to have ω exceeding 1. 
Only the LBD of the PXR gene had a sub-population of residues with an inferred 
value of ω to be greater than 1. Along with the CAR and PXR genes, the same 
analysis using more species in this study found 26 other genes to have exhibited 
adaptive evolution throughout the history of the gene. I also found the DBDs of 4 
genes and the LBDs of 5 genes to contain codons under positive selection. The site 
models used in previous studies (Zhang et al., 2004; Krasowski et al., 2005) tend to 
average rates over time and hence lack power, compared to the branch-site models 
(Zhang et al., 2005). Moreover, the M3 model used in the Krasowski study has been 
shown to be not as precise in distinguishing positive selection as the M8 or M2a 
models. When there is a large fraction of neutral sites, the M3 model can yield a 
large number of incorrectly predicted sites and hence is no longer supported (Yang, 
2007). This study using only mammalian sequences also narrows the length of 
evolutionary time under analysis. Hence short bursts of positive selection would be 
easier to detect under the branch-site model.  
 Many of the genomes used in this study were sequenced at low coverage (2-
4x) and will inevitably exhibit increased levels of error in base calls, genome 
assemblies, orthologue identification (due to short contigs), and alignment, which 
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can all lead to spurious signals for positive selection. The genes predicted to be 
under positive selection from this study in the low-coverage genomes provide an 
indication into the number and type of nuclear receptors that could potentially be 
under positive selection. These results will need to be confirmed when further 
releases of the low-coverage genome sequences are provided with improved data 
quality and sequence coverage.  
 I found that the androgen receptor gene had gone through positive selection 
in the AB domain with residue 233 having a high posterior probability of being 
under selection. This region also contains the activation domain, AF-1. The 
androgen receptor is unusual among nuclear receptors in that most, if not all, of its 
activity is mediated via the constitutive activation function in the N terminus (Bevan 
et al., 1999). This is in contrast to what occurs with the closely related estrogen 
receptor (ER), in which AF-2 is the major activation domain and AF-1 has little 
independent activity. Hence, the site of positive selection could possibly affect the 
function of the androgen receptor in humans. The most potent ligand of the androgen 
receptor is a metabolite of testosterone, 5α-dihydrotestosterone, among other 
molecules with agonist and antagonistic activity (Laudet and Gronemeyer, 2002). 
However, ligand binding in receptors varies among species and the ability to bind to 
new substrates can evolve from gene duplication (Emes et al., 2004). Frequently 
duplicated genes are often associated with adaptation and neo-functionalisation 
(Ohno, 1999; Blomme et al., 2006).  
 The RTR (retinoid-related, testis-associated receptor) gene was also 
positively selected along the human lineage with a positively selected site present in 
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the DBD region. The RTR participates in the regulation of neurogenesis and 
reproductive functions (Greschik and Schule, 1998). No ligand or activator has yet 
been described for RTR. However, it is known that the RTR gene represses 
transcription via its DBD and the DBD has been shown to be essential for the 
function of RTR during early embryogenesis (Lan et al., 2002). Positive selection of 
the RTR gene along the human lineage may change the function of the DBD in 
humans.  
 The unusually large number of positively selected genes in the platypus 
lineage is perhaps an indication of its multifaceted reproductive and lactative 
systems, characteristics of both reptiles and mammals. The genome of this 
fascinating monotreme is still in the early stages of analysis (Warren et al., 2008). 
Much work still needs to be done before we can determine the contribution nuclear 
receptors make to the platypus’ biology. 
 The patterns of evolution within the nuclear receptor family are complex, 
with many events of duplication, sometimes followed by pseudogenisation. This 
analysis demonstrates that domains within the nuclear receptor genes evolve 
independently of each other, which perhaps gives rise to new members of a family 
within some species. Furthermore, this study has shown that all domains, not just the 
LBD, are under positive selection in one or more species, which indicates that each 
and every one of the regions of these genes have an important function.    
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Genomic scans to detect the action of positive selection pressure can provide great 
insights into the underlying factors that contribute to biological differences between 
species. I identified genes that underwent positive selection during the evolution of 
humans and four mammals which are often used to model human diseases (mouse, 
rat, chimpanzee and dog) using maximum likelihood methods. This is the largest 
number of species investigated to date. Inclusion of more species increases the 
sensitivity of the methods and provides information about gene evolution in 
important animal models of human disease. Sources of error in genome scans such 
as sequencing errors, orthologue identification and alignment were rigorously 
addressed and the results subjected to an unprecedented level of quality control.  
 I show that genes that have been subject to positive selection pressure during 
human evolution are implicated in diseases such as epithelial cancers, schizophrenia, 
autoimmune diseases and Alzheimer’s disease. This is one of the primary analyses 
trying to connect positive selection and phenotypic evidence from literature. These 
genes may be causative of the phenotypic disease differences between species and 
are promising targets for therapeutic intervention. This approach is of interest to 
drug development as detection of positive selection in a drug target or members of a 
disease pathway may cause animal models to be nonpredictive of human biology 
and explain some observed biomedical differences between species (Vamathevan et 
al., 2007). The dataset I present, of PSGs in five species, serves as an informative 
resource that can be consulted prior to selecting appropriate animal models during 
drug target validation.  
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 The chimpanzee lineage was found to have many more genes under positive 
selection than any of the other lineages and three times more than the number of 
genes in the human lineage. I present evidence to argue against the possibility that 
this result is due to artefacts introduced by genome sequence coverage, gene sample 
selection or algorithmic sensitivity to errors in sequence data or alignments. Instead, 
we conclude that the elevated number of chimpanzee PSGs is a true reflection of 
evolutionary history and is most likely due to positive selection being more effective 
in the large population sizes chimpanzees have had in the past or possibly 
remarkable adaptation in the chimpanzee lineage. The extravagant adaptation seen in 
the chimpanzee lineage is interesting. Whether this pattern is specific to the 
chimpanzee can only be realised when more Old World monkeys are sequenced and 
analysed.  
 From these sets of genes, evidence was found to support the hypothesis that 
PSGs are significantly more likely to interact with other PSGs than genes evolving 
under neutral evolution or purifying selection, presumably because the functional 
divergence in one gene drives selection in its functional partners. This is the first 
such evidence to be detected widely among mammalian genes and is exemplified by 
evidence of co-evolution in integrin genes. It is suggested that the high level of 
connectivity between PSGs is caused by compensatory change of a protein’s 
interaction partners when a protein undergoes change in response to selection. 
 One of the outcomes from a large-scale genome scan is the identification of 
potentially interesting genes or gene families that can then be analysed further. One 
gene family that arose from this genome scan was the nuclear receptors, which 
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previously had been thought to be under strong purifying selection. The extended 
study of nuclear receptors, which have a well-studied, conserved structure that has 
been maintained throughout evolution from flies to humans, found that several 
domains were under positive selection. The co-evolution experiment demonstrated 
that positively selected genes do not have less interactors than genes under negative 
selection or neutral evolution. Even genes with key roles such as transcriptional 
regulation and those which interact with many other genes and play roles in vital 
functions can be under adaptive evolution. Regions of genes that were previously 
thought to be unimportant, if under strong selection pressure, must have key 
functions which we are yet to uncover. To further extend the co-evolution 
hypothesis, a wide study of nuclear receptors and their co-repressors and co-
activators can be performed to investigate if these molecules, which are known to 
interact together, show signals for positive selection in the same species. The 
positive selection signals detected can indicate subtle variations in the functions of 
nuclear receptors among species. 
 
This study encompasses several avenues of exploration into the fascinating area of 
molecular evolution. As Dobzhansky’s famous quote “Nothing in biology makes 
sense except in the light of evolution” implies, an evolutionary point of view can 
shed light on almost all aspects of biology. It is becoming clear that the marriage of 
disciplines such as molecular evolution and genomics is going to bring about great 
advances and we are now only at the threshold.  
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In the years to come, as more genomes are sequenced using next-generation 
sequencing technology (Gupta, 2008), the potential to uncover the hidden truths of 
our past only becomes more tantalising. Current projects such as the Tree of Life 
project (http://www.tigr.org/tol/), the 1000 Genomes Project 
(http://www.1000genomes.org/) and the Encode project (Birney et al., 2007) are 
already making headway to improve the understanding of the complex genetic 
variation that exists. The Encode project, which I am currently a member of, has 
already changed the traditional definition of a gene and has uncovered complex 
patterns of dispersed regulation and abundant transcriptional landscape produced by 
the human genome. Understanding the patterns of variation in the genome that 
reveal where unusual selective forces have been acting is important in understanding 
the mechanisms underlying human disease. 
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APPENDIX 2 
Names of genes under positive selection in each lineage 
 
Human Chimpanzee Hominid Mouse Rat Murid Dog 
ABCF1 ABCF1 ABCC11 ADMR ABTB2 ABCB10 ALB 
ALPPL2 ACTN2 ADAD2 AQP9 ACTN2 ACRBP ALS2CL 
ANGEL1 ACVRL1 ADRB2 AVPR1B AIM1 ADRB3 APBB1 
ANKRD35 ADCY5 AMAC1 C11ORF34 APOF ARMC3 B4GALT4 
ARID2 ADCY6 APOE C19ORF16 ARHGAP27 BLVRA BCAS1 
ATPBD3 ALG10 AZGP1 C1QA ARHGEF17 C10ORF88 BCL2 
C8ORF42 ALOX12 C11ORF34 C1R ASPH C10ORF93 BCL3 
CA14 ALPPL2 C18ORF34 C20ORF102 ATP11C C1ORF156 BMS1 
CACNA1A ANGEL1 C1QA C20ORF186 ATRX C5ORF32 C11ORF34 
CACNA1S ANKRD35 C9ORF75 CA6 C11ORF34 C6ORF170 C12ORF34 
CEACAM20 AQP2 CCL19 CCDC83 C19ORF16 C6ORF194 C15ORF27 
CENPB ARHGEF17 CD86 CCDC95 C3 CACNA1A C20ORF186 
CNGA4 ARMC3 CDC42EP2 CD86 C8B CCDC73 C6ORF182 
COL11A1 ARMCX5 CDKN2B CDC14B CA6 CD86 C8A 
CTAGE6 ARRB1 CLSTN2 CENPC1 CARD11 CDCA2 CACNA1S 
EDNRB ATP6AP1 COL11A1 DHDH CAST CLSTN2 CCDC66 
EMB BLK COL4A4 DOCK3 CCDC108 CNR1 CD79A 
FLJ40722 BMP4 COMP DSPP CCDC18 CX62 CDCA2 
GFRA3 C10ORF93 CXYorf1 FAIM3 CCDC7 CXCL13 CDH17 
GIPC2 C11ORF24 DRD2 FLJ40722 CDC14B DAG1 CDH22 
GPR111 C14ORF39 EMP1 FLT1 CDH22 EFCAB5 CFP 
GPR83 C16ORF48 ENG FZD6 CDKN1B ELOVL4 CLCN1 
GPRC6A C17ORF28 ENSA GIMAP8 CDKN2D ENAM COMP 
HIVEP3 C1ORF129 F5 GPR83 CFD ETV2 CRB2 
IFRD2 C1ORF174 FLJ46266 H6PD CHRNA7 F5 CREBL1 
INPP5B C21ORF13 FZD2 HECW1 CILP FZD2 DAG1 
KCNK5 C3 GDPD4 HLA-DQA2 COL11A1 GAS2L2 DBX1 
KIAA0372 C8ORF42 GIPC2 HLA-DRB1 CYB561 GJC1 DPP6 
LOC388969 CCDC27 GPR116 HOXC6 DAGLB GP1BA DSPP 
LOC389072 CCDC88C GPR97 IZUMO1 DHDH GPR1 EFCAB4B 
LOC619207 CCDC97 GSTO2 KIAA1949 DNM1 GPR111 ENSA 
MC1R CDH15 HSPA1B KLF11 DPP6 GPR113 EPHA1 
MGC50722 CHKA HTR1D KRT2 DSC2 HBD EVI2A 
MICALCL CLTB HTR2C LOC253012 EIF2C3 HECW1 F5 
MOV10 CNGA4 ITGAV LOC388323 FLJ13305 HLA-C FGF20 
MYF5 COL11A2 LOC220686 LOC497190 FLJ40722 HOXA11 FLJ45187 
NR5A1 COMP LOC619207 MARCH3 FXYD1 HRH2 GALNS 
OR4F17 CPNE9 MADCAM1 MGC71993 FZD2 HSPA1A GAS2L2 
PDE6A CSTF1 MCAM MMPL1 GPR141 HSPE1 GDPD4 
PIK3C2G CXORF38 MMPL1 MRVI1 HDAC4 IFIT2 GGTLA1 
RBM16 DBX1 MRC2 MYH15 HLA-B INSL3 GPRASP1 
RDM1 DIP2C MSH2 NDUFC1 ICAM1 ITGAV GRID1 
REPIN1 DOPEY1 MYCT1 NLRP9 IMPG1 KRT2 GRM3 
RKHD1 DUSP2 NRAP NOVA2 INPP4A KRTAP3-3 HADHB 
RUFY4 DYRK2 NUDT22 NXPH4 IQSEC3 LAMC2 HCLS1 
SLC5A9 EEF1G PHYHD1 PHYH IQUB LIPC HDAC4 
SRL EFCAB4A RUFY4 PZP ITGB2 LYZ HDC 
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ST8SIA3 EFCAB4B SCML4 RAB11FIP2 KCNA4 MAGEB4 HLA-DMB 
TMPRSS12 EHHADH TFF1 RAPGEF2 KIFAP3 MAST3 HRG 
TRIM67 ELF4 TFPT RRAGA KRT31 MCOLN2 HSPA6 
UMPS EMD TH SASP LASS2 MDC1 IFT88 
XRCC1 ENTPD5 TRAF6 SCD LCTL MRC2 IL18RAP 
ZNF324B EOMES TXNDC3 SEPT1 LDHD MRPL54 INPP5B 
ZRSR2 ETAA1 WDR42B SERINC5 MAN1A2 NLGN4Y ITGA5 
 FAM134A ZNF384 SH2D6 MSL-1 NLRP5 ITPKA 
 FLRT1 ZNF665 SLC1A5 NKX2-5 NLRP9 KIAA1727 
 GALNT6  SSTR2 LOC619207 NR1I2 KRTAP2-4 
 GDPD4  STS OPN5 NUF2 LCP2 
 GFPT2  SYCP3 PCDHB14 OR7C1 LRP5 
 GIPC2  SYT4 PDE6C OXSM MCAM 
 GIYD1  TARP PELI3 PHACTR1 MDGA1 
 GPC3  TIMD4 PIK3R5 PHYH MGC50722 
 GPD1L  TMF1 PIM1 PNLIP MMP12 
 GPR19  TST PLIN PSMB6 MTDH 
 GPX2  UNQ9438 PLXNC1 PTGIR MUSK 
 GRIK5   PRSS1 RAPGEF1 NLRP5 
 GSTP1   PRSS35 RBM16 NOS1AP 
 HCRTR1   PRSS36 RP5-1054A22.3 NRTN 
 HLA-DRB1   PSMB4 SAFB PALM2-AKAP2 
 ICA1L   RAB11FIP3 SCNN1G PAX1 
 IGFALS   RGSL1 SLC34A3 PCDHB6 
 INPP5B   RP9 SNRPA PCTK2 
 IRAK2   RRAGA SPTA1 PDE6C 
 ISG15   RS1 TAS2R39 PLA1A 
 ITGB6   SLCO2A1 TLR5 PRF1 
 JUB   STON1 TRPC3 PTGFRN 
 KIAA0372   STS TXNDC3 PTX3 
 KRT15   SYT4 VGLL2 RASGRF2 
 KRT34   TAC4 ZC3H6 SCN8A 
 LGALS7   TARP ZNF658B SEPP1 
 LHB   TEKT4 ZNF665 SERPINB1 
 LOC553158   THEM5  SIDT1 
 MAGEH1   TMEM162  SIGLEC5 
 MAP2K4   TRIM21  SIRT1 
 MAPK4   UBR1  SLC17A8 
 MAST3   UNC13A  SLC22A18 
 MFAP4   ZBTB38  SLC26A2 
 MGC50722   ZNF43  SLC2A2 
 MICALCL   ZNF780B  SLC31A1 
 MIPEP     SLCO4C1 
 MORC2     SNTA1 
 MSH2     TAL1 
 MSI1     TRY1 
 MYO18A     UGCGL1 
 MYO1A     XRCC1 
 NLRC3     ZFP36 
 NPR1     ZNF282 
 NTSR1      
 NUCB1      
 OR4F17      
 OTX1      
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 PAK2      
 PCSK5      
 PEX12      
 PEX19      
 PHOX2A      
 PI16      
 PIGV      
 PIK3C2G      
 PPP2R1A      
 PSD2      
 PSMB4      
 PTGS1      
 RAD23A      
 RBM16      
 RNF10      
 RNF145      
 RUFY4      
 SAFB      
 SALL1      
 SCUBE3      
 SERINC2      
 SERINC5      
 SERPINA5      
 SH3PXD2B      
 SLC14A1      
 SLC22A18      
 SLC45A1      
 SMC3      
 SNAPC1      
 SPATA1      
 SPATA21      
 SPERT      
 SPR      
 SREBF2      
 SYNC1      
 TBC1D10C      
 TEF      
 TEX264      
 TFR2      
 TKTL1      
 TLE2      
 TLR5      
 TMEM175      
 TPCN2      
 TRADD      
 TRIM65      
 UGT1A8      
 UPK3A      
 USP54      
 VMO1      
 WDR27      
 WDR34      
 WDR90      
 XPC      
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 ZFP36L1      
 ZNF289      
 ZNF324B      
 ZNF43      
 ZNF653      
 ZNF768      
 ZRSR2      
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APPENDIX 3 
 
Branch-site analysis of individual domains in nuclear receptors: names of 
species under positive selection 
 
Gene Domain          
AR AB MOD OCU HUM MIC ETE     
ESR1 AB MLU BTA STO OGA ETE     
ESR2 AB LAF         
ESRRA AB CAF OCU        
ESRRB AB BTA         
ESRRG AB OAN         
HNF4A AB MLU EEU CPO MMU PTR     
NR1D2 AB MOD         
NR1H3 AB OAN MMU        
NR1I2 AB SUS STO OGA ETE      
NR2C1 AB DNO MLU        
NR2C2 AB OCU LAF        
NR2E1 AB MLU SAR TBE MIC      
NR2F1 AB BTA CAF EEU SAR STO MUS OPR TBE PTR 
NR2F2 AB OPR         
NR2F6 AB MOD CAF        
NR3C1 AB DNO FCA STO TBE MIC ETE    
NR3C2 AB MOD EQC OCU MIC ETE     
NR4A1 AB OCU OPR        
NR4A2 AB SAR         
NR4A3 AB OAN CAF EEU OCU MIC     
NR5A2 AB EQC         
NR6A1 AB HUM         
PGR AB BTA CAF STO OPR TBE PTR OGA MIC  
PPARA AB OAN         
PPARG AB CAF OPR        
RARB AB MUS MMU        
RARG AB CAF EEU MUS PTR      
RORA AB MLU OGA        
RXRB AB MOD EQC OGA ETE      
RXRG AB OGA         
VDR AB CAF         
ESR2 C LAF         
ESRRB C MMU LAF        
HNF4A C EEU STO        
HNF4G C STO         
NR1D1 C MMU         
NR1D2 C STO         
NR1H2 C STO         
NR1H4 C MLU         
NR1I3 C MLU OGA        
NR2E1 C OAN OCU MIC       
NR2F1 C BTA         
NR2F6 C CAF         
NR3C1 C OCU         
NR3C2 C SAR TBE MMU       
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NR4A2 C LAF         
PGR C LAF         
PPARA C CAF         
RARA C EEU CPO        
RARB C DNO MMU LAF       
RXRB C CAF EEU TBE       
RXRG C DNO         
THRA C EEU         
AR D STO ETE        
ESRRA D DNO         
NR0B1 D OCU         
NR0B2 D ETE         
NR1D1 D MMU         
NR1D2 D MOD MLU STO CPO      
NR1H2 D STO HUM        
NR1H3 D FCA         
NR1I2 D CAF         
NR1I3 D MLU CAF        
NR2C2 D FCA         
NR2E1 D MIC         
NR2E3 D OGA         
NR2F2 D OGA         
NR2F6 D CAF         
NR3C1 D FCA         
NR3C2 D STO         
NR4A2 D MLU OCU        
NR5A1 D OAN OPR        
NR5A2 D MLU OGA        
NR6A1 D MOD OCU        
PPARD D TBE         
PPARG D SAR TBE OGA MIC      
RORA D OAN         
RORB D OAN CAF OPR       
RORC D OAN MOD        
RXRB D MOD CAF        
RXRG D CPO         
THRA D OGA         
THRB D OAN SAR        
VDR D CPO PTR        
AR E CPO         
ESR1 E OAN RNO        
ESR2 E EQC         
ESRRA E TBE         
ESRRB E MOD OCU        
ESRRG E DNO OCU OGA       
HNF4A E STO         
HNF4G E OAN EEU        
NR0B2 E OAN MIC        
NR1D1 E MMU         
NR1H2 E BTA MIC        
NR1H3 E CPO         
NR1H4 E SAR         
NR1I2 E MOD OPR        
NR1I3 E MLU MUS        
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NR2C1 E OAN OGA        
NR2C2 E EEU STO MMU OGA      
NR2E1 E OAN         
NR2F1 E MOD TBE MIC       
NR2F2 E MLU         
NR3C1 E FCA MMU OGA       
NR3C2 E STO RNO        
NR4A2 E DNO         
NR4A3 E BTA MIC        
NR5A1 E OAN STO        
NR5A2 E OGA MIC        
NR6A1 E MOD DNO        
PGR E BTA         
PPARA E OAN STO MMU OGA      
PPARD E CAF MMU OGA       
PPARG E OAN BTA TBE       
RARA E CAF HUM OGA       
RARB E FCA ETE        
RARG E OAN CPO        
RORA E DNO         
RORB E MOD CAF SAR LAF      
RORC E OAN         
RXRA E CAF FCA RNO OGA LAF     
RXRB E MOD CAF LAF       
RXRG E FCA STO RNO       
THRA E OAN CAF OGA       
THRB E BTA         
VDR E OAN PTR        
ESRRB F STO         
NR1H3 F OAN         
NR3C2 F RNO         
RARA F DNO EEU SAR STO OPR TBE MIC LAF  
RARB F EQC OGA MIC       
THRA F MOD BTA RNO       
  
 
